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“Some two days after my arrival, I saw a boy staggering through the streets. He fell, stopped 
and fell again.” (Negrette A. Personal communication 2001 to 2003)" This was the !rst 
encounter in 1952 of Amerigo Negrette, a Venezuelan doctor, with a person with Hun-
tington’s disease (HD) (Box 1.1) in Maracaibo, Venezuela. In this region a large population 
is a#ected by HD. These large kindred played an important role in unraveling the gene 
that caused this disease. 
Falls are common in many neurological diseases, including Parkinson’s disease (PD) (Box 
1.2) and HD.$%& These movement disorders share symptoms such as rigidity, bradykinesia, 
chorea (in HD as part of the disease itself, in PD as a side e#ect of dopaminergic medi-
cation) and postural instability. In both diseases, gait gradually becomes unstable, and 
postural instability increases as the disease progresses. This almost inevitably leads to 
falls, frequently with devastating consequences. In the elderly, falls are associated with 
fractures, hospital admission and nursing home placement.'%(%) Next to these sequelae, 
fallers may also develop an incapacitating fear of renewed falls, and this may in turn lead 
to a decreased mobility and a lower quality of life.*
Box 1.1
Huntington’s disease (HD)
Huntington’s disease is an autosomal dominant neurodegenerative disorder characterized by motor, cognitive, 
psychiatric, and behavioral disturbances. The prevalence in the United States and Europe is estimated at 5-10 
per 100.000 inhabitants and about 5 times as much persons are at risk of developing the disease.!" Mean age of 
onset ranges between 43.7 and 55.8 years#$%#& and mean disease duration is approximately 16 years.!' In 1993 
the gene mutation responsible for HD was identi(ed.#) The ‘interesting transcript 15’ (IT15) gene on the short 
arm of chromosome 4 contains an expanded CAG repeat of 36 or more repeats in a*ected individuals. A repeat 
of 36-40 is considered as incomplete penetrance, 40 or more repeats invariably lead to symptomatic disease. 
The length of the CAG repeat plays a role in disease onset leading to an earlier onset for subjects carrying longer 
repeats.#!%## 
The gene encodes for a protein called huntingtin, and the expanded trinucleotide repeat results in a mutant 
huntingtin protein containing an expanded polyglutamine tract. Since 1993 research is aimed at the function of 
huntingtin and the damage that is caused by the mutant huntingtin. 
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Despite these devastating consequences, relatively little is known about the epidemi-
ology, circumstances and consequences of falls in patients with PD and HD. There are 
only few studies that reported the incidence of falls in these disorders. Retrospective 
studies reported high fall rates, up to 83% in patients with PD+%, and 85% in HD.$ The 
circumstances and risk factors for falls in these patient groups were not described in 
detail. Therefore, we prospectively studied the incidence of falls in both diseases, aiming 
to gain more detailed insight into the potential risk factors and circumstances of these 
falls (Chapter 3).
The pathophysiology underlying falls is complex and multifactorial, and typically involves 
combinations of both ‘extrinsic’ (environmental) factors and ‘intrinsic’ (patient-related) 
factors."- Examples of extrinsic risk factors include loose rugs or other obstacles on the 
.oor, the presence of stairs in the house, or a cat that wanders about the house. Intrinsic 
risk factors include, for example, underlying balance impairment, orthostatic hypoten-
sion, or violent dyskinesias that may literally perturb the patient beyond the limits of 
stability. Some of these intrinsic risk factors are speci!c for PD (e.g. freezing of gait), but 
patients may also fall due to ‘generic’ risk factors for falls that would apply to any elderly 
person. Examples of such generic risk factors include the use of alcohol, visual impair-
ment or the use of sedative medication (in particular benzodiazepines). After mapping 
all of these intrinsic and extrinsic risk factors, it is possible to develop an individually 
tailored prevention program that aims to prevent future falls and to reduce the risk of 




ASSESSMENT OF PATIENTS AT RISK OF FALLING
History taking
History taking is the !rst vital element in assessing fall risk and to screen for the presence 
of balance disorders. Asking about prior falls is crucial, as these are associated with an 
increased fall risk in the future in elderly populations."$%"&%"'%"( However, recall bias because 
of cognitive impairment may lead to underreporting of the number of falls.")%"* It is there-
fore crucial to interview caregivers to fully elucidate balance problems and to obtain 
an adequate fall history. Prospectively studying the frequency of falls would avoid such 
recall problems, and is therefore likely more accurate. For this purpose, falls need to be 
evaluated on a regular and frequent basis, ideally using a combination of standardized 
retrospective surveys and prospectively documented falls questionnaires to identify the 
actual fall circumstances. This method was applied in Chapter 3 and Chapter 4.
Another important element of the assessment is to search for any fear of falling (or its 
counterpart, balance con!dence). Fear of falling may even be present in patients without 
a history of falls"+, and should always be a part of history taking. In this thesis, we have 
Box 1.2
Parkinson’s disease (PD)
Parkinson’s disease (PD) is a progressive neurodegenerative disorder. Its cardinal motor features include a rest-
ing tremor, rigidity, bradykinesia and postural disturbances. It also encompasses a wide range of non-motor 
symptoms, such as mood disorders, autonomic dysfunction, olfactory loss and cognitive decline. Some of these 
non-motor symptoms typically develop in later stages of the disease. Presence of prominent postural instability 
or severe cognitive disturbances early in the course of the disease is not characteristic for PD and points to the 
presence of a form of aypical parkinsonism, such as PSP or vascular parkinsonism.  The estimated prevalence in 
Europe is 160 per 100.000 inhabitants.#+ Mean age at onset is approximately 58 years and the prevalence of PD 
increases with age rising to 360 per 100.000 for those aged 80-84.
The cause of PD remains largely unknown, but genetic and environmental factors are thought to play a role.#,%#- 
The histological hallmarks of PD are a loss of dopaminergic neurons in the substantia nigra and cytoplasmatic 
inclusions termed Lewy bodies, that are composed principally of alpha-synuclein. Therapy is mainly focused at 
correcting the central dopaminergic de(cit. Dopaminergic medication improves the main motor symptoms, es-
pecially rigidity and bradykinesia. However, not all symptoms improve equally well with dopaminergic therapy. 
For example, the resting tremor and postural disturbances are typically refractory or respond only partly to 
dopaminergic therapy. A contribution of non-dopaminergic lesions is supposed to underlie these dopa-resistant 
symptoms. We hypothesize that a noradrenergic de(cit may partially underlie postural disturbances in PD. For 
this purpose, we review the literature on noradrenergic de(cits and the locus coeruleus in PD, and discuss the 
potential role of this nucleus in postural disturbances in PD (Chapter 2).
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studied to what extent fear of falling is associated with falls, and how this may a#ect the 
patient’s quality of life (Chapter 3 and Chapter 5).
Physical examination 
Physical examination should include a generic examination (e.g. blood pressure) and 
a complete neurological examination. For both PD and HD, speci!c rating scales have 
been developed. The Uni!ed Parkinson’s Disease Rating Scale (UPDRS) and the Uni!ed 
Huntington’s Disease Rating Scale (UHDRS) include severity ratings of disease-speci!c 
symptoms, such as rigidity and tremor for PD, or chorea and dystonia for HD.",%$- These 
scales are subdivided into di#erent sections and include not only motor aspects, but 
also cognitive, behavioral, and functional aspects. Both motor scales include gait and 
balance evaluations, of which the retropulsion test is probably known best, but this is 
also the most debated balance test.$"%$$%$& The retropulsion test is controversial, because it 
is di/cult to execute and evaluate in a standardized manner. Both the test performance 
and the rating of the test result are hindered by intrarater and interrater di#erences.
Therefore, one of the study questions in this thesis was to evaluate the reliability of the 
retropulsion test in identifying fallers, and its ability to predict future fallers (as docu-
mented during prospective follow-up). Furthermore, we wanted to know whether other 
tests would be more reliable. Several other balance tests have been developed, and we 
included the most widely used tests in our evaluation (Chapter 3,4 and 5).
Elderly persons commonly encounter di/culties when they have to perform two tasks 
at the same time (multi-tasking). The ‘Stops walking when talking’-test was introduced 
as a simple test to screen for such di/culties with multitasking.$' This test examines 
the ability of subjects to walk and talk at the same time. Di/culty to perform the test 
adequately turned out to be a good predictor of future falls in the elderly population, at 
least when patients had some cognitive decline. Speci!cally, persons who stopped walk-
ing as soon as they started a routine conversation were at substantial risk for developing 
future falls.$& This is an easy test that can readily be executed in the outpatient clinic, in 
fact, it can already be carried out when walking the patient to the examination room. 
We expected this test to have extra good predictive value for patients with PD, because 
these patients are known to have di/culties performing multiple motor tasks simultane-
ously or sequentially due to basal ganglia dysfunction.$( We therefore studied this ‘Stops 
walking when talking’-test in patients with PD, and analyzed its ability to predict future 
falls in this population (Chapter 6). Dual tasking itself was an important item of the fall 
questionnaires, and we hypothesized that this would be a di/cult task for both PD and 
HD patients, and also that dual task impairment would be related to an increased fall risk 




The clinical rating scales described above are all hampered by their subjective nature. 
Therefore, there is considerable interest in the development of quantitative measure-
ments of gait and balance, hoping that these might o#er a more objective perspective 
on the risk of falls in daily life. Such quantitative studies should investigate both the 
‘static’ and ‘dynamic’ components of balance. An example of static balance assessment 
is static posturography, where subjects are quietly standing on a pressure sensitive (but 
steady) forceplate, which can record spontaneous changes in body sway.$( An example of 
dynamic balance assessment is dynamic posturography, where the balance of subjects 
is actively challenged using either self-in.icted balance perturbations (for example, 
lifting a weight) or externally induced balance perturbations (for example, the sudden 
movement after supporting platform upon which subjects are standing).$) In both cases, 
the outcome can be objectively recorded using a combination of full body kinematics, 
surface reactive forces under the feet or surface electromyography. Both techniques 
have been used quite extensively to evaluate the nature of balance disorders in both PD 
and HD$"%$*%$+%$,%&-%&", although it has thus far proved di/cult to correlate these qualitative 
!ndings to the problems experienced by patients in daily life.
Next to these qualitative balance studies, several methods have been developed to 
analyze gait in more detail. This includes comprehensive laboratory-based approaches, 
where subjects are instructed to walk on a motorized treadmill, and where gait details 
can be studied in detail using full body kinematics, surface reactive forces under the 
feet or surface electromyography. Examples of outcome measures include qualitative 
documentation of step length, step time, walking velocity or the width of the base of 
support. A speci!c new development is the use of body-worn accelerometers, that can 
be used to quantify gait in freely moving subjects.&$%&&%&'%&( In this thesis, we have used this 
technique in combination with a pressure sensitive walkway to objective measure several 
basic gait and balance parameters in freely moving patients with HD (box 1.3) (Chapter 
4). Speci!cally, we wanted to explore the relationship between the documented gait 
characteristics and the risk of falls in daily life. We expected that studying any di#erences 
in gait parameters between fallers (persons who experienced two or more falls in the 
past year) and non-fallers could identify gait disturbances that were associated with an 
increased fall risk in HD (Chapter 4).
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QUALITY OF LIFE
Do recurrent falls a#ect the quality of life of patients with movement disorders? In 
various earlier studies, falls were associated with a lower quality of life in patients with 
PD.&)%&*%&+ It is di/cult to di#erentiate between the impact of falls themselves, versus the 
various factors that are associated with recurrent falls. Disease progression, fear of future 
falls, injuries or immobilization may all play a role in reducing the patient’s quality of life. 
Therefore, we evaluated the quality of life in PD patients in relation to previous falls and 
other fall-related factors (Chapter 5).
Box 1.3
Accelerometry and electronic walkway.
Assessment of balance control during dynamic tasks can be performed with angular velocity transducers worn 
on the trunk (Swaystar system, Balance  Int. Innovations GmbH, Switzerland).#' These sensors can measure 
angular deviations from the centre of mass (COM) in the pitch (anterior-posterior) and roll (lateral) plane during 
walking without interfering with natural body movements.
Gait disturbances can be quanti(ed using an electronic pressure sensitive walkway that records each footfall as 
a function of time (GAITRite, CIR Systems, Inc.:Havertown, PA). Outcome measures are spatial and temporal gait 
parameters such as step length, step time, walking velocity or the base of support. The GAITRite has shown a 




The consequences of falls can be devastating for patients with movement disorders. It is 
therefore crucial to prevent falls in this vulnerable population. As the pathophysiology 
of falls is multifactorial, any therapeutic approach should include an integrated interven-
tion program aimed at all of the di#erent factors that play a role. A !rst crucial step is 
to map all of the intrinsic and extrinsic risk factors that might contribute to the risk of 
falls for each individual patient. Both generic and disease-speci!c risk factors should be 
identi!ed. Only then is it possible to develop an individually tailored prevention program 
that aims to prevent future falls, and to reduce the risk of the associated complications 
(such as fall-related injuries, or a secondary fear of falling). The other important goals of 
such intervention programs should be the preservation of mobility and independence. 
There is currently no program that describes the development of an individually tailored 
intervention. We have therefore reviewed all potential risk factors in PD (both generic 
and disease-speci!c; and both ‘extrinsic’ and ‘intrinsic’), and propose a multifactorial 
intervention program to prevent future falls in this population (Chapter 7). 
SPECIFIC AIMS OF THE THESIS
This thesis describes the impact of balance disturbances on patients with either PD or 
HD, and aims to provide better insight into the assessment of risk factors of falls in these 
two patient groups, as a basis for falls prevention and improvement of the quality of life. 
The main goals of this study were as follows:
1. To review the neuropathological changes underlying falls in PD, with speci!c empha-
sis on the possible role played by the locus coeruleus and the associated changes in 
noradrenergic neurotransmission (Chapter 2).
2.  To prospectively study the epidemiology of falls in PD and HD (Chapter 3 and 4).
3. To gain better insight into the pathophysiology of falls in PD and HD, and to assess 
potential risk factors of falls (Chapter 3,4 and 6)
4.  To evaluate the impact of falls on the quality of life for patients with PD (Chapter 5).
5.  To develop a multifaceted prevention program to reduce falls in PD (Chapter 7).
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Postural instability in 
Parkinson’s disease:  the 
adrenergic hypothesis 
and the locus coeruleus
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Netherlands;
) The Parkinson’s Institute, Sunnyvale, CA, USA; 
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Parkinson’s disease (PD) is traditionally viewed as a mainly hypodopaminergic syndrome, 
with symptoms resulting predominantly from loss of dopamine-producing neurons in the 
substantia nigra. However, while most of the cardinal motor features of PD respond well 
to dopaminergic therapy, many other features of the disease do not. Balance impairment 
and the associated risk of falling represent one of the most prominent and potentially 
disabling features that are typically refractory to dopaminergic treatment. Therefore, it is 
possible that lesions in non-dopaminergic systems contribute to the pathop hy siolo gy of 
postural instability in PD. Such non-dopaminergic lesions are well recognized, certainly in 
advanced stages of PD where postural instability and falls dominate the clinical presenta-
tion. However, it remains unclear which of the identi!ed non-dopaminergic lesions is 
speci!cally responsible for postural instability and balance impairment. In this review, we 
argue that cell loss in the locus coeruleus and a resultant central norepinephrine de!cit 
are intimately involved in the pathophysiology of postural instability in PD. If proven to be 
correct, this link between defective noradrenergic neurotransmission and postural insta-
bility could have important implications for the future development of new symptomatic 
treatments aimed to correct postural instability and preventing falls. Studies in the next 5 
years could test this hypothesis, using a battery of complementary research techniques, 
including advanced neuroimaging (structural, functional imaging and nuclear), neuro-
chemical studies of cerebrospinal .uid, post-mortem clinicopathological analyses, and 
detailed clinical balance evaluations supplemented by posturography studies.
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INTRODUCTION
Idiopathic Parkinson’s disease (PD) is traditionally said to be characterized by a varying 
combination of at least two of the following core features: bradykinesia, tremor, rigidity 
and postural instability, although there is increasing evidence that these features are just 
a part of a much broader clinical complex." Postural disturbances represent one of the 
most disabling features of the disease.  They are typically a late manifestation of PD$ 
and include the distinctive stooped posture, the shu0ing gait disorder and progressive 
balance impairment. Postural instability leads to frequent falls, often with devastating 
consequences, such as fractures or long-term hospitalization.&
The pathophysiology of postural instability in PD remains insu/ciently understood, but 
is likely complex and multifactorial. It is good to realize that what patients and clinicians 
perceive as “a poor balance” actually encompasses a fairly broad range of pathophysi-
ological processes, and this makes it di/cult to easily correlate any given factor to “bal-
ance impairment”.  Indeed, it is now broadly accepted that de!ciencies in many of the 
a#erent and e#erent postural systems that normally contribute to balance control' 
can contribute to the complex pathophysiology underlying postural instability in PD.( 
Examples include inadequately organized automatic postural reactions, poor anticipa-
tory postural responses, a slowing of compensatory stepping reactions, inappropriately 
directed protective arm movements, and a defective somatosensory integration of a#er-
ent sensory information. The net result is that patients frequently fall (or nearly so), which 
is de!ned as inadvertently landing on any lower surface (the de!nition usually also states 
that this should not be caused by an overwhelming external force). 
Clinically based studies have underscored the magnitude of the problem and the impact 
on quality of life, but to date have failed to provide good pathophysiological insights, 
mainly because bedside balance tests are relative crude and subjective techniques.( For 
example, the widely used retropulsion test of the UPDRS (Uni!ed Parkinson’s Disease 
Rating Scale) provides only a gross measure of overall balance disturbances in PD, but 
is not designed to unravel the complex underlying pathophysiology. This situation has 
improved with the advent of posturography, which is an umbrella term for a variety of 
techniques that entail an objective electrophysiological assessment of human balance. 
In this review, we will refer to papers that used either static or dynamic posturography.) 
Static posturography refers to all those techniques that measure quiet standing, with or 
without an instrumented !xed support surface, and without any physical body perturba-
tion. By contrast, dynamic posturography techniques employ physical perturbations of 
stance, using either an unstable or motorized support surface, or an external force ap-
plied to one or more body parts.* Technological advances such as these have allowed this 
!eld to progress at a relatively rapid pace, helping to clarify fundamental disturbances at 
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the neurophysiological level when PD patients begin to fall. Thus, researchers using this 
approach have identi!ed various factors that can each contribute to postural instability, 
including impairment of automatic postural responses (both reactive and anticipatory), 
bradykinesia of corrective stepping movements, abnormally directed protective arm 
movements, and axial sti#ness.+%,%"- These improved neurophysiological insights now 
need to be backed up by a clear understanding of the underlying neurochemical and 
neuropathological changes. However, this is where much work remains to be done.
PD: A HYPODOPAMINERGIC SYNDROME?
The cardinal symptoms of PD are generally conceived as the clinical o#print of a central 
dopamine loss, for several reasons. First, progressive destruction of dopaminergic neu-
rons in the substantia nigra pars compacta is a neuropathological hallmark of PD. Second, 
both neurochemical analyses of the cerebrospinal .uid (CSF) and positron emission to-
mography (PET) imaging of the nigrostriatal pathway indicate that nigral cell loss leads to 
decreased levels of dopamine and its metabolites in the central nervous system (CNS).""%"$ 
Interestingly, nigral cell loss – as documented with .uorodopa PET scans – shows and 
excellent correlation with bradykinesia, but much less so with postural instability."& Third, 
symptomatic treatment of PD with dopaminergic drugs (especially levodopa) generally 
leads to marked alleviation of most cardinal symptoms. Bradykinesia and rigidity usually 
respond best, particularly in early stages of the disease. (Note that tremor responds less 
well to dopaminergic treatment, and PET studies have in fact associated tremor with 
serotonergic lesions"'). Finally, fairly selective nigrostriatal neurotoxins such as 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) can induce a hypokinetic-rigid syndrome in 
both humans and animals which shares many clinical, neuropathological and biochemi-
cal features of idiopathic PD, including prominent postural instability."(%")%"*%"+ Treatment 
with levodopa also markedly alleviates the symptoms of MPTP-induced parkinsonism.", 
Taken together, these di#erent lines of evidence imply that PD is largely a hypodopami-
nergic syndrome.
POSTURAL INSTABILITY AND DOPAMINERGIC DEFICITS IN PD
There is reason to believe that not all clinical manifestations of PD result solely from do-
pamine loss in the nigrostriatal pathway. While this is particularly true of the nonmotor 
features of this disease, it also applies to some of the motor features, including includ-
ing balance impairment and freezing of gait – although other signs (such as rigidity or 
bradykinesia) do continue to improve with dopaminergic treatment within the same 
patients$-%$" (!gure 1). Indeed, once present, postural instability is notoriously refractory 
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to treatment with dopaminergic drugs.$-%$"%$$%$&%$' Balance problems are sometimes even 
aggravated by the adverse e#ects of dopaminergic drugs, such as dyskinesias (which can 
be su/ciently violent to throw patients o# balance), orthostatic hypotension or confu-
sion.$(
Studies using dynamic posturography have therefore taken these clinical observations 
one step further, trying to unravel the contribution of dopaminergic and non-dopami-
nergic lesions using two di#erent approaches. First, postural responses can be assessed 
in patients with presumably selective hypodopaminergic syndromes and in patients 
with PD (where lesions are known to extend beyond the substantia nigra). Responses 
that are abnormal in both groups might be in.uenced by supraspinal dopaminergic 
control (because dopamine loss occurs in both conditions), whereas responses that are 
merely abnormal in PD could be under non-dopaminergic in.uence. Following this line 
of reasoning, automatic postural responses have been assessed in patients with what 
are presumed to be relatively pure hypodopaminergic syndromes such as neuroleptic-
induced parkinsonism$), MPTP-induced parkinsonism, and young-onset PD., Some 
postural abnormalities that are commonly present in patients with late-onset PD+%$*%$+ 
were found to be absent in these hypodopaminergic syndromes, suggesting that non-
dopaminergic lesions probably contributed to their development in PD. However, other 
Fig 1 Dopaminergic, nondopaminergic and dopa-induced features in Parkinson’s disease, with suggestions 
for corresponding treatment strategies.
DOPS: Dihydroxyphenylserine
Redrawn with permission from 117 ©John Wiley & Sons.
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postural abnormalities were present in patients with a selective dopamine de!ciency as 
well as typical late-onset PD, raising the interesting proposition that balance impairment 
in PD might be related to a combination of both dopaminergic and non-dopaminergic 
abnormalities. We should note that MPTP-induced parkinsonism is not a perfect model 
for idiopathic PD, because the onset is subacute and the syndrome does not have the 
same inevitable process of progressive neurodegeneration. A limitation to studying 
neuroleptic induced parkinsonism is that postural de!cits are often only mild, so this 
syndrome may not fully re.ect the severity of balance impairment in PD.
A second approach to assessing postural responses in patients with PD involves examin-
ing patients  both before and after administration of dopaminergic drugs.$&%$' Using this 
approach, some postural abnormalities (for example, the defective voluntary postural 
corrections) have been found to be responsive to dopaminergic medication, whereas 
other abnormalities (including the overall instability during dynamic posturography 
testing, as measured by excursions of the center of mass following a sudden platform 
movement) persist despite antiparkinson treatment. These observations con!rm the 
results obtained in patients with hypodopaminergic syndromes described and, again, a 
concept emerged of postural instability as a combined dopaminergic and hypodopami-
nergic syndrome.
NON!DOPAMINERGIC LESIONS IN PD
It appears that postural instability and other poorly dopa-responsive symptoms are likely 
to be the clinical results of ‘extra-nigral’ or ‘non-dopaminergic’ lesions. Post-mortem stud-
ies have clearly identi!ed the presence and extent of these non-dopaminergic lesions, 
and also shown that these typically develop in elderly patients with long-lasting PD. 
A#ected neurotransmitters include, among others, noradrenaline, serotonin and acetyl-
choline.  For example, cell loss in the noradrenergic locus coeruleus, the cholinergic basal 
nucleus of Meynert and the mixed cholinergic-glutaminergic pedunculopontine nucleus 
(PPN) has been demonstrated.$,%&- The latter has recently been studied as a new target 
for stereotactic surgery, aimed speci!cally to improve walking and freezing of gait in 
PD.&"%&$%&& Animal studies have shown that the PPN is normally responsible for gait initia-
tion and stepping maintenance, and a recent paper reported a patient with freezing after 
a bilateral infarction of the PPN, thus suggesting  a clinical correlation in humans.&'%&(
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POSTURAL INSTABILITY AND THE LOCUS COERULEUS
In the remainder of this review, we propose the hypothesis that postural disturbances 
in PD are closely related to cell loss in one speci!c non-dopaminergic nucleus, namely 
the locus coeruleus and the resultant norepinephrine de!cit in the CNS. We realize that 
evidence supporting a link between balance impairment in PD and the locus coeru-
leus is only indirect. However, to support our hypothesis, we will carefully address all 
circumstantial evidence, !rst by reviewing the normal functions of the locus coeruleus. 
We then discuss how and when the locus coeruleus is likely to become involved in the 
pathophysiology of PD, drawing mainly on neuropathological and neurochemical evi-
dence. We conclude by summarizing the available data that therapeutic correction of the 
central norepinephrine de!cit might reduce postural disturbances in neurodegenerative 
disorders, including PD.
ANATOMY OF THE LOCUS COERULEUS
The locus coeruleus is a small nucleus (the rostrocaudal extent approximates 16 mm) 
which is situated bilaterally in the pontine tegmentum. Its neurons are pigmented due 
to presence of neuromelanin in the cell bodies. In the CNS, the locus coeruleus is the 
main source of norepinephrine&), an excitatory neurotransmitter which is metabolized 
mainly to 3-methoxy-4-hydroxy-phenyleneglycol (MHPG). The locus coeruleus also uses 
various neurotransmitters other than norepinephrine, and this includes among others 
glutamate, dopamine and GABA.&* However, these other neurotransmitters and their 
corresponding pathways are thought to be less important for the functions of the locus 
coeruleus. In humans, the locus coeruleus has been mapped through immunocyto-
chemical labeling of the biosynthetic enzymes tyrosine hydroxylase (TH) and dopamine-
beta-hydroxylase&+%&,, as well as by visualizing neuromelanin content.&+%'-%'"
Despite its relatively small size, the locus coeruleus innervates widespread areas in the 
CNS, including the spinal cord, neocortex, hippocampus and cerebellum.'$%'& Retrograde 
tracer transport studies in rats have identi!ed a topographic arrangement of these pro-
jections within the locus coeruleus. The more caudal and ventral part, which consist of 
densely packed small cells, contain neurons that project to the spinal cord and cerebel-
lum. The more rostral and dorsal part, which are formed by large multipolar cells, project 
mainly to the neocortex.'$%'' A single neuron originating within the locus coeruleus 
may branch to widely divergent areas, for example with one !ber to the spinal cord and 
another to the neocortex.
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NORMAL FUNCTIONS OF THE LOCUS COERULEUS
In accordance with these widespread projections, the locus coeruleus and its transmitter, 
norepinephrine, have rather diverse functions, including the regulation of autonomic re-
sponses, cognition and motor control. Interestingly, most functions could be important 
for normal balance control. First, studies of cats with acute spinal cord lesions suggest 
that noradrenergic systems are are involved in gait initiation.'(%') As this may involve 
the coeruleo-spinal noradrenergic pathway this raises the interesting question whether 
dysfunction of the locus coeruleus could underlie, at least in part, the freezing of gait 
phenomenon that, in turn, is one of the leading causes of falls in PD.'* Second, studies in 
rats, cats and monkeys found evidence that the locus coeruleus is activated in situations 
demanding immediate attention and coping responses.'+%',%(- Although the link is only 
very indirect, this function of the locus coeruleus could be relevant for balance control, 
because immediate handling of unexpected postural perturbations is of vital impor-
tance to prevent falls. The locus coeruleus is known to have various !ring patterns: tonic 
activity is positively correlated with the arousal state, while phasic activity is aroused by 
sensory stimuli.'+%(" In this respect, one might speculate that the phasic patterns of the 
locus coeruleus are more task-oriented and related to immediate action, whereas the 
tonic !ring patterns would re.ect a more continuous exploration of the environment 
and thereby help regulate postural control. Third, involvement of the locus coeruleus in 
autonomic regulation could also be relevant for balance control, because dysfunction 
could lead to orthostatic hypotension and thereby cause falls. Syncopal falls in PD ap-
pear to be relatively rare (perhaps because of inadequate ascertainment), but do occur in 
more advanced states of PD.($ Fourth, the coeruleospinal pathway appears to contribute 
to gain control of vestibulospinal limb re.exes.(&%('%(( For example, work in decerebrate 
cats subjected to passive neck rotation has shown that activation of coeruleo subcoe-
ruleospinal neurons is opposite to that of the lateral vestibulospinal neurons projecting 
to the same segments of the spinal cord.() Together, this functional coupling could assist 
in regulating the excitability of limb extensor motoneurons to neck stimulation. A link 
to human balance may be placed because gain control of vestibulospinal responses is 
important for regulating upright stance in healthy subjects, particularly when the head 
is being displaced.(*  Although direct evidence is lacking, it is possible that the in.uence 
of coeruleospinal pathways on excitability of limb extensor motoneurons may also a#ect 
other automatic balance responses in the legs that are involved in regulation of upright 
stance in response to externally imposed postural perturbations.(+%(, Gain control of 
these automatic  balance reactions is severely impaired in PD+%$*%)-, possibly due to loss of 
descending coeruleospinal in.uence., The controlling action of the locus coeruleus on 
the cerebellum may also be relevant in this respect, because cerebellar output is required 
to optimally tune postural re.exes.*%)"%)$ Finally, given its widespread projections, the lo-
cus coeruleus may play a coordinating role in linking di#erent brain functions. As balance 
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control requires a linkage between many di#erent brain areas and separate functional 
systems, including both motor and cognitive functions)&, the locus coeruleus could be 
adequate positioned to serve as “coordinator”. Again, dysfunction would lead to postural 
instability.
THE LOCUS COERULEUS IN PD "AND OTHER NEURODEGENERATIVE 
DISORDERS#
Neuropathological studies
Post-mortem brain studies of PD patients have identi!ed substantial cell loss in the 
locus coeruleus, particularly in its caudal part.)'%)( As this caudal part projects mainly to 
the spinal cord and cerebellum, it could well be related to balance impairment in PD. 
This cell loss in PD is likely superimposed upon the normal age-related decline of locus 
coeruleus cell volume, which relatively spares the caudal part of the locus coeruleus.&-%&, 
If the locus coeruleus is indeed involved in postural control, the combination of these 
two processes could explain why postural disturbances are a late manifestation of PD. 
To support this latter contention, it would be interesting to investigate whether cell loss 
in the locus coeruleus occurs mainly in advanced PD. Unfortunately, most post-mortem 
studies did not speci!cally investigate the in.uence of duration or severity of the disease. 
Two studies found no relation between disease duration and total cell loss within the 
locus coeruleus.))%)* However, total cell loss is possibly a poor parameter because, as 
stated earlier, cell loss in PD occurs especially in the caudal part of the locus coeruleus. 
According to the Braak staging of neuropathology of PD, lesions in the caudal brainstem 
precede pathology in the mesencephalon.)+ This would argue against a role in producing 
postural instability, as this is typically a late feature of PD. In fact, this raises the interest-
ing question whether an isolated lesion in the locus coeruleus would su/ce to produce 
postural abnormalities or balance impairment, even in the absence of a concurrent le-
sion in the substantia nigra. Answering this question would require selective lesioning 
studies in primates (which is technically possible), followed by careful control of changes 
in posture and balance, but this has thus far never been done. Finally, it is worth noting 
that accelerated cell loss in the locus coeruleus also occurs in other neurodegenerative 
diseases. A disease that bears particular mention in this regard is progressive nuclear 
palsy (PSP) where early, severe postural instability and high fall rates are a prominent 
feature.), Cell loss in the locus coeruleus of PSP has been reported, but the extent to 
which cell loss occurs is controversial,and cell counts have not been directly studied in 




Consistent with the reported cell loss in the locus coeruleus of PD patients, most CSF anal-
yses and post-mortem studies have shown reduced levels of norepinephrine.*"%*$%*&%*'%*(%*) 
However, a few studies did not !nd such a reduction, perhaps because of di#erences in 
patient material or the techniques that were used.**%*+ Unlike norepinephrine itself, CSF 
levels of its main metabolite MHPG are not signi!cantly reduced."$%&)%*' However, MHPG 
does not re.ect adrenergic activity accurately because, unlike norepinephrine, MHPG is 
rapidly exchanged across the blood-brain barrier (BBB).
The post-mortem brain studies rarely reported a clinical correlate of the observed patho-
logical changes. The possible clinical relevance was addressed in several CSF studies, 
but postural disturbances were only mentioned  rarely. However, one study reported a 
signi!cant correlation between the reduced concentration of norepinephrine and the 
severity of clinically rated gait and postural disturbances in PD.*$ In another study, levels 
of norepinephrine were signi!cantly reduced in PD patients with a frozen gait, again 
linking the locus coeruleus to falling via freezing of gait.*"
Neuroimaging studies
Nuclear imaging techniques using position emission tomography (PET) or single photon 
emission computed tomography (SPECT) can assess various neurotransmitter functions. 
There is increasing attention for speci!c markers of non-dopaminergic functions, includ-
ing the noradrenergic system.*, A PET study that examined the uptake of ""C-RTI 32 (a 
combined marker for noradrenaline and dopamine transporter binding) showed a lower 
uptake in the locus coeruleus of depressed patients with PD+-, suggesting an in.uence 
of noradrenergic function on mood. Balance was not assessed in this study. Based on the 
hypothesis put forth in the article, we would argue that attempts to explore the role of 
noradrenergic dysfunction in PD by developing imaging techniques that could assess 
the integrity of the locus coeruleus are both needed and fully warranted.
CORRECTION OF THE CENTRAL NOREPINEPHRINE DEFICIT
Another way to demonstrate a role for the locus coeruleus on balance control is to ex-
plore the therapeutic e#ects of pharmacologically replenishing the central norepineph-
rine de!ciency. Noradrenergic drugs have mainly been tested because of their potential 
to suppress levodopa-induced dyskinesias.+" However, several investigators have used 
noradrenergic drugs with the speci!c aim of improving gait or balance (Table 1).
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Dihydroxyphenylserine 
There are several possibilities to correct the central norepinephrine de!cit. Thus far, the 
compound dihydroxyphenylserine (DOPS), a synthetic precursor of norepinephrine, has 
been studied most extensively. DOPS has four di#erent stereoisomers that are termed 
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L-threo-, D-threo-, L-erythro and D-erythro-DOPS. The L-isomer is converted directly 
to natural (-)-norepinephrine by aromatic L-amino acid decarboxylase. By contrast, D-
threo-DOPS inhibits the decarboxylation of L-threo-DOPS in vitro+$ and is therefore theo-
retically unsuitable for restoring norepinephrine levels. Nonetheless, both L-threo-DOPS 
and racemic mixtures of both D- and L-threo-DOPS have been used in therapeutic trials.
(D) L-threo-DOPS can restore depleted norepinephrine levels in plasma of both rats+&  and 
humans, including patients with postprandial hypotension+', DßH de!ciency+(, multiple 
system atrophy+) or PD+*. (D) L-threo-DOPS can pass across the BBB of PD patients.++%+,%,- 
However, there is disagreement as to whether (D) L-threo-DOPS can actually increase 
norepinephrine concentrations in the CSF. Several investigators could not detect an 
increase in norepinephrine or its metabolites in the CSF after administration of L-threo- 
or (D) L-threo-DOPS to rats,"%,$ and patients with PD.+,%,- Conversely, others have found 
increased MHPG-levels in the brains of mice after administration of L-threo-DOPS.,&%,' 
Signi!cantly, Tohgi and colleagues found a dose-dependent increase in norepinephrine 
concentrations in the CSF after long-term administration of L-threo-DOPS to patients 
with PD.,(%,)
Several investigators have studied the in.uence of L-threo-DOPS on various ‘non-
dopaminergic’ manifestations of PD, including freezing, gait impairment, retropulsion 
and postural disturbances. Quinn et al.  found no improvement of freezing of gait in 
a single-dose, placebo-controlled study of (D) L-threo-DOPS in six PD patients.,* Nara-
bayashi et al. studied the e#ect of oral L-threo-DOPS in a prospective, double blind and 
placebo-controlled study of 226 patients with longstanding PD (Hoehn and Yahr stages 3 
and 4) and related disorders.,+ After six weeks of treatment, gait, retropulsion and festina-
tion had improved according to the clinical impression of a neurologist. Unfortunately 
this study did not ascertain balance changes with objective assessments as dynamic 
posturography. Another study reported that administration of (D) L-threo-DOPS during 
10 days improved clinically rated gait impairment in a small group of four patients with 
longstanding PD in an open uncontrolled study.+, Tohgi et al. noted a moderate to marked 
improvement of freezing in three out of six PD patients (Hoehn and Yahr stage 3 and 4) 
treated with L-threo-DOPS.*" In a later extended study, freezing improved signi!cantly in 
7 out of 13 patients, but again this was not a controlled study.,) Freezing was assessed in 
four grades while watching the patient walk 10 meters up and down; an improvement by 
more than one grade was considered signi!cant. Other Japanese investigators reported 
improvement of postural control and freezing of gait by L-threo-DOPS in Parkinson pa-
tients, but these were open trials and details on the outcome parameters of these studies 
are di/cult to obtain.,,%"--
31
 Postural instability in Parkinson’s disease:  the adrenergic hypothesis and the locus coeruleus 
2
(D) L-threo-DOPS has also been tested in patients with other neurodegenerative dis-
orders. For example, (D) L-threo-DOPS can reduce orthostatic hypotension in patients 
with severe autonomic failure"-", and such e#ects could also be relevant for patients with 
PD su#ering from syncopal falls. Its e#ect on orthostatic hypotension has never been 
compared directly with other anti-orthostatic measures. Autonomic failure is particularly 
problematic in patients with multiple system atrophy (MSA), and one study found an in-
creased upright blood pressure after administration of L-threo-DOPS to four patients with 
MSA.+) In a single blind placebo-controlled study of two patients with DßH de!ciency, 
stance ability was prolonged after DL-threo-DOPS administration.+( Interestingly, (D) L-
threo-DOPS may also ameliorate orthostatic hypotension in PD patients. One preliminary 
report mentioned a signi!cant increase in standing blood pressure in PD patients."-$ In 
addition, subjective complaints of orthostatic hypotension disappeared in seven out of 
twelve patients.
One caveat to using L-threo-DOPS needs to be mentioned. While it may elevate norepi-
nephrine levels, (D) L-threo-DOPS may adversely a#ect dopamine levels. Thus, cerebral 
dopamine levels were signi!cantly decreased in rats after administration of L-threo-
DOPS."-& It is unclear whether norepinephrine levels were actually increased. Similar 
mechanisms may exist in humans, as the raised dopamine plasma concentration of a 
patient with DßH de!ciency was reduced during treatment with DL-threo-DOPS."-' By 
contrast, norepinephrine concentration in plasma was raised and the patient was free 
of orthostatic symptoms. However, in another study, dopamine concentrations in the 
CSF did not change in patients treated with levodopa prior to L-threo-DOPS adminis-
tration.*"%,) In fact, dopamine levels actually increased in patients who received only 
L-threo-DOPS. Therefore, the precise e#ects of L-threo-DOPS on dopamine metabolism 
remain unresolved. However, the potential inhibition of dopamine by L-threo-DOPS 
could obviously limit its use in the treatment of PD and could partially explain the thus 
far disappointing results with this compound.
Idazoxan
Another pharmacological strategy aimed at restoring central norepinephrine de!cit is 
to use the  selective alpha-2 adrenoreceptor inhibitor idazoxan. Activation of the pre-
synaptic alpha-2 receptor decreases norepinephrine transmission in the locus coeruleus. 
Hence, inhibition of this receptor with compounds such as idazoxan should boost nor-
epinephrine neurotransmission. The !rst relevant experiment with idazoxan involved a 
double-blind crossover study of nine patients with PSP. Treatment over 4 weeks resulted 
in signi!cant improvement in the ability to rise from a chair, as well as in gait and postural 
instability."-( This improvement was scored by a physician according to, among others, 
the UPDRS and global assessment by patients on a 4-point scale. Thus far, idazoxan has 
not been tested in PD with a speci!c focus on assessing gait and postural instability. A 
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drawback could be the dose-dependent side-e#ects, such as hypertension and head-
ache. A study on the e#ects of idazoxan on levodopa-induced dyskinesias showed a 
drop-out rate of 50% at a dose of 60 mg/day."-) Moreover, a large phase III trial that aimed 
to examine the e#ects of idazoxan on levodopa-induced dyskinesias was terminated 
early for unpublished reasons"-*, but perhaps this was owing to tolerability problems.
Methylphenidate
Methylphenidate, a drug traditionally used to combat attention-de!cit/hyperactiv-
ity disorder, has predominantly dopaminergic e#ects through blocking presynaptic 
dopamine re-uptake. However, it  may also improve noradrenergic neurotransmission 
by presynaptic inhibition of the norepinephrine transporter."-+ Recent work has shown 
that methylphenidate can decrease fall risks in community dwelling older adults, either 
by increasing the availability of central dopamine and norepinephrine or by improving 
attention."-, Three further trials have shown that methylphenidate can also improve gait 
and freezing in patients with PD.""-%"""%""$ However, another double-blind, randomized 
placebo-controlled cross-over study in 13 PD patients failed to demonstrate a clinically 
relevant e#ect on walking speed""&, but these are very small numbers.  Furthermore, 
postural stability was not speci!cally tested in any of these studies, so the jury is still 
undecided with respect to methylphenidate.
COULD OTHER NON!DOPAMINERGIC NEUROTRANSMITTERS BE INVOLVED?
Of course there the possibility remains that loss of other non-dopaminergic neurotrans-
mitters also play a role in the pathophysiology of postural disturbances in PD. Biochemical 
analyses of CSF and post-mortem neuropathological studies of PD brains have identi!ed 
various other ‘non-dopaminergic’ lesions, besides the lesion in the locus coeruleus. We 
previously mentioned the mixed cholinergic-glutaminergic PPN and its presumed role 
in gait disturbances. Other examples include serotonin and choline acetyltransferase, 
whose levels are also reduced in patients with PD.&-%""'%""( Serotonin is an interesting 
candidate player in the pathophysiology of postural instability in PD, because in one 
study, serotonin levels in the CSF were signi!cantly lower in PD patients with severe 
postural instability and gait disorders, compared with a control group of  PD patients 
with predominantly hyperkinetic symptoms.""( However, a 4-week treatment with L-5-
hydroxytryptophan, a biosynthetic precursor of serotonin, did not improve balance in a 
small group of six PD patients in an open label trial."") Therefore, at the current time there 
is no compelling evidence that correction of the serotonergic de!cit would be likely to 
improve postural disturbances in PD. Acetylcholine is the second interesting candidate, 
mainly because cholinergic de!ciencies seem responsible for at least some of the cogni-
tive de!cits in PD. This is relevant because gait and balance are now increasingly seen as 
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a’ cognitive disorder’, and it has been speculated that cholinesterase inhibitors should 
be tested as adjunctive treatment for gait and balance de!cits in PD.""* However, at the 
present time there is no compelling evidence to suggest that cholinesterase inhibitors 
lead to signi!cant improvements of gait and balance. Once again, this leaves cell loss in 
the locus coeruleus as the prime suspect. 
A COMBINATION OF DOPAMINERGIC AND NON!DOPAMINERGIC LESIONS?
Before concluding, we wish to reiterate that postural disturbances in PD are most likely 
related to the combined presence of both non-dopaminergic lesions – in particular a 
central norepinephrine depletion due to cell loss in the locus coeruleus – and a concur-
rent dopaminergic lesion. This view is supported by our severely a#ected patients with 
MPTP-induced parkinsonism, whose gait and balance were markedly compromised, yet 
they almost certainly had a selective nigrostriatal lesion and a severe hypodopaminergic 
syndrome."( Indeed, CSF studies in these patients con!rmed the presence of a selective 
central dopamine de!ciency, possibly even with a compensatory increase in norepi-
nephrine turnover.""+ Gait and balance also improved considerably when these patients 
!rst received levodopa, and this is also common clinical experience in early stages of PD, 
a situation in which gait bradykinesia can improve with dopaminergic therapy. Freez-
ing of gait is typically seen in the ‘o# ’ state'*, and most patients with freezing improve 
with dopaminergic therapy (‘on’ state freezing is a relatively rare phenomenon). Finally, 
although balance impairment is usually refractory to dopaminergic treatment, careful 
analyses using dynamic posturography have shown that some postural abnormalities 
can be at least partially dopa-responsive. Thus, static sway (in some reports"",, but not 
all"$-), voluntary weight shifts"$", some automatic postural responses$&, anticipatory 
postural adjustments"$$, voluntary toe rises"$& and compensatory steps"$' improved to 
some extent in PD patients after levodopa administration, albeit typically not to normal 
levels. One might even speculate that some of the balance abnormalities in PD are only 
seemingly refractory to dopaminergic treatment, because by the time postural instabil-
ity emerges, the central dopamine loss has become so severe that it can no longer be 
overcome by mounting doses of oral levodopa. Furthermore, in this stage of the disease, 
the cumbersome side e#ects of levodopa become an important dose-limiting factor. 
For practicing clinicians, it is therefore always worth trying to treat postural instability 




EXPERT COMMENTARY AND FIVE!YEAR REVIEW
In this review, we have argued for the hypothesis that postural disturbances in advanced 
PD may well be related to a combination of a severe central dopamine loss, plus a concur-
rent norepinephrine de!ciency caused by cell loss in the locus coeruleus. This adrenergic 
hypothesis should now be tested directly in prospective, randomized and placebo-
controlled trials, designed to investigate the in.uence of norepinephrine precursors on 
postural instability in PD. Ideally, such trials should be controlled and include appropriate 
(relevant and reliable) outcome measures. Evaluation of treatment e#ects should not 
just rely on clinically based measures of balance impairment (such as the retropulsion 
test), because clinical judgments are subjective and di/cult to standardize.( Additional 
outcome measures should include a prospective assessment of fall rates during a suf-
!cient time frame (at least six months), standardized balance and gait rating scales, and 
objective measures of postural instability using dynamic posturography. Quality of life, 
as a re.ection of regained mobility and con!dence, should also be an outcome measure. 
If successful, such studies would provide a much welcome therapeutic approach to a 
hitherto poorly treatable and incapacitating feature of PD, and one of the leading causes 
of disability as the disease progresses.
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We studied prospectively the epidemiology, clinical impact and prediction of falls in 59 
moderately a#ected patients with Parkinson’s disease (PD) (mean UPDRS motor score 
31.5;mean age 61 years) and 55 controls (mean age 60 years).At baseline, balance and 
gait were evaluated extensively. The retropulsion test (response to sudden shoulder pull) 
was executed !rst unexpectedly and !ve more times following prior warning. All persons 
used standardised scoring forms to document their falls during six months. 
Thirty patients (50.8%) and eight controls (14.5%) fell at least once (relative risk [RR] 
6.1;95% con!dence interval [CI] 2.5–15.1,p < 0.001).Recurrent (12) falls occurred in 
15 patients (25.4%), but in only two controls (RR 9.0;95% CI 2.0–41.7;p=0.001). Recur-
rent falls were more common among persons taking benzodiazepines (RR 5.0;95% CI 
1.6–15.5;p < 0.01). Sixty-two percent of the falls in patients caused soft tissue injuries, 
but no fractures occurred. A fear of future falls was common (45.8% of patients) and was 
accompanied by restriction of daily activities (44.1% of patients). Seventy percent of falls 
reported by patients were ‘intrinsic’ (due to patient-related factors), but falls in controls 
were mainly (50%) ‘extrinsic’ (due to environmental factors). None of the baseline posture 
and gait variables predicted falls adequately. The !rst ‘unexpected’retropulsion test was 
more often abnormal than all subsequent (predictable) tests. Irrespective of its method 
of execution, the retropulsion test did not predict falls. A combination of asking for prior 
falls, disease severity and the Romberg test yielded the best overall diaginostc utility 
(sensitivity 65% and speci!city 98%). Recurrent fallers were best predicted by disease 
severity (RR for Hoehn and Yahr stage 3 was > 100; 95% CI 3.1–585) and asking for prior 
falls (RR 5.0; 95% CI 1.2–20.9). We conclude that falls are common and disabling, even 
in relatively early stage PD. Recurrent fallers were best predicted by disease severity 
and presence of prior falls. Strategies to prevent falls in PD should particularly focus at 
intrinsic (patient-related) factors, such as minimising the use of benzodiazepines. 
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INTRODUCTION 
Postural instability and falls are among the most incapacitating features of Parkinson’s 
disease (PD)."%$' The epidemiology of falls in PD remains largely unknown. Furthermore, 
prediction of falls is di/cult. Because history taking is often unreliable"*, clinicians 
depend upon clinical tests to estimate falling risks. The ‘retropulsion test’ (also termed 
‘sternum push’ or ‘pull test’) is commonly used to probe postural instability$)%&', but this 
test can be criticised for several reasons.' 
We therefore prospectively investigated falls in PD. Our goal was to clarify the epide-
miology, circumstances and clinical impact of falls. We also examined what clinical test 
(including the retropulsion test) could predict falls in daily life. A more detailed account 
of the fall circumstances has been presented elsewhere.'' 
METHODS 
Subjects 
We studied 59 patients with idiopathic PD and 55 age-matched controls (Table 1). Subjects 
were eligible subjects if they were ambulant community residents (with or without walking 
aids) and able to follow simple instructions (Mini Mental State Examination [MMSE] 1 24). 
We included only patients who full!lled the criteria for idiopathic PD as de!ned by the brain 
bank of the United Kingdom Parkinson’s Disease Society$" and who sustained a clear and 
lasting bene!cial response to chronic treatment with levodopa and/or a dopamine agonist 
(see below for details of medication)."' Exclusion criteria were any other neurological dis-
Table 1. Baseline clinical characteristics. Data are displayed as mean ± standard deviation or as the number 
of persons, as well as the number of persons for which this information was available (percentage between 
parentheses).
Patients (N = 59) Controls (N = 55) Signi$cance
Demographics
Age (years) 60.8  ±  9.7 59.6  ±  8.5 p = 0.51
Women 21/59 (35.6) 37/55 (67.3) p = 0.001
Living with partner 48/59 (84.2) 50/55 (90.9) p = 0.39
Stairs within the house 46/59 (78.0) 44/55 (80.0) p = 0.82
(Partially) dependent for 
ADL
23/59 (39.0)   0/55 (  0.0) p < 0.001
Alcohol (units/day)   0.8 ±   1.0   1.3  ±  1.4 p = 0.03
Duration of disease (years)   7.1 ±   4.8        —        —
Age (years) 60.8  ±  9.7 59.6  ±  8.5 p = 0.51
Women 21/59 (35.6) 37/55 (67.3) p = 0.001




Patients (N = 59) Controls (N = 55) Signi$cance
Stairs within the house 46/59 (78.0) 44/55 (80.0) p = 0.82
(Partially) dependent for 
ADL
23/59 (39.0)   0/55 (  0.0) p < 0.001
Fall questionnaire
Number of prior falls (£ 6 
months)
  2.1 ±   5.4   0.3 ±   0.5 p = 0.16
Fallers (£ 6 months) 23/59 (39.0) 15/55 (27.3) p = 0.23
Fear of falling 27/59 (45.8)   4/59 (  7.4) p < 0.001
Restriction of activities 26/59 (44.1)   6/54 (11.1) p < 0.001
Problems with multiple 
tasks 
31/54 (57.4)   3/48 (  6.3) p < 0.001
Walking aids 13/58 (22.4)   0/55 (  0.0) p < 0.001
Neurological examination
Hoehn & Yahr stage   2.3 ±   0.7        —        —
UPDRS motor score 31.5 ± 11.0   0.8  ±  1.7 p < 0.001
UPDRS total score 48.3 ± 15.2   1.8  ±  2.1 p < 0.001
MMSE 28.1 ±   2.0 29.2  ±  1.2 p < 0.001
Gait and balance
Tinetti balance score   3.9 ±   3.0   0.4 ±   0.7 p < 0.001
Tinetti gait score   2.7 ±   2.3   0.1 ±   0.3 p < 0.001
Tinetti total score   6.6 ±   4.8   0.4 ±   0.8 p < 0.001
Romberg test   3/58 (  5.2%)   0/55 (  0.0%) p = 0.24
Orthostatic hypotension   7/35 (20.0%)   3/30 (10.0%) p = 0.32
Tandem stance
   Eyes open 23/59 (39.0%)   2/55 (  3.6%) p < 0.001
   Eyes closed 44/59 (74.6%) 23/55 (41.8%) p = 0.001
Tandem gait 24/56 (42.9%)   5/54 (  9.3%) p < 0.001
Standing up   9/58 (15.5%)   1/55 (  1.8%) p = 0.02
Sitting down 19/53 (32.8%)   0/55 (  0.0%) p < 0.001
Turning around 36/58 (62.1%)   2/55 (  3.6%) p < 0.001
Reaching   1/39 (  2.6%)   0/35 (  0.0%) p = 0.53
Picking up object from 
.oor
  3/39 (  8.3%)   0/35 (  0.0%) p = 0.24
Stops walking when 
talking
  7/58 (12.1%)   0/55 (  0.0%) p = 0.01
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orders, and visual or orthopaedic problems that were su/ciently severe to interfere with 
balance. We asked all eligible patients who visited our outpatient department between 
May 1998 and July 1999 to participate (Figure 1). Sixty-one patients consented to partici-
pate, but two of them were later excluded because they were lost to follow-up shortly after 
inclusion (one patient died, one patient could no longer be reached). Age and sex of the 
remaining 59 patients were comparable to the entire outpatient population. Thirty-eight 
healthy partners of the patients were chosen as controls because their domestic risk factors 
for falls are identical to those of the patients. This is important because domestic variables 
such as stairs and slippery .oors are important risk factors for falls.'" For the same reason, 
domestic variables of the remaining 17 controls (healthy acquaintances of the patients or 
the investigators) were matched to those of the patients. The exclusion criteria used for the 
patients also applied to the controls. Medication taken during the study included levodopa 
(50 patients), dopamine receptor agonists (36 patients), anticholinergics (seven patients), 
amantadine (30 patients), selegiline (six patients), tolcapone (one patient), atypical neu-
roleptics (six patients), antidepressants (!ve patients), benzodi-azepines (16 patients and 
three controls) and antihypertensive drugs (nine patients and 10 controls). All subjects 
gave informed consent, as approved by the Ethical Committee of Leiden University Medical 
Centre. 
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We therefore prospectively investigated fall  in PD. Our
goal was to clarify the epidemiology, circumstances and
clinical impact of falls. We also examined what clinical
test (including the retropulsion test) could predict falls
in daily life. A more detailed account of the fall circum-
stances has been presented elsewhere [44].
Methods
! Subjects
We studied 59 patients with idiopathic PD and 55 age-matched con-
trols (Table 1). Subjects were eligible subjects if they were ambulant
community residents (with or without walking aids) and able to fol-
low simple instructions (Mini Mental State Examination [MMSE] !
24).We included only patients who fullfilled the criteria for idiopathic
PD as defined by the brain bank of the United Kingdom Parkinson’s
Disease Society [21] and who sustained a clear and lasting beneficial
response to chronic treatment with levodopa and/or a dopamine ag-
onist (see below for details of medication) [14]. Exclusion criteria
were any other neurological disorders, and visual or orthopaedic
problems that were sufficiently severe to interfere with balance. We
asked all eligible patients who visited our outpatient department be-
tween May 1998 and July 1999 to participate (Fig. 1). Sixty-one pa-
tients co sented to participate, but two of them were later excluded
because they were lost to follow-up shortly after inclusion (one pa-
tient died, one patient could no longer be reached).Age a d sex of the
remaining 59 patients were comparable to the entire outpatient pop-
ulation. Thirty-eight healthy partners of the patients were chosen as
controls because their domestic risk factors for falls are identical to
those of the patients. This is important because domestic variables
such as stairs and slippery floors are important risk factors for falls
[41].For the same reason,domestic variables of the remaining 17 con-
trols (healthy acquaintances of the patients or the inves igators) were
matched to those of the patients. The exclusion criteria used for the
patients also applied to t e controls. Medication taken during the
study included levodopa (50 patients), dopamine receptor agonists
(36 patients), anticholinergics (seven patients), amantadine (30 pa-
tients), selegiline (six patients), tolcapone (one patient), atypical neu-
roleptics (six patients), antidepressants (five patients), benzodi-
Table 1 Baseline clinical characteristics. Data are displayed as mean ± standard
deviation or as the number of persons, as well as the number of persons for which
this information was available (percentage between parentheses).
Patients Controls Significance
(N = 59) (N = 55)
Demographics
Age (years) 60.8 ± 9.7 59.6 ± 8.5 p = 0.51
Women 21/59 (35.6) 37/55 (67.3) p = 0.001
Living with partner 48/59 (84.2) 50/55 (90.9) p = 0.39
Stairs within the house 46/59 (78.0) 44/55 (80.0) p = 0.82
(Partially) dependent for ADL 23/59 (39.0) 0/55 (0.0) p < 0.001
Alcohol (units/day) 0.8 ± 1.0 1.3 ± 1.4 p = 0.03
Duration of disease (years) 7.1 ± 4.8 – –
Fall questionnaire
Number of prior falls 2.1 ± 5.4 0.3 ± 0.5 p = 0.16
(" 6 months)
Fallers (" 6 months) 23/59 (39.0) 15/55 (27.3) p = 0.23
Fear of falling 27/59 (45.8) 4/59 (7.4) p < 0.001
Restriction of activities 26/59 (44.1) 6/54 (11.1) p < 0.001
Problems with multiple tasks 31/54 (57.4) 3/48 (6.3) p < 0.001
Walking aids 13/58 (22.4) 0/55 (0.0) p < 0.001
Neurological examination
Hoehn & Yahr stage 2.3 ± 0.7 – –
UPDRS motor score 31.5 ± 11.0 0.8 ± 1.7 p < 0.001
UPDRS total score 48.3 ± 15.2 1.8 ± 2.1 p < 0.001
MMSE 28.1 ± 2.0 29.2 ± 1.2 p < 0.001
Gait and balance
Tinetti balance score 3.9 ± 3.0 0.4 ± 0.7 p < 0.001
Tinetti gait score 2.7 ± 2.3 0.1 ± 0.3 p < 0.001
Tinetti total score 6.6 ± 4.8 0.4 ± 0.8 p < 0.001
Romberg test 3/58 (5.2 %) 0/55 (0 %) p = 0.24
Orthostatic hypotension 7/35 (20 %) 3/30 (10 %) p = 0.32
Tandem stance
Eyes open 23/59 (39 %) 2/55 (3.6 %) p < 0.001
Eyes closed 44/59 (74.6 %) 23/55 (41.8 %) p = 0.001
Tandem gait 24/56 (42.9 %) 5/54 (9.3 %) p < 0.001
Standing up 9/58 (15.5 %) 1/55 (1.8 %) p = 0.02
Sitting down 19/53 (32.8 %) 0/55 (0 %) p < 0.001
Turning around 36/58 (62.1 %) 2/55 (3.6 %) p < 0.001
Reaching 1/39 (2.6 %) 0/35 (0 %) p = 0.53
Picking up object from floor 3/39 (8.3 %) 0/35 (0 %) p = 0.24
Stops walking when talking 7/58 (12.1 %) 0/55 (0 %) p = 0.01
Fig. 1 Selection procedure for the patients.
Fig 1 Selection procedure for the patients.
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Baseline clinical examination 
The same investigator (BRB) examined all subjects (patients approx- imately one hour 
after intake of their usual medication). Baseline examination included a medical history, 
detailed evaluation of prior falls (using a standardised questionnaire) and a neurologi-
cal examination, including the modi!ed Hoehn and Yahr stages, the Uni!ed Parkinson’s 
Disease Rating Scale (UPDRS)$) and the MMSE. Individual Hoehn & Yahr scores were 
stage 1 (N=5), stage 1.5 (N=5),stage 2 (N=19),stage 2.5 (N=11),stage 3 (N=18) and 
stage 4 (N=1).To reduce di#erences in answers due to e.g. education, the standardised 
questionnaire about falls was administered in the form of a personal interview. This was 
always performed in the presence of a partner, other close family member or carer, and 
these persons were asked to con!rm the accuracy of all answers whenever possible. In 
addition, the standard questions were further clari!ed if patients misinterpreted our 
questions or volunteered ambiguities. The standardised interview included a descrip-
tion of living circumstances (alone or with partner / carer; presence of stairs yes/no), 
dependence (none, partial, or complete) in activities of daily living (ADL), accounts of 
recent falls (26 months),any fear of falling, any restrictions in daily activities because of 
this fear, and any problems with simultaneous performance of multiple tasks in daily life. 
Before asking about prior falls, we explained the de!nition of a fall as ‘any unexpected 
event that caused the person to unintentionally land on any lower surface (object, .oor, 
or ground), regardless of any sustained injury’.""%$(%$, We restricted the account of recent 
falls to a 6-month period to minimise the risk of recall bias."* The question about prob-
lems with simultaneous performance of multiple tasks in daily life was illustrated by two 
standard examples (“We will give you two examples. In the last six months, did you have 
more di/culty than previously to walk and talk to someone at the same time? Did you 
have more di/culty than previously to walk and carry something in your hands?”). These 
two examples were chosen because elderly persons and Parkinson patients are known 
to have di/culty with these tasks.)%,%$*%$+ We also posed an open question about problems 
with any other simultaneous tasks. Persons were regarded as fallers if they reported at 
least one previous fall in the preceding six months. Equilibrium and mobility were tested 
with Tinetti’s Mobility Index'-, the normal Romberg test, the sharpened Romberg test (i.e. 
standing with eyes open and eyes closed, with the feet in tandem stance) &*, tandem gait 
(walking 10 steps with feet directly in front of each other), reaching for an object (stan-
dardised for each subject at a level just above the head) and bending forward to pick up 
an object from the .oor. These additional tests were scored as either normal or abnormal. 
The ‘Stops walking when talking’test$* was also administered. The results of this test in 
the !rst 38 patients and 35 controls are brie.y described elsewhere.( In 35 patients and 
30 controls, blood pressure was measured in a recumbent position and after two minutes 
of standing. Orthostatic hypotension was de!ned as a drop in systolic blood pressure 
of more than 20mm Hg or a drop in diastolic blood pressure of more than 10mm Hg.&$ 
Speci!c attention was paid to the retropulsion test, which is commonly used to probe 
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postural disturbances in PD.$) Despite widespread clinical use, it remains unclear how 
the retropulsion test should be executed. The patient can be warned verbally or prepared 
by practice$)%&,%'$, but some authors claim that the !rst and most unexpected test is most 
informative.'%&' We therefore assessed several variants of the retropulsion test to identify 
the best predictive version. The test consisted of a sudden and unexpected shoulder pull, 
performed by an examiner standing behind the person.'%$) In all subjects,the test was 
executed the !rst time without any warning. Directly thereafter, the retropulsion test was 
repeated with prior warning. In 39 patients and 35 controls, the test was repeated four 
additional times with prior warning to study habituation e#ects.+ The amount ofretropul-
sion was scored as described by the Parkinson’s Study Group.$) In addition, we counted 
the number of backward steps needed to restore balance. 
Prospective assessment of falls 
Both patients and controls were instructed to directly document the circumstances and 
consequences (injuries or fear) of all falls for six months, using standardised scoring forms. 
Subjects were asked to describe the fall in their own words, and to tick pre-speci!ed 
options regarding the environment where the fall occurred (indoors or outdoors), the 
speci!c activity at the time of the fall and any complaints that preceded the fall. Subjects 
were also asked to tick whether they performed multiple tasks simultaneously at the 
time of the fall. Patients recorded the e#ect of their antiparkinson medication at the time 
of the fall, by ticking one o the three following options: (a) insu/cient e#ect, very sti# 
and slow; (b) good e#ect, not very sti# and slow; or (c) good e#ect, but excessive involun-
tary movements (‘dyskinesias’). Persons were carefully instructed to return these scoring 
forms by mail directly after each fall. In addition, persons were contacted by telephone 
every two weeks to assure that all falls were documented. 
Persons were classi!ed as a ‘faller’ if they su#ered at least one fall, whereas ‘recurrent fall-
ers’ had at least two falls. ‘Injurious fallers’ were persons who sustained fractures or soft 
tissue injuries (including bruises, skin lacerations, haematomas and joint dislocations) 
after at least one fall. Finally, persons were de!ned as ‘serious fallers’ if their falls were 
recurrent (12), injurious, or both. This variable encompasses all clinically relevant falls. 
Recurrent falls are a better index of chronic disorders than single falls, which are often 
caused by environmental accidents with a low recurrence rate&& and therefore have little 
clinical importance, unless injury occurs. Based upon the answers to the scoring forms, 
we scored a fall as ‘extrinsic’ if it was caused by an environmental cause (e.g. collisions), as 
‘intrinsic’ if it was caused by mobility or balance disorders, misperception of the environ-
ment or loss of consciousness, and as ‘non-bipedal’ if it occurred while the person was not 
in a bipedal stance (e.g. fall from a chair).$( Falls were also categorised as ‘base of support 
falls’ (e.g. trips or slips), ‘centre of mass falls’, either self-induced (e.g. bending, reaching or 
turning) or externally applied (e.g .a push or collision), or as falls in which there was no 
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obvious perturbation (with or without loss of consciousness).$, The remaining falls were 
labelled as ‘unclassi!ed’. 
Statistical analyses 
Baseline variables were compared between patients and controls using the unpaired t-
test, the chi square test and Fisher’s exact test, with a p-value of 0.01 as a Bonferroni-type 
correction. Duration of the disease was compared between fallers and non-fallers using 
the unpaired t-test. The recurrent fallers of both groups will be reported as the primary 
outcome measure. However, very similar results were obtained when single, serious 
or injurious falls were used as the primary outcome variable, and when patients were 
analysed separately. The sensitivity and speci!city for prediction of recurrent falls were 
calculated for all baseline variables. In addition, stepwise forward logistic regression 
analysis was performed to evaluate which combination of variables best predicted recur-
rent falls. In this model, we successively entered variables from the baseline history (age, 
sex, alcohol use, dependence in ADL, disease duration), the prior fall history (faller status, 
fear of falls, restriction of activities, problems with multiple tasks, use of walking aids), 
the general physical examination (Hoehn and Yahr stages, UPDRS score) and, !nally, the 
balance and gait examination (Tinetti score and the additionally recorded measures).
RESULTS 
Baseline assessment (Table 1) 
There were more women among controls than among patients (a consequence of our 
choice for partners, rather than sex-matched persons, as controls). Domestic variables (as 
exempli!ed in Table 1 by the proportions of subjects that lived together with a partner, 
and by the proportions of subjects with stairs within the house) did not di#er between 
patients and controls. Patients were more often dependent for ADL than controls. The 
MMSE of patients was slightly but signi!cantly lower than in controls, but owing to our 
inclusion criteria, none of the patients had obvious cognitive impairment. The average 
number of prior falls and the proportion of self-reported fallers (11 fall) during the six 
previous months were somewhat higher for patients than controls, but these di#erences 
were not signi!cant. Almost 50% of patients expressed a fear of falling. A restriction of 
daily activities because of this fear was also more common among patients than controls. 
Furthermore, many patients reported di/culties with simultaneous performance of 
multiple tasks, such as walking and carrying a tray. 
Patients performed worse than controls on most tests of balance and gait (Table 1). 
Tandem stance with eyes closed was most often abnormal in patients, but also in about 
42% of the controls. Balance while turning and tandem gait were also sensitive measures 
of PD, and these tests were rarely abnormal in controls. Several other measures, such 
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as the Romberg test and orthostatic hypotension, did not di#er between patients and 
controls. The ‘Stops walking when talking test’ was abnormal in only seven patients, and 
in none of the controls. 
The responses to the six consecutive retropulsion tests are shown in Figure 2. The !rst 
retropulsion test (i.e. without prior warning) was abnormal (UPDRS score 11) in 10 pa-
tients (16.9%) and six controls (10.9%;p = 0.55). Only three patients and one control had 
to be caught by the examiner (UPDRS score = 2). No person had a spontaneous tendency 
to fall (UPDRS score = 3). Most corrective steps were taken after the !rst unexpected 
shoulder pull by both patients (1.6 ±1.3) and controls (1.6 ±1.2;p = 0.81). Overall, for sub-
jects who received six consecutive retropulsion tests, test abnormality decreased with 
warning and repetition in patients and controls (p < 0.001),both for the UPDRS score 
and the number of corrective steps taken. These warning and learning e#ects did not 
di#er between both groups (p = 0.47). The warning and learning e#ects were largely 
attributable to the second test, which was performed better than the !rst test in both 
groups. No relevant further improvement was noted for the remaining retropulsion tests 
(no di#erence between the second and sixth test in both groups; p = 0.30). None of the 
retropulsion tests discriminated well between patients and controls. 
Prospective follow-up (Table 2) 
During the six-month follow-up, patients reported 205 falls, whereas controls reported 
only 10 falls. The period between baseline examination and the !rst fall was somewhat 
shorter for patients than controls, but this di#erence was not signi!cant. However, the 
mean (±standard deviation) period between baseline examination and the !rst fall was 
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Results
! Baseline assessment (Table 1)
There were more women among controls than among
patients (a consequence of our choice for partners,
rather than sex-matched persons, as controls). Domestic
variables (as exemplified in Table 1 by the proportions of
subjects that lived together with a partner, and by the
proportions of subjects with stairs within the house) did
not differ between patients and controls. Patients were
more often dependent for ADL than controls. The
MMSE of patients was slightly but significantly lower
than in controls, but owing to our inclusion criteria,
none of the patients had obvious cognitive impairment.
The average number of prior falls and the proportion
of self-reported fallers (! 1 fall) during the six previous
months were somewhat higher for patients than con-
trols, but these differences were not significant. Almost
50 % of patients expressed a fear of falling. A restriction
of daily activities because of this fear was also more
common among patients than controls. Furthermore,
many patients reported difficulties with simultaneous
performance of multiple tasks, such as walking and car-
rying a tray.
Patients performed worse than controls on most tests
of balance and gait (Table 1). Tandem stance with eyes
closed was most often abnormal in patients, but also in
about 42 % of the controls. Balance while turning and
tandem gait were also sensitive measures of PD, and
these tests were rarely abnormal in controls. Several
other measures, such as the Romberg test and orthosta-
tic hypotension, did not differ between patients nd
controls. The ‘Stops walking when talking test’ was ab-
normal in only seven patients, and in none of the con-
trols.
The responses to the six consecutive retropulsion
tests are shown in Fig. 2. The first retropulsion test (i. e.
without prior warning) was abnormal (UPDRS score
! 1) in 10 patients (16.9 %) and six controls (10.9 %; p =
0.55). Only three patients and one control had to be
caught by the examiner (UPDRS score = 2). No person
had a spontaneous tendency to fall (UPDRS score = 3).
Most corrective steps were taken after the first unex-
pected shoulder pull by both patients (1.6 ± 1.3) and
controls (1.6 ± 1.2; p = 0.81).Overall, for subjects who re-
ceived six consecutive retropulsion tests, test abnormal-
ity decreased with warning and repetition in patients
and controls (p < 0.001), both for the UPDRS score and
the number of corrective steps taken.These warning and
learning effects did not differ between both groups (p =
0.47). The warning and learning effects were largely at-
tributable to the second test, which was performed bet-
ter than the first test in both groups. No relevant further
improvement was noted for the remaining retropulsion
tests (no difference between the second and sixth test in
both groups; p = 0.30). None of the retropulsion tests
discriminated well between patients and controls.
! Prospective follow-up (Table 2)
During the six-month follow-up, patients reported 205
falls, whereas controls reported only 10 falls. The period
between baseline examination and the first fall was
somewhat shorter for patients than controls,but this dif-
ferenc  was ot s gnificant. H wever, the mean (± stan-
dard deviation) period betw en baseline ex mination
and the first fall was signific ntly shorte  for p rsons
wh  sustaine  recurrent falls (1.0 ± 1.0 month) than for
persons with maximally one fall (2.9 ± 1.8 month) (p <
0.005). Among patients, the proportion of prospectively
identified fallers (50.8 %) tended to exceed the self-re-
ported estimate during the six previous months (39 %; p
= 0.27). In contrast, fewer controls tended to fall during
follow-up (14.5 %) than during the previous six months
(27.3 %; p = 0.16). The proportion of persons that re-
ported at least one fall was much higher for patients than
controls (relative risk [RR] 6.1; 95 % confidence interval
[CI] 2.5–15.1; p < 0.001). The proportion of persons who
fell more than once during follow-up was also higher for
patients. One quarter of patients had recurrent (! 2)
falls, as opposed to only two controls (RR 9.0; 95 % CI
2.0–41.7; p = 0.001).
Complete documentation about circumstances of
falls was available for 150 falls of patients and all 10 falls
of controls (Table 2). Information about the falls could
not be obtained reliably for 55 falls of the patients (usu-
ally due to poorly legible handwriting; a few falls were
only detected during the reminding telephone calls, but
details of these falls were not included to avoid any re-
call problems). Patients fell mostly indoors, whereas
controls usually fell outdoors. Patients mostly suffered
Fig. 2 Responses to the six consecutive retropulsion tests for patients and con-
trols. The UPDRS-score is used as outcome measure. Similar results were obtained
for the number of corrective steps.
Fig 2 Responses to the six consecutive retropulsion tests for patients and controls. The UPDRS-score is 
used as outcome measure. Similar results were obtained for the number of corrective steps.
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signi!cantly shorter for persons who sustained recurrent falls (1.0 ±1.0 month) than 
for persons with maximally one fall (2.9 ±1.8 month) (p < 0.005).Among patients, the 
proportion of prospectively identi!ed fallers (50.8%) tended to exceed the self-reported 
estimate during the six previous months (39%;p = 0.27).In contrast, fewer controls tended 
to fall during follow-up (14.5%) than during the previous six months (27.3%; p = 0.16). 
The proportion of persons that reported at least one fall was much higher for patients 
than controls (relative risk [RR] 6.1;95% con!dence interval [CI] 2.5–15.1;p < 0.001).The 
proportion of persons who fell more than once during follow-up was also higher for 
patients. One quarter of patients had recurrent (12) falls, as opposed to only two controls 
(RR 9.0; 95% CI 2.0–41.7;p = 0.001). 
Complete documentation about circumstances of falls was available for 150 falls of 
patients and all 10 falls of controls (Table 2). Information about the falls could not be 
obtained reliably for 55 falls of the patients (usually due to poorly legible handwriting; 
a few falls were only detected during the reminding telephone calls, but details of 
these falls were not included to avoid any recall problems). Patients fell mostly indoors, 
whereas controls usually fell outdoors. Patients mostly su#ered intrinsic falls, whereas 
environmental hazards (extrinsic falls) caused most falls in controls. ‘Centre of mass falls’ 
predominated among patients, whereas controls had more ‘base of support falls’. Centre 
of mass falls among patients occurred most commonly while turning around (24% of 
the 150 falls), standing up (15%) and bending forward (16%). About one third of falls 
occurred when patients rated their symptoms as poorly controlled. About two-thirds 
of all falls by patients occurred when they rated their symptoms as well controlled, 
although concurrent dyskinesias were present in half of them. Six falls were related to 
sudden freezing, all when symptoms were poorly controlled. Only one fall was preceded 
by sudden loss of consciousness. 
The proportion of injurious fallers tended to be highest among patients, but the propor-
tion of injurious falls did not di#er between both groups (Table 2). Among those persons 
who fell at least once, the proportion of injurious fallers tended to be even higher for 
controls (six out of eight fallers or 75%) than for patients (15 out of 30 fallers or 50%; p = 
0.26). Serious fallers (recurrent, injurious, or both) were more common among patients 
than controls. No fractures or life-threatening complications occurred, but soft tissue in-
juries were very common. An inability to get up after a fall occurred in both patients and 
controls, and several patients lay on the .oor for hours. In addition, falls often induced or 
aggravated a fear of future falls that led patients to further restrict their activities.
Prediction of falls (Table 3) 
Of the questionnaire items, asking for earlier falls attained the best sensitivity (76.5%) 
with a comparable speci!city (74.2%) in identifying recurrent fallers. Asking for problems 
with multiple tasks also had a reasonable sensitivity and speci!city. Overall, the propor-
tion of women did not di#er between recurrent fallers (9/17; 52.9%) and persons with 
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Table 2. Fall rates, circumstances and consequences of falls.
Patients (N = 59) Controls (N = 55) Signi$cance
Fall rates
Time to !rst fall (months)     1.7 ±  1.7   2.5  ±  2.0 p = 0.35
Fallers (11 fall)   30 (50.8%)   8 (14.5%) p < 0.001
Recurrent fallers (12 fall)   15 (25.4%)   2 (  3.6%) p = 0.001
Characteristics 3
Falls indoors 124 (82.7%)   2 (20.0%) p < 0.001
Lach classi!cation (25)
   Intrinsic falls 105 (70.0%)   4 (40.0%)
   Extrinsic falls   20 (13.3%)   5 (50.0%) p = 0.02
   Non-bipedal falls     2 (  1.3%)   0 (  0.0%)
   Non-classi!able falls   23 (15.3%)   1 (10.0%)
Maki classi!cation (29)
   Base of support falls   21 (14.0%)   5 (50.0%)
   Center of mass falls 108 (72.0%)   4 (40.0%) p = 0.02
   No obvious perturbation falls     8 (  5.3%)   0 (  0.0%)
   Non-classi!able falls   13 (  8.7%)   1 (10.0%)
Clinical condition 
   Poorly controlled   44 (29.3%)        —        —
   Well controlled (no
     dyskinesias)
  54 (36.0%)        —        —
   Well controlled (with
     dyskinesias)
  52 (34.7%)        —        —
Consequences
Injurious fallers   15 (25.4%)   6 (10.9%) p = 0.06
Serious fallers b   21 (35.6%)   6 (10.9%) p < 0.005
Number of falls with: 3
   Injury   93 (62.0%)   7 (70.0%) p = 0.74
   Inability to get up   37 (24.7%)   3 (30.0%) p = 0.71
   (More) fear of future falls   63 (42.0%)   1 (10.0%) p = 0.05
Data are displayed as mean ± standard deviation or as individual counts (percentage between 
parentheses) with an abnormal test result. 3 Complete documentation available for 150 falls of patients 
and all 10 falls of controls; b persons with recurrent falls, injurious falls, or both.
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maximally one fall (49/97; 50.5%). However, all eight fallers among our controls were 
women, whereas men (n=8) and women (n=7) were equally distributed among the re-
current fallers in the patient group. Recurrent falls were more common in more severely 
a#ected patients and persons with higher scores on the Tinetti Mobility Index. Among 
patients, fallers had a somewhat longer duration of the disease than non-fallers, but this 
di#erence was not signi!cant. For example, disease duration was 8.5 ±4.6 years among 
patients with recurrent falls, compared with 6.6 ±4.8 years among patients without recur-
rent falls (p = 0.18). The MMSE was only slightly lower among recurrent fallers, but this 
di#erence was not signi!cant. Benzodiazepines were used more often by patients (n = 
16; 27.1%) than by controls (n =3; 5.5%) (Fisher’s exact test, p < 0.005). Recurrent falls 
were reported by 36.8% (7/19) of persons using benzodiazepines, and by 10.5% (10/95) 
of persons not using benzodiazepines (RR 5.0;95% CI 1.6–15.5;p < 0.01). 
Most balance and gait tests predicted falls insu/ciently. This included the retropulsion 
test (irrespective of how it was executed or scored), which had a good speci!city, but 
a very low sensitivity. The area under the receiver-operating curve (calculated for the 
average of all six retropulsion tests) was 0.62 (standard error 0.07), re.ecting an insuf-
!cient sensitivity and speci!city to predict falls. Tandem stance with eyes closed, turning 
around and tandem gait had a moderate to good sensitivity, but the speci!city was only 
acceptable for tandem gait (79.8%) and turning around (72.9%). The proportion of per-
sons with orthostatic hypotension did not di#er signi!cantly between recurrent fallers 
(23.1%) and non-fallers (13.5%; p = 0.41). The ‘Stops walking when talking’test was rarely 
abnormal in recurrent fallers. 
The logistic regression analysis has to be interpreted with some caution given the 
relatively small sample size. When all variables were entered into the logistic regression 
model simultaneously, the combination of asking for prior falls, disease severity and the 
Romberg test yielded the best overall diagnostic utility (sensitivity 65% and speci!city 
98%). However, the added bene!t of the Romberg test was limited for practical purposes 
because this test was impaired in only three recurrent fallers (and in none of the remain-
ing subjects). In contrast, disease severity (as indexed by the Hoehn and Yahr scores) was 
helpful in identifying subjects at risk for recurrent falls. Thus, the RR of recurrent falls was 
13.4 (95% CI 0.4–27) for patients with Hoehn and Yahr stage 1 to 2.5, and > 100 (95% CI 
3.1–585) for the most severely a#ected patients (who were all but one in Hoehn and Yahr 
stage 3). Asking for prior falls in the previous 6 months was also helpful in identifying 
subjects at risk for recurrent falls (RR 5.0, 95% CI 1.2–20.9). Identical results were obtained 
when the prediction model was applied to patients only, and when patients and controls 
were pooled (where controls were given a Hoehn and Yahr score of 0 and disease dura-
tion of 0 years).
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Table 3. Prediction of recurrent fallers (pooled results of patients and controls). Non-fallers included 
persons without any falls or a single fall. Data are displayed as mean ± standard deviation or as individual 
counts (the percentage shown between parentheses for fallers denotes the sensitivity; the percentage 
shown for non-fallers is equivalent to 100% minus the speci!city). Abnormal retropulsion tests shown here 
include all UPDRS scores 41, but statistical analyses were performed using the actual scores. Only variables 
that di#ered (p < 0.01) between recurrent fallers and non-fallers are displayed, plus several pertinent 




fallers (N = 97)
Signi$cance
Fall questionnaire
Fallers (£ 6 months) 13 (76.5) 25 (25.8) p < 0.001
Fear of falling 3   9 (52.9) 22 (22.9) p = 0.02
Problems with multiple tasks b 11 (73.3) 23 (26.4) p = 0.001
Use of walking aids 3   6 (35.3)   7 (  7.3) p < 0.005
Neurological examination
Hoehn & Yahr stage   2.8 ±   0.6   2.1 ±   0.6 p < 0.001
UPDRS motor score 34.8 ± 12.5 17.1 ± 16.6 p < 0.001
UPDRS total score 52.8 ± 17.9 26.5 ± 24.7 p < 0.001
MMSE 27.8 ±   2.2 28.7 ±   1.6 p = 0.13
Gait and balance
Tinetti balance score   5.1 ±   2.8   1.7 ±   2.5 p < 0.001
Tinetti gait score   3.8 ±   2.4   1.0 ±   1.8 p < 0.001
Tinetti total score   8.9 ±   4.6   2.7 ±   4.0 p < 0.001
Retropulsion tests 
   First   5 (29.4) 11 (11.3) p = 0.07
   Second   1 (  5.9)   2 (  2.1) p = 0.05
Tandem stance
   Eyes open   9 (52.9) 16 (16.5) p < 0.005
   Eyes closed 15 (88.2) 52 (53.6) p < 0.01
Romberg test a   3 (17.6)   0 (  0.0) p < 0.005
Sitting down a   8 (47.1) 11 (11.5) p = 0.001
Turning around a 12 (70.6) 26 (27.1) p = 0.001
Tandem gait c 10 (62.5) 19 (20.2) p = 0.001
Stops walking when talking   2 (12.5)   5 (  5.2) p = 0.26
a Data were unavailable for one non-faller,
b two fallers and 10 non-fallers,




The !rst important conclusion is that falls are very common, even relatively early in the 
course of PD. More than 200 falls occurred in 59 patients during six months, 50% of the 
patients fell at least once, and about 35% su#ered recurrent or injurious falls. Comparable 
fall rates emerged from an uncontrolled study where 59% of Parkinson patients fell at 
least once during three months.", In contrast to the latter study, we also investigated falls 
in healthy controls, which permitted us to estimate relative risks for falls. Thus, Parkinson 
patients had a nine-fold increased risk of sustaining recurrent falls. These prospectively 
determined fall rates exceed those of retrospective studies$&%&"%&(%&) (and the retrospective 
estimate in this study), perhaps because merely asking for falls underestimates the true 
incidence."* An ‘amnesia for falls’ may well occur in PD patients who are often cognitively 
impaired."+%&- Indeed, patients had a lower MMSE than controls, and elaborate tests might 
have unveiled more cognitive decline. Another possibility is that concurrent disease 
progression during the study explained why the prospectively obtained fall rate in our 
patients exceeded their own retrospective estimate. 
The fall rates for patients well exceeded those of controls, despite the female preponder-
ance in controls. This sex di#erence was a consequence of our choice for partners as 
controls, which we considered important because domestic variables such as stairs and 
slippery .oors are important risk factors for falls.'" This advantage outweighed the resul-
tant sex di#erence between patients and controls. In fact, the actual di#erence between 
patients and controls is perhaps even greater than in this study because women fall more 
often than men.'" Indeed, all eight fallers among our controls were women. 
Our analysis of fall circumstances is the second important result, as this could form the 
basis for potential preventive measures. PD patients usually fell indoors, suggesting that 
reduction of domestic hazards could be fruitful. However, this approach may eliminate 
only a minority of falls, because patients often fell unrelated to environmental hazards 
(they had a high proportion of ‘intrinsic’ falls). Indeed, patients commonly had centre of 
mass falls (most often while turning around), which again suggests that the underlying 
balance disorder caused most falls. Apparently, antiparkinson medication did not reduce 
these balance problems, because two- thirds of falls occurred when patients considered 
their symptoms to be well controlled. Other studies also suggest that postural instabil-
ity in PD is resistant to conventional pharmacotherapy.&%"-%$$%$& In fact, treatment may 
paradoxically aggravate falls because amelioration of other symptoms improves mobility 
(and thus increases the risk of falling)&+, without improving balance. Furthermore, our 
results suggest that drug-induced dyskinesias may contribute to some of the falls.&( How-
ever, more detailed research is needed here because we did not quantify the severity and 
daytime duration of dyskinesias. Certainly, development of improved therapeutic strate-
gies to reduce postural instability is needed. One important measure that could already 
be taken is reduction of benzodiazepines, which were commonly used by our patients. 
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Similar to other studies"&%"), we found that use of benzodiazepines was associated with 
a !ve-fold increase in the risk of recurrent falls. A third important !nding was the high 
rate of adverse consequences of falls. No fractures occurred, but soft tissue injuries were 
very common. The proportion of injurious fallers was slightly higher in controls than 
in patients, possibly because patients fell mostly indoors where soft carpets may have 
absorbed the impact of their falls. In addition, patients may su#er more ‘low-energy’ falls 
because they walk more slowly or fall from a low height, for example while reaching for 
objects on the .oor. This di#ers from healthy persons who rarely fall, but if they do, it is 
usually due to overwhelming external causes that often induce injuries. 
A commonly overlooked, yet incapacitating consequence of falls is a fear of future falls, 
which was common among patients. This fear of falls forced patients to restrict their 
physical activities and sometimes led to social isolation. This restriction of activities 
perhaps explains the high proportion of indoor falls in our patients. The immobilisation 
and reduced ability to participate in social life are as important as falling itself in reducing 
the quality of life for PD patients.* Immobilisation also underlies the complex relation 
between falls and disease duration, which only tended to be longer in fallers compared 
to non-fallers. We suspect that falls are most common in relatively early stage PD (as 
was the case in our patients), when postural instability develops and patients are suf-
!ciently mobile to be actually at risk for falls.* Indeed, in our study, fall risks were highest 
for patients with Hoehn and Yahr stage 3 PD. As the disease progresses further, both 
postural instability and the fear of falls worsen, causing patients to become increasingly 
immobilised. In e#ect, this ‘prevents’ additional falls and obscures the relation between 
falls and disease duration.* 
The fourth aspect of our study related to prediction of falls. Recurrent fallers were best 
predicted by a combination of asking for prior falls, disease severity and the Romberg 
test. Although the speci!city of this combination was excellent (98%), the overall 
diagnostic utility was somewhat limited by the moderate sensitivity (65%), indicating 
that a substantial proportion of recurrent fallers would be misclassi!ed as non-fallers. 
Because of the grave consequences of falls and the emerging possibilities for therapeutic 
intervention*%"$%"(, a test with a higher sensitivity (perhaps at the cost of a lower speci!c-
ity) would be preferable. Presently, the best predictors of falls were disease severity and 
asking for prior falls. For example, the risk of recurrent falls was increased !ve-fold in 
persons with earlier falls. The moderate sensitivity is perhaps explained by the amnesia 
for falls mentioned previously.
Interestingly, none of the commonly used clinical tests of balance and gait could 
predict falls adequately. This included the retropulsion test which is commonly used 
to document balance impairment in PD. The retropulsion test has several theoretical 
shortcomings, and how this test should be executed is debated.'%* The response to 
the !rst shoulder pull is presumably most informative (certainly when given without 
prior notice) because this best resembles the unexpected falls that occur in daily life. 
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Because patients adapt to the test&' learning e#ects (that are not operative in daily life) 
could confound subsequent shoulder pulls. The !rst retropulsion test is also preferable 
because PD patients cannot cope with unexpected external perturbations.&* Indeed, the 
!rst and unexpected shoulder pull yielded di#erent results (more corrective steps and a 
higher UPDRS-score) than all subsequent tests, which produced largely similar results. 
Both the prior warning signal and learning e#ects may explain the better performance 
for the second to sixth retropulsion tests. However, none of the six retropulsion tests 
discriminated well between patients and controls, and all tests predicted falls poorly. This 
predictive capability was perhaps insu/cient because our patients were relatively mildly 
a#ected (even the !rst and unexpected retropulsion test was normal in most patients).
Yet,this moderately a#ected group is interesting because the added bene!t of a screen-
ing test for falls would be greatest. We therefore conclude that the retropulsion test is not 
suitable for early detection of fallers. Perhaps the test is more useful in later stages of PD 
to rate the severity of balance impairment. 
Assessment after overnight withdrawal of levodopa might predict falls better than the 
present scores. However, major di#erences are unlikely because most falls occurred 
when symptoms were well controlled. Furthermore, scores for postural instability usually 
change little with dopaminergic medication.&%"-%$$%$& 
A potential shortcoming of our study was created by the inclusion of outpatients at-
tending a university hospital with an interest in movement disorders. This selection bias 
might preclude extrapolation of our !ndings to the more general population of patients 
with PD, for example because relatively severely a#ected patients are more likely to visit 
specialised outpatient clinics. However, this possible selection bias by disease severity 
appeared negligible in our study because we excluded patients with severe signs (in-
ability to walk without assistance, MMSE < 24). Indeed, the average UPDRS motor score 
of our patients was 31.5 and none of them had a Hoehn and Yahr score of 4. Such patients 
are also commonly seen in outpatient clinics outside specialised university centres. We 
also reduced the risk of including patients with atypical hypokinetic-rigid syndromes 
(who fall more frequently and earlier in the course of the disease'& by using the inclusion 
criteria for idiopathic PD as de!ned by the brain bank of the United Kingdom Parkinson’s 
Disease Society.$" In addition, all patients responded well to chronic treatment with an-
tiparkinson medication, which always included levodopa and/or a dopamine agonist."' 
We cannot entirely exclude that our study was underpowered to detect variables with a 
modest ability to detect falls. However, most comparisons between prospectively deter-
mined fallers and non-fallers were highly signi!cant, which generally does not suggest 
insu/cient power. Although the number of subjects was relatively small, the incidence 
of falls was very high. Furthermore, the observed sensitivities were consistently low to 
moderate. A larger sample size may have helped to reduce the uncertainty surrounding 
these sensitivities and attain statistical signi!cance, but it is unlikely that very di#erent 
sensitivities would have been obtained. Certainly, further studies in larger patient groups 
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remain necessary. Such studies should also include tests with a ‘multiple task’ design 
(simultaneous assessment of di#erent aspects of postural control) as these may predict 
falls better than simple tests of isolated postural components.$* This may be particularly 
true in PD where the pathophysiology of postural instability is multifactorial.$%&%$- Indeed, 
during the standardised interview, 57% of our patients reported di/culties with execut-
ing simultaneous tasks, such as carrying a tray or talking while walking. Although these 
answers may be subject to interindividual variability (e.g. due to di#erences in educa-
tion) and recall bias"*, it was interesting that very comparable results emerged from the 
more reliable prospective survey where multiple-task performance played a role in about 
50% of the falls (see reference (44) for details). In the present study, we also corroborated 
our earlier report( in a smaller patient group that simple dual-task performance, such as 
the ‘Stops walking when talking’ test$*, is rarely abnormal in PD, perhaps because this 
test is only abnormal in cognitively impaired patients.( However, preliminary results sug-
gest that simultaneous or sequential performance of truly multiple (up to eight) tasks 
can discriminate much better between PD patients and controls, even in relatively early 
stages of the disease.) We are now prospectively investigating whether this ‘Multiple Task 
Test’ can also predict actual falls in daily life. 
Acknowledgements 
We thank Professor R.A.C. Roos and Dr. J.J.van Hilten, neurologists, and Prof. F.R.Rosendaal, 




 1. Bloem BR. Postural instability in Parkinson’s disease. Clin Neurol Neurosurg. 1992; 94 (Suppl.): S41-
S45. 
 2. Bloem BR, Beckley DJ, Remler MP et al. Postural re.exes in Parkinson’s disease during ‘resist’and 
‘yield’tasks.J Neurol Sci. 1995; 129: 109–119.
 3. Bloem BR, Beckley DJ, van Dijk JG et al. In.uence ofdopaminergic medication on automatic pos-
tural responses and balance impairment in Parkinson’s disease. Mov Disord. 1996; 11: 509–521. 
 4. Bloem BR,Beckley DJ,van Hilten JJ et al. Clinimetrics of postural instability in Parkinson’s disease. J 
Neurol 1998; 245: 669–673. 
 5. Bloem BR, Grimbergen YAM, Cramer M et al. “Stops walking when talking”does not predict falls in 
Parkinson’s disease.Ann Neurol 2000; 48: 268. 
 6. Bloem BR,Valkenburg VV, Slabbekoorn M et al. The Multiple Tasks Test.Strategies in Parkinson’s 
disease.Exp Brain Res 2001.
 7. Bloem BR, van Vugt JPP, Beckley DJ. Postural instability and falls in  Parkinson’s disease.Adv Neurol. 
2001. 
 8. Bloem BR, van Vugt JPP, Beckley DJ et al. Habituation of lower leg stretch re.exes in Parkinson’s 
disease.Electroencephalograph Clin Neurophysiol 1998; 109: 73-77. 
 9. Bond JM, Morris M. Goal-directed secondary motor tasks: their e#ects on gait insubjects with 
Parkinson disease.Arch Phys Med Rehabil 2000; 81: 110–116. 
 10. Bonnet AM, Loria Y, Saint-Hilaire MH et al. Does long-term aggravation ofParkinson’s disease result 
from nondopaminergic lesions? Neurology 1987; 37: 1539-1542.
 11. Buchner DM, Cress ME, Delateur BJ et al. The e#ect of strength and endurance training on 
gait,balance, fall risk,and health services use in community-living older adults. J Gerontol Med Sci 
1997; 52: M218-M224. 
 12. Campbell AJ, Robertson MC, Gardner MM, et al. Randomised controlled trial of a general prac-
tice programme of home based exercise to prevent falls in elderly women.Br Med J 1997; 315: 
1065–1069. 
 13. Caramel VMB, Remarque EJ, Knook DL et al. Use of medications related to function and falls in the 
85-plus population ofLeiden,the Netherlands.J Am Geriatr Soc 1998; 46: 1178–1179.
 14. Clarke CE, Davies P. Systematic review ofacute levodopa and apomorphine challenge tests in the 
diagnosis of idiopathic Parkinson’s disease.J Neurol Neurosurg Psychiatry 2000; 69: 590–594.
 15. Close J, Ellis M, Hooper R et al. Prevention of falls in the elderly trial (PROFET): a randomised con-
trolled trial.Lancet 1999; 353: 93–97. 
 16. Cumming RG. Epidemiology of medication-related falls and fractures in the elderly.Drugs Aging 
1998; 12: 43–53. 
 17. Cummings SR, Nevitt MC, Kidd S. Forgetting falls, The limited accuracy of recall o#alls in the 
elderly.J Am Geriatr Soc 1988; 36: 613–616. 
 18. Dubois B, Pillon B, Sternic N, Age-induced cognitive disturbances in Parkinson’s disease.Neurology 
1990; 40: 38–41. 
 19. Gray P, Hildebrand K. Fall risk factors in Parkinson’s disease.J Neurosci Nurs 2000; 32: 222–228. 
 20. Horak FB, Nutt JG, Nashner LM. Postural in.exibility in parkinsonian subjects.J Neurol Sci 1992; 
111: 46–58. 
 21. Hughes AJ, Daniel SE, Kilford L et al. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: 
a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181–184. 
 22. Klawans HL. Individual manifestations of Parkinson’s disease after ten or more years of levodopa.
Mov Disord 1986; 1: 187–192. 
63
 Prospective assessm
ent of falls in Parkinson’s disease 
3
 23. Koller WC, Glatt S, Vetere-Over!eld B et al. Falls and Parkinson’s disease.Clin Neuropharmacol 
1989; 2: 98–105. 
 24. Koller WC, Silver DE, Lieberman A. An algorithm for the management of Parkinson’s disease. 
Neurology 1994; 44(Suppl.10): S5-S51.
 25. Lach HW, Reed AT, Arfken CL et al. Falls in the elderly: reliability ofa classi!cation system.J Am 
Geriatr Soc 1991; 39: 197–202.
 26. Lang AE. Clinical rating scales and videotape analysis.In: Koller WC, Paulson G, editors.Therapy of 
Parkinson’s disease.2 ed.New York: Marcel Dekker, 1995: 21–46. 
 27. Lundin-Olsson L, Nyberg L, Gustafson Y. “Stops walking when talking” as a predictor o#alls in 
elderly people. Lancet 1997; 349: 617. 
 28. Lundin-Olsson L, Nyberg L, Gustafson Y. Attention,frailty,and falls: the e#ect of a manual task on 
basic mobility.J Am Geriatr Soc 1998; 46: 758–761. 
 29. Maki BE, Holliday PJ, Topper AK. A prospective study of postural balance and risk o#alling in an 
ambulatory and independent elderly population.J Gerontol 1994; 49: M72-M84. 
 30. Marsden CD. Parkinson’s disease.J Neurol Neurosurg Psychiatry 1994; 57: 672–681. 
 31. Martinez-Martin P, Urra DG, Quijano TD et al. A new clinical tool for gait evaluation in Parkinson’s 
disease. Clin Neuropharmacol 1997; 20: 183–194. 
 32. Mathias CJ, Kimber JR. Treatment ofpostural hypotension.J Neurol Neurosurg Psychiatry 1998; 65: 
285–289.
 33. Nevitt MC, Cummings SR, Kidd S et al. Risk factors for recurrent nonsyncopal falls.A prospective 
study.JAMA 1989; 261: 2663–2668. 
 34. Nutt JG, Hammerstadt JP, Gancher ST. Parkinson’s disease: 100 maxims.London: Edward Arnold. 
1992. 
 35. Paulson GW, Schafer K, Hallum B. Avoiding mental changes and falls in older Parkinson’s patients. 
Geriatrics 1986; 41: 59–67. 
 36. Sato Y, Manabe S, Kuno H et al. Amelioration ofosteopenia and hypovitaminosis D by 1 alpha-
hydroxyvitamin D3 in elderly patients with Parkinson’s disease.J Neurol Neurosurg Psychiatry 
1999; 66: 64–68. 
 37. Smithson F, Morris ME, Iansek R. Performance on clinical tests of balance in Parkinson’s disease.
Phys Ther 1998; 78: 577–592.
 38. Speechley M, Tinetti ME. Falls and injuries in frail and vigorous community elderly persons.J Am 
Geriatr Soc 1991; 39: 46–52.
 39. Sudarsky L. Geriatrics: gait disorders in the elderly..N Engl J Med 1990; 322: 1441–1446. 
 40. Tinetti ME. Performance-oriented assessment of mobility problems in elderly patients.J Am Geri-
atr Soc 1986; 34: 119–126. 
 41. Tinetti ME, Speechley M. Prevention of falls among the elderly. N Engl J Med 1989; 320: 1055–1059. 
 42. Weiner WJ, Nora LM, Glantz RH. Elderly inpatients: postural re.ex impairment.Neurology 1984; 34: 
945–947. 
 43. Wenning GK, Ebersbach G, Verny M et al. Progression of falls in postmortem-con!ned parkinso-
nian disorders. Mov Disord  1999; 14: 947–950. 
 44. Willemsen MD, Grimbergen YAM, Slabbekoorn M et al. Vallen bij de ziekte van Parkinson: vaker door 




of six prospective 
studies of falling in 
Parkinson’s disease
R.M. Pickering&, Y.A.M. Grimbergen), U. Rigney &, A. Ashburn!, G. 
Mazibrada #, B.Wood+, P. Gray,, G. Kerr-, B.R. Bloem )%' 
& Public Health Sciences and Medical Statistics, University of 
Southampton, United Kingdom; 
) Department of Neurology, Leiden University Medical Centre, The 
Netherlands;
 ! Rehabilitation Research Unit, University of Southampton, United 
Kingdom; 
# Sobell Department for Motor Neurosciences and Movement Disorders, 
Queen Square, London, United Kingdom;
 + Northumbria Healthcare NHS Trust; Newcastle upon Tyne, UK
, Parkinson’s Clinic, Ottawa, ON, Canada; 
- Institute of Health and Biomedical Innovation, Queensland University 
of Technology, Brisbane, Australia; 
' Department of Neurology, Radboud University Nijmegen Medical 
Centre, Nijmegen, The Netherlands.
Mov Disord. 2007; 22(13): 1892-1900
ABSTRACT
Recurrent falls are a disabling feature of Parkinson’s disease (PD). We have estimated the 
incidence of falling over a prospective 3 month follow-up from a large sample size identi-
!ed predictors for falling for PD patients, repeated this analysis for patients without prior 
falls,   and examined the risk of falling with increasing disease severity. We pooled six 
prospective studies of falling in PD (n = 473), and examined the predictive power of vari-
ables that were common to most studies.The 3-month fall rate was 46% (95% con!dence 
interval: 38% to 54%). Interestingly, even among subjects without prior falls, this fall rate 
was 21% (12% to 35%). The best predictor of falling was two or more falls in the previ-
ous year (sensitivity 68%; speci!city 81%). The risk of falling rose as UPDRS increased, to 
about 60% chance of falling for UPDRS values 25-35, but remained at this level thereafter 
with a tendency to taper o# towards later disease stages. These results con!rm the high 
frequency of falling in PD, as almost 50% of patients fell during a short period of only 3 
months. The strongest predictor of falling was prior falls in the preceding year, but even 
subjects without any prior falls had a considerable risk of sustaining future falls. Disease 
severity was not a good predictor of falls, possibly due to the complex U-shaped relation 
with falls. Early identi!cation of the very !rst fall therefore remains di/cult, and new 
prediction methods must be developed.
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Recurrent falls are an important and disabling feature of idiopathic Parkinson’s disease 
(PD)."%$%&%' Fall-related injuries such as hip fractures or head traumas are among the most 
recognizable consequences of falls.(%) However, falls have many other sequelae that may 
be less obvious clinically, but which have a signi!cant negative impact on the patients’ 
quality of life. For example, PD patients who have sustained prior falls often develop a 
fear of renewed falls*%+ and this may cause or aggravate a concurrent loss of mobility. In 
turn, this reduced mobility is associated with a host of negative consequences, including 
a loss of independence, development of weakness, promotion of osteoporosis and, even-
tually, a deterioration of overall !tness, leading to cardiovascular disease and reduced 
survival.,%"- Furthermore, postural instability and falls are associated with increased risk 
of admission to hospitals"" or nursing homes."$
In light of these consequences of falls, it would be helpful to identify which persons are 
most at risk of sustaining a fall in the near future. Postural instability and falls are gener-
ally di/cult to treat pharmacologically, but a host of additional therapeutic measures 
may help to alleviate falls in individual patients."&%"' Because asking about previous falls 
is often unreliable, falls are best studied using a prospective design where patients are 
asked to document the occurrence of falls shortly after they have occurred. In the past 
few years, six prospective studies have examined fall rates and consequences of falls 
in PD.*%"(%")%"*%"+%", These studies emphasised the high incidence of falls in PD: depending 
on the duration of follow-up (which ranged from 3 to 12 months), the percentage of 
patients with at least one fall amounted to almost 70% for those who were followed for 
a full year.", However, they produced inconsistent !ndings in their search for a clinically 
useful risk factor for falls in PD. Ashburn et al"( concluded that a reported history of two 
or more falls in the previous year was the best predictor of future falls, and a previous 
review including all six studies indicated that the presence of prior falls was the only 
consistently present predictor of future falls.$-
However, presence of prior falls as a predictor is suboptimal because ideally intervention 
should occur before the !rst fall has occurred. Indeed, no previous study has attempted 
to predict future falls in PD patients who are not currently falling. Moreover, previous 
studies were based on relatively small numbers, with no study including substantially 
more than 100 subjects. Here, we report a meta-analysis of individual data from 473 
patients in all six previous prospective studies. Our speci!c aims were: to estimate the in-
cidence of falling from larger numbers; to examine predictors of falling, not only among 
the group as a whole, but also among patients who had not fallen in the previous year; 
and to examine the relationship between increasing severity of disease – as measured 




The six studies were identi!ed from a PubMed search using the following search terms: 
“Parkinson’s disease” AND “accidental falls” AND (“prospective studies” OR “longitudinal 
studies”), and this yielded four studies that had been published as full papers.*%"(%"*%", This 
was supplemented with information available to the authors from international confer-
ences, and this yielded two further studies that have thus far appeared only in abstract 
form."+%$" The studies were performed among community-dwelling patients with PD living 
in Ottawa Canada"*, Leiden the Netherlands*, Brisbane Australia"+, and three centres in 
the United Kingdom: Southampton"(, North Tyneside",  and London.$" The London study 
was originally designed as a study focused on progressive supranuclear palsy, but this 
study was included because the PD patients – that served as controls in this study – were 
followed in the same way as in the other !ve PD studies.$"
There was some heterogeneity across the six identi!ed studies, but the methods were 
su/ciently similar to allow for a pooling of the data (Table 1). The duration of follow-
up ranged from a minimum of 3 months to a maximum of 12 months. The prospective 
follow-up data were therefore recalculated for a comparable 3-month interval for all 
studies, which was possible because all studies included in this meta-analysis provided 
actual number of falls over the !rst three months, so ascertainment of falls was identical 
for all studies. Methods used to ascertain falls during the follow-up period also varied 
somewhat across studies, but were all deemed of su/cient quality to reliably ascertain 
faller status (single or recurrent faller). There was also a discrepancy in the time interval 
over which previous falls and near falls were reported (Table 1). To accommodate this, 
we only used the three studies in analyses incorporating prior faller status or number of 
falls. Some patients had large numbers of previous falls, the extreme being 500 falls. To 
reduce the impact of outliers, numbers of falls above 25 were replaced with the value 25, 
though sensitivity analyses with di#erent numbers or using the original variable showed 
little di#erence.
Table 2 shows the number of patients with PD in each study, totalling 473 across all six 
studies. Whether or not a patient fell in a 3-month prospective follow-up period was 
available from all the studies. The following potentially predictive variables were com-
mon to all (or most) of the studies: age, gender, Hoehn and Yahr stage, UPDRS, previous 
falls, and fear of falling. The distribution of these variables was broadly similar across 
studies (Table 2).The UPDRS motor examination score was not recorded using the same 
version in all studies. The majority recorded the full version in which key symptoms are 
rated speci!cally for di#erent areas of the body, making 27 items in total.$$ Two stud-
ies (Southampton and North Tyneside) used a reduced version in which only an overall 
rating of symptoms across body areas was obtained from each patient, resulting in 14 
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items. To produce a score that was compatible across studies, we assumed that singly 
rated symptoms in the reduced version were the average of values that would have been 
obtained had symptoms been rated separately for speci!c body parts, and weighted the 
symptom by the number of parts rated in the full version of the UPDRS score. One could 
justly argue that this “scaling up” of these values to calculate the full UPDRS is a .awed 
assumption with subsequent overestimation of the full UPDRS scores. Therefore, in a 
separate approach, we also repeated our analyses when the available full scores were 
scaled down to the reduced version - using the single maximum score for each item 
instead. The results were very similar according to these alternative analyses. We prefer 
the !rst approach because the majority of cases came from studies where 27 UPDRS 
items were checked, so only the minority had to be scaled up to become consistent with 
the 27 item version. Hence only the analyses using the “scaled up” UPDRS scores will be 
reported here.
Con!dence intervals (CIs) around risks of falling were obtained from logistic regression 
with study included as a random e#ect, !tted in Stata 9. We examined the potential of 
age, gender, Hoehn and Yahr stage, UPDRS and reported number of falls in the previ-
Table 1. Characteristics of the six contributing studies.
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ous year, as predictors of falling in the three month follow-up period in uncontrolled 
logistic regression models, and models controlled for all the other variables. Because 
these models were based on only three studies (number of falls in the previous year 
only being available in Leiden, Southampton and North Tyneside), study was included 
as a !xed rather than random e#ect taking account of possible di#erences in falling 
between studies. The possibility of non-linear dependency of risk of falling and UPDRS 
score was examined by additionally including as a regressor UPDRS squared: if the risk of 
falling were to decrease at higher values of UPDRS the squared term would be needed 
in the model. Estimated risks from the logistic models are reported as odds ratios with 
their associated 95% CIs, and likelihood ratio tests are reported. A similar set of logistic 
models examined the predictive power of items within the UPDRS in relation to risk of 
subsequent falling. For studies that reported the full version of the UPDRS, symptoms 
rated over di#erent body parts were averaged and included as a single regressor in the 
model. Number of previous falls, UPDRS and Hoehn and Yahr stage were also examined 
as predictors of falling in ROC curves; and the area under the curve (AUC) statistics are 
reported, along with sensitivity and speci!city at selected cut points. Lowess smoothed 
curves of the relationship between increasing severity of disease (as measured by the 
UPDRS motor examination score) and risk of falling were produced in Stata. The default 
bandwidth of 80% was used.
RESULTS
Table 2 shows the baseline characteristics of all contributing studies, as well as the 
!ndings on prior and prospectively documented falls. The rate of falling in the 3-month 
follow-up period amongst all subjects was 213/461 (46%; CI 38%- 54%). Amongst sub-
jects who reported not having fallen in the previous year the rate was 21/99 (21%; CI 
12% - 35%), while among those reporting falling once or more the rate was 71/124 (57%; 
CI 53% - 61%). Observations on injuries falls were only available for three studies (Table 
2). Two of these studies reported the proportions of subjects with injurious falls, and the 
!ndings were remarkably comparable (24% in the Leiden study, and 27% in the London 
study). The third study (Ottawa) merely reported the number of falls that was associated 
with injuries, and this proportion was very high (78%).
The single most important predictor of subsequent falling was the reported number of 
falls in the previous year (Table 3). Number of previous falls was also the only variable 
to provide independent predictive power (P=0.000) that was not explained by the two 
disease severity measures (Hoehn and Yahr stage and UPDRS).
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Of the two severity measures, the Hoehn and Yahr stage contributed most to predict-
ing falling in the 3-month follow-up. Hoehn and Yahr stage was associated with large 
increases in risk in the uncontrolled model which were reduced to borderline non-
signi!cance (P=0.051) in the presence of the other variables. The UPDRS was signi!cant 
in the uncontrolled models, but its explanatory power was largely explained by the 
other variables. Age and gender had little predictive value, in controlled or uncontrolled 
models.
Figure 1a-c show the ROC curves for reported number of falls in the previous year, the 
UPDRS, and the Hoehn and Yahr stage. The curves agree with the results of the logistic 
regression in showing the superiority of number of previous falls in predicting future 
falls, both in terms of the area under the curve, and the closeness of the curve to the top 
left corner of the plot (indicating perfect prediction). The point closest to the top left 
corner of Figure 1a indicates a sensitivity of 68% and speci!city of 81% from predicting 
future falling based on two or more previous reported falls. The point to the right with 
increased sensitivity of 77% was obtained by predicting patients to fall if they had one or 
more previous falls, but this was only achieved at the cost of increasing 1-speci!city to 
40%. Figure 1d shows the predictive power of a combined score, obtained from logistic 
regression including the three variables together. The combination was not superior to 
that from number of previous falls alone, the optimal cut point having sensitivity of 72% 
and speci!city of 79%. Figure 1e shows the ROC curve for UPDRS in the subgroup of 
patients reporting no falls in the previous year. The curve was close to the diagonal line 
Table 3. Odds ratios (OR) of falling in three months for study, age, Hoehn and Yahr, UPDRS and number of 
falls reported in the previous year (n=219).
Variable
UNCONTROLLED CONTROLLED*












Age (years) per unit increase 1.00 (0.98, 1.03) 0.781 0.98 (.94, 1.01) 0.183
Sex Female/male 1.03 (0.60, 1.77) 0.921 0.78 (0.40, 1.51) 0.452
Hoehn and Yahr per unit increase 2.05 (1.41, 2.98) 0.000 1.72 (0.99, 2.97) 0.051
UPDRS27          per unit increase 1.10 (1.00, 1.21) 0.0233 1.05 (0.94, 1.17) 0.661b
UPDRS27a 1.00 (1.00, 1.00) 0.2233 1.00 (0.98, 1.00)
Number of falls in 
the previous year
per unit increase 1.54 (1.32, 1.81) 0.002 1.49 (1.25, 1.78) 0.000
* Controlled for the other predictor variables in the table.
3  P values for uncontrolled UPDRS27 are based on likelihood ratio tests for the linear term on its own, 
and the quadratic term in the presence of the linear term.
b  P value for controlled UPDRS27 is based on likelihood ratio test for the linear and quadratic terms
removed together, df =2.
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of equality (indicating no predictive power) and the AUC statistic was not much greater 
than 0.50. Finally, Figure 1f shows slightly better predictive power from the Hoehn and 
Yahr stage in this group.
Table 4 presents the sensitivity and speci!city of various potential predictors of subse-
quent falling. The sensitivity and speci!city of previous repeat falling was better in the 
Southampton study than the others. The accuracy of prediction is acceptable in the 
North Tyneside study, while in the Leiden study the sensitivity of previous repeat falling 
is lower. Figures combined over these three studies show only moderately high sensitiv-
ity (68%), although speci!city was high (81%). Figures from the Ottawa study were based 
on falling in the previous three months, and higher sensitivity would be anticipated 
had falls over the previous year been reported. Speci!city in the Ottawa study was high 
(88%), and this would be likely to drop were fall histories over a longer period to be used. 
A Hoehn and Yahr stage of more than two showed only moderately high sensitivity and 
0.051) in the presence of the other variables. The
UPDRS was significant in the uncontrolled models, but
its explanatory power was largely explained by the other
variables. Age and gender had little predictive value, in
controlled or uncontrolled models.
Figure 1a–c show the ROC curves for reported num-
ber of falls in the previous year, the UPDRS, and the
Hoehn and Yahr stage. The curves agree with the results
of the logistic regression in showing the superiority of
number of previous falls in predicting future falls, both in
terms of the area under the curve, and the closeness of
the curve to the top left corner of the plot (indicating
perfect prediction). The point closest to the top left
corner of Figure 1a indicates a sensitivity of 68% and
specificity of 81% from predicting future falling based
on two or more previous reported falls. The point to the
right with increased sensitivity of 77% was obtained by
predicting patients to fall if they had one or more previ-
ous falls, but this was only achieved at the cost of
increasing 1-specificity to 40%. Figure 1d shows the
predictive power of a combined score, obtained from
logistic regression including the three variables together.
The combination was not superior to that from number of
previous falls alone, the optimal cut point having sensi-
tivity of 72% and specificity of 79%. Figure 1e shows the
ROC curve for UPDRS in the subgroup of patients
reporting no falls in the previous year. The curve was
close to the diagonal line of equality (indicating no
predictive power) and the AUC statistic was not much
greater than 0.50. Finally, Figure 1f shows slightly better
predictive power from the Hoehn and Yahr stage in this
group.
Table 4 presents the sensitivity and specificity of var-
ious potential predictors of subsequent falling. The sen-
sitivity and specificity of previous repeat falling was
better in the Southampton study than the others. The
accuracy of prediction is acceptable in the North Tyne-
side study, while in the Leiden study, the sensitivity of
FIG. 1. ROC curves for possible predictors of falling in 3 months:
(a–d) all patients; (e–f) patients reporting no falls in the previous year.
TABLE 3. Odds ratios (OR) of falling in 3 mo for study, age, Hoehn and Yahr, UPDRS, and number of falls reported
in the previous year (n ! 219)
VARIABLE
Uncontrolled Controlled*
OR (95% CI) P value OR (95% CI) P value
Study
Leiden 1.00 0.303 1.00 0.188
Southampton 1.12 (0.52, 2.42) 0.70 (0.25, 1.95)
North Tyneside 1.61 (0.88, 3.11) 1.63 (0.63, 4.22)
Age (years; per unit increase) 1.00 (0.98, 1.03) 0.781 0.98 (0.94, 1.01) 0.183
Sex
Female/male 1.03 (0.60, 1.77) 0.921 0.78 (0.40, 1.51) 0.452
Hoehn and Yahr (per unit increase) 2.05 (1.41, 2.98) 0.000 1.72 (0.99, 2.97) 0.051
UPDRS27 (per unit increase) 1.10 (1.00, 1.21) 0.023a 1.05 (0.94, 1.17) 0.661b
UPDRS27a 1.00 (1.00, 1.00) 0.223a 1.00 (0.98, 1.00)
Number of falls in the previous year (per unit increase) 1.54 (1.32, 1.81) 0.002 1.49 (1.25, 1.78) 0.000
*Controlled for the other predictor variables in the table.
aP values for uncontrolled UPDRS27 are based on likelihood ratio tests for the linear term on its own, and the quadratic term in the presence of
the linear term.
bP value for controlled UPDRS27 is based on likelihood ratio test for the linear and quadratic terms removed together, df ! 2.
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Movement Disorders, Vol. 22, No. 13, 2007
Fig  1 ROC curves for the possible predictors of falling in 3 months: (a-d) all patients; (e-f ) patients 
reporting no falls in the previous year.
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speci!city. Prediction from the combined score mirrored that from two or more previous 
falls in the studies separately and combined. Moderately high sensitivity and speci!city 
for fear of falling is also shown.
For the subgroup reporting no falls in the previous year, a reported fear of falling showed 
only moderate sensitivity (50%) and higher speci!city (71%), while sensitivity was some-
what higher (54%) for Hoehn and Yahr stage greater than 2.0, with a speci!city of 69%.
Figure 2a shows the relationship between risk of subsequent falling and the UPDRS. The 
curve starts at low levels of risk for UPDRS close to zero, and then increases to a risk of 
about 60% chance of falling in 3 months for UPDRS values above 50. The curve shows a 
tendency for the risk of falling to drop with increasing UPDRS over values of 50, but the 
observed decrease is slight and is estimated from only few cases. In Table 3 including a 
quadratic term in UPDRS which would allow the risk of subsequent falling to decrease 
after an initial rise with UPDRS showed no additional predictive power over the linear 
previous repeat falling is lower. Figures combined over
these three studies show only moderately high sensitivity
(68%), although specificity was high (81%). Figures
from the Ottawa study were based on falling i the
previous 3 months, and higher sensitivity would be an-
ticipated had falls over the previous year been reported.
Specificity in the Ottawa study was high (88%), and this
would be likely to drop were fall histories over a longer
period to be used. A Hoehn and Yahr stage of more than
two showed only moderately high sensitivity and speci-
ficity. Prediction from the combined score mirrored that
from two or more previous falls in the studies separately
and combined. Moderately high sensitivity and specific-
ity for fear of falling is also shown.
For the subgroup reporting no falls in the previous
year, a reported fear of falling showed only moderate
sensitivity (50%) and higher specificity (71%), while
sensitivity was somewhat higher (54%) for Hoehn and
Yahr stage greater than 2.0, with a specificity of 69%.
Figure 2a shows the relationship between risk of sub-
sequent falling and the UPDRS. The curve starts at low
levels of risk for UPDRS close to zero, and then in-
creases to a risk of about 60% chance of falling in 3
months for UPDRS values above 50. The curve shows a
tendency for the risk of falling to drop with increasing
UPDRS over values of 50, but the observed decrease is
slight and is estimated from only few cases. In Table 3
including a quadratic term in UPDRS which would allow
the risk of subsequent falling to decrease after an initial
rise with UPDRS showed no additional predictive power
over the linear term (P ! 0.223), indicating that any
decrease at high values of UPDRS is not important in
explaining falling. Figure 2b shows the relation between
risk of falling and UPDRS for the subgroup reporting no
falls in the previous year. The risk of falls is much lower
when compared to the entire group, and a tendency for
risk of falling to decrease with increasing UPDRS over
35 to 40 can be detected.
We also calculated the odds ratios of individual items
of the UPDRS as predictors of falling, for the group as a
whole (data not shown). Except for resting tremor, all
items were associated with risk of falling when con-
trolled only for study. Speech, gait, and postural stability
TABLE 4. Performance of various predictors of falling at 3 mo in each study and overall. Figures are number (%)
Predictor
Ottawa* Leiden Southampton North Tyneside Brisbane** London Overall
Sens Spec Sens Spec Sens Spec Sens Spec Sens Spec Sens Spec Sens Spec










































































































*Previous falls and near falls in the Ottawa study over 3 mo.
**Previous falls and near falls in the Brisbane study over 6 mo, only the presence of falls n t the numb r was available.
aCombined over Leiden, Southampton, and North Tyneside.
bCombined over Leiden, Southampton, and London
FIG. 2. Lowess smoothed curves of risk of falling in 3 months for
increasing UPDRS: (a) all patients; (b) patients reporting no falls in the
previous year. Points plotted with symbol (#) and subject to jittering.
FALLS IN PARKINSON’S DISEASE 1897
Movement Disorders, Vol. 22, No. 13, 2007
Fig 2 Lowess smoothed curves of risk of faling in 3 months for increasing UPDRS: (a) all patients; (b) 
patients reporting no falls in the previous year. Points plotted with symbol (+) and subject to jittering.
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term (P=0.223) indicating that any decrease at high values of UPDRS is not important in 
explaining falling. Figure 2b shows the relation between risk of falling and UPDRS for the 
subgroup reporting no falls in the previous year. The risk of falls is much lower compared 
to the entire group, and a tendency for risk of falling to decrease with increasing UPDRS 
over 35 to 40 can be detected.
We also calculated the odds ratios of individual items of the UPDRS as predictors of fall-
ing, for the group as a whole (data not shown). Except for resting tremor, all items were 
associated with risk of falling when controlled only for study. Speech, gait and postural 
stability were the most important predictors in this analysis, and were the only items 
that contained independent predictive power after controlling additionally for the other 
UPDRS items. Within the subgroup of patients reporting no falls in the previous year, 
none of the items showed signi!cant predictive power (data not shown).
DISCUSSION
The main !ndings of this meta-analysis were as follows. First, among the total group 
of patients with PD, we observed a very high rate of falling (46% of subjects) during a 
relatively brief follow-up of only three months. Injuries were common and occurred in 
about a quarter of subjects. An interesting new !nding was that even subjects reporting 
no falls in the previous year had a substantial risk of falling during this period (21%). 
Second, falling was best predicted by the presence of two or more prior falls during 
the previous year, but even the optimal combination of sensitivity (68%) and speci!city 
(81%) remained less than perfect. Prediction was not improved by the addition of the 
severity measures UPDRS and Hoehn and Yahr stage. Finally, we identi!ed fear of falling 
as possible predictors for falls, but this needs to be scrutinized further.
Incidence of falls
Our meta-analysis represents the largest study of falls in PD to date. The observed 
high rate of falls in the total group con!rms the impression gained previously from the 
contributing individual studies. Fall rates over three months were reasonably consistent 
across the six studies, despite some methodological di#erences and possible variation 
introduced by cultural di#erences. Injuries were common and occurred in about a quar-
ter of subjects (available from two studies). A third study expressed this di#erently, and 
reported that 78% of all individual falls was associated with injuries. A likely explanation 
is that those persons with injurious falls apparently sustain recurrent injuries. A new and 
important observation is that even subjects who reported not having fallen in the previ-
ous year had a substantial risk of falling during the next three months (21%). Although 
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this rate is lower than that of the group as a whole, it constitutes an unexpectedly high 
risk for people reporting not having fallen in the previous year.
Prediction of falls
The best predictor of falls in the next three months was simply asking patients whether 
they had fallen in the past year. The importance of previous falls in predicting future 
falling is not unexpected, given earlier observations in elderly persons$& and in one of the 
contributing studies in PD."( There are a number of issues concerning the practicalities 
of using reported histories of falls in predicting future falls. First, elderly people tend to 
forget prior falls$', or they may have di/culty remembering the timing of previous fall 
events. It is not unlikely that persons demonstrate inaccuracy in remembering whether 
events occurred within the speci!ed time window, particularly when these are longer 
periods of time. But despite these inaccuracies, self-report of prior falls still predicted 
future falls. We have not attempted to show the predictive power of the “true” number of 
previous falls, because the accuracy of the reported answer probably depends on how 
subjects were speci!cally interviewed. Indeed, methodological di#erences in ascertain-
ing the fall history may explain some of the observed di#erences in predictive power 
across studies included in this meta-analysis.
A second issue is the choice for the cut point. In our meta-analysis, the combined sensi-
tivity and speci!city was better using the cut point of two or more falls (sensitivity 68% 
and speci!city 81%) compared to one or more falls (sensitivity 82% and speci!city 59%). 
As expected, when previous falls were ascertained over a shorter period (three months 
in the Ottawa study"*), the cut point of two or more falls achieved lower sensitivity. What 
is judged as the best combination depends on how a test is intended to be used. In 
order to prevent future falls and potential injuries (assuming there is an e#ective treat-
ment program), a high sensitivity is required to optimally detect possible candidates for 
falls. However, this is inevitably achieved at the expense of lower speci!city, resulting in 
higher immediate costs because more persons are falsely identi!ed as fall candidates, so 
interventions are o#ered to people who may not fall.
A third important issue is that, by de!nition, prior falls are unable to predict the very !rst 
falls. We repeated the analysis for the subgroup of 100 subjects who reported no falls 
in the previous year. The results suggested that along with the Hoehn and Yahr stage, 
asking about fear of falling has some potential to identify these new fallers. Fear of falling 
had only moderate sensitivity and higher speci!city in the reduced group in which the 
data was available. It may be that “asking is better than measuring”, and this may also 
prove true for other potential predictors, given the lack of validated and reliable clinical 
tests of balance and gait in PD., Fear of falling can be evaluated using the ABC scale, 
which has been validated for use in PD+ and, more recently, also in abbreviated form.$( 
One or two of the studies obtained information about prior near-falls, but more work is 
needed to develop clear de!nitions and a reliable way of ascertaining near-falls.
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Relation with disease severity
Another objective of this meta-analysis was to examine the pattern of increasing risk of 
falling with disease severity, which in a large retrospective study was related to falls.$) 
We addressed this question using the UPDRS motor examination score, because this 
continuous scale has more potential to show trends than the wider categories of the 
Hoehn and Yahr scale. In a previous paper* the risk was hypothesised to initially increase 
to a plateau, but to decline thereafter because of compensatory strategies adopted by 
patients and eventually become e#ectively zero as severely a#ected patients became 
immobilised and therefore no longer at risk of falling. This pattern was not observed as 
clearly as expected. The risk of falling did indeed increase to a plateau around the 60% 
chance of falling in three months (for UPDRS values of about 50), but there was only a 
slight decline in risk of falling observed amongst very few cases thereafter, and inclusion 
of a quadratic term allowing risk to decline at high severity did not produce signi!cant 
improvement in the !t of the logistic risk model. The most likely explanation is that the 
constituent studies recruited patients from the community. Hence, many patients who 
were “beyond moving” could have moved to a nursing home or other institutional care 
and were e#ectively excluded. The drop in risk of falls anticipated at high disease sever-
ity might have been observed had institutionalized people been included, or within the 
context of a long term follow-up study.
We also analyzed the relation between falls and individual items of the UPDRS. Except for 
tremor, all items were related to falls, the strongest being the scores for gait and speech. 
In the multiple regression analysis, only speech, and to a marginal level gait and pos-
tural stability, had independent predictive power in the presence of the other items. The 
intuitively more logical items of posture, gait, balance and rising from a chair were not 
independently associated with falls, possibly because they all act as markers of disease 
severity and being interrelated did not provide independent predictive power. Another 
explanation is that current clinical tests for balance and gait are imperfect predictors of 
falls in everyday life. For example, the retropulsion test is only poorly related to prospec-
tively monitored falls in PD.* The relation with speech was unexpected and could well be 
coincidental, but might also re.ect an interdependence between “axial” motor features 
of PD (which speech and falls both are). Such interdependence has been observed previ-
ously, for example in terms of resistance to dopaminergic medication.$*%$+
Shortcomings
This study was not without shortcomings. First, the contributing studies were somewhat 
heterogeneous in design. We partially accommodated this by restricting the analyses to 
time frames common to all studies, but this does not deal with di#erences in fall ascer-
tainment. However, all studies used a reasonable approach to identify faller status. Di#er-
ences in ascertainment are likely to have introduced a discrepancy in absolute numbers 
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of reported falls, but we feel con!dent that all approaches reliably classi!ed subjects 
as non-faller, single faller or recurrent faller, which was the main outcome measure in 
this study. Second, baseline assessment included only a limited number of balance tests 
common to all studies, and it is possible that certain combinations of di#erent gait and 
balance tests – along with asking for prior falls – may yield a better prediction of future 
falls.$, Third, it would have been interesting to look at the in.uence of polypharmacy. 
We had to drop this analysis because the methods of recording medications were not 
consistent across the studies. The issue is also compounded by potential di#erences 
in prescribing across countries. Future research should further focus on the e#ects of 
drugs, prescribed for either PD or co-morbid conditions, on the risk of falls in PD patients. 
Finally, it would have been interesting to correlate falls to mental decline (in particular 
frontal executive dysfunction), given the increasing evidence for links between cognition 
on the one hand, and gait, balance and falls on the other.&- However, this analysis was 
not possible because cognitive status was either not examined or studied using methods 
that were inconsistent across studies.
CONCLUSION
Our !ndings suggest that simple clinical measures are insu/cient predictors of falling in 
PD. It proves particularly di/cult to identify fallers before they have sustained their very 
!rst fall. For these prior nonfallers, asking about fear of falling may have some potential 
as an early predictor of falling. This will need to be clari!ed in future large-scale studies 
among prior non-fallers. Additional work is required to broaden our understanding of 
the aetiology underlying falling, as this might o#er new clues for early detection.
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Falls are common in patients with Huntington’s disease, but the incidence, falling cir-
cumstances and contributing factors have never been examined. We recorded falls in 45 
early to midstage Huntington’s disease patients, both retrospectively (12 months) and 
prospectively (3 months). Fall rates were related to relevant baseline measures, including 
the Uni!ed Huntington’s Disease Rating Scale (UHDRS) and quantitative measures of bal-
ance (using angular velocity sensors) and gait (using a pressure-sensitive walkway). Bal-
ance and gait measures were compared between patients and 27 healthy age-matched 
controls. Twenty-seven patients (60%) reported two or more falls in the previous year 
and were classi!ed as fallers. During prospective follow-up 40% reported at least one 
fall. A high proportion of falls (72.5%) caused minor injuries. Compared to non-fallers, 
fallers showed signi!cantly higher scores for chorea, bradykinesia and aggression, as well 
as lower cognitive scores. Compared to controls, Huntington patients had a decreased 
gait velocity (1.15 m/sec versus 1.45 m/sec, p<0.001) and a decreased stride length (1.29 
m versus 1.52 m, p<0.001). These abnormalities were all signi!cantly greater in fallers 
compared to non-fallers. In addition, fallers had an increased stride length variability and 
a signi!cantly greater trunk sway in medio-lateral direction compared to non-fallers. We 
conclude that falls are common in Huntington’s disease. Contributing factors include a 
combination of “motor” de!cits (mainly gait bradykinesia, stride variability and chorea, 
leading to excessive trunk sway), as well as cognitive decline and perhaps behavioral 
changes. These factors should be considered as future targets for therapies that aim to 
reduce falls in Huntington’s disease.
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Gait may become unstable even in early stages of Huntington’s disease (HD)." Falling is 
another feature of HD, and fall-related complications frequently result in hospitalization 
or nursing home placement.$%&%' Despite these devastating consequences of falls, little 
is known about the epidemiology, circumstances and consequences of falls in HD. One 
small study on falls in HD reported that 11 of 13 patients had experienced several falls in 
the past, and most patients fell monthly.(
Equally little is known about the pathophysiology underlying falls in HD. A complex in-
teraction seems likely and motor symptoms such as chorea or bradykinesia may disturb 
balance and gait and thereby contribute to falls. Bradykinesia can lead to slowing or 
inappropriate execution of corrective steps or protective arm movements. Bradykinesia 
is also associated with a reduced step height, and this increases the risk of tripping over 
uneven surfaces. Several studies have identi!ed a decreased step length, decreased 
walking speed and increased stride time compared to healthy controls .(%)%*%+%,   Increased 
stride-to-stride variability has also been found, and this may re.ect a defective neural 
gait machinery plus a contribution from excessive choreatic movements.(%)%"-%"" 
Second, balance may be compromised by abnormal postural re.exes, leading to inad-
equate responses to external perturbations and falls. Balance correcting responses in leg 
muscles of HD patients are inadequately scaled to cope with externally imposed postural 
perturbations, even when corrected for chorea."$%"& Third, disturbances in behaviour and 
cognition, such as “motor recklessness”, inattention or lack of insight can underlie falls in 
patients with HD." Finally, apart from these “disease-speci!c” factors (related directly to 
HD), other “generic” risk factors for falls such as use of sedative medication and alcohol 
intake may play a role."'%"(%") The relative contribution to falls of these various postulated 
risk factors remains unclear. The main objective of this study was therefore bifold. Our 
!rst goal was to establish the incidence, circumstances and consequences of falls in a 
large group of HD patients. Our second goal was to clarify the pathophysiology underly-
ing falls in HD, and to disentangle the relative contributions from bradykinesia, chorea, 
gait impairment, postural instability and cognitive decline. 
METHODS
Subjects
Inclusion criteria were early to mid-stage ambulatory HD patients. Exclusion criteria 
included juvenile HD, concurrent neurological disorders, other causes for balance dis-
orders and severe visual problems. Because cognitive decline may be one of the factors 
associated with falls, we purposely did not exclude patients with cognitive impairment, 
but we did exclude patients with marked dementia who were unable to follow instruc-
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tions or give informed consent. Eighty-nine patients ful!lled these criteria and were 
invited to participate. Forty-!ve patients gave informed consent, while the remaining 
patients refused or did not respond. There was no di#erence in gender and age between 
the participating patients and those who refused. 
Twenty-seven healthy controls were recruited from hospital personnel, acquaintances 
of the investigators and spouses of participants. Mean age and gender of patients and 
controls were comparable (mean age 51.9 ± 10.1 years for patients versus 52.2 ± 8.5 years 
for controls; 23 (51.1%) women for patients versus 21 (60.0%) women for controls). The 
Ethical Boards of the participating centres approved the study.
Baseline clinical assessment  
Medical history, current medication use, living circumstances, alcohol intake and daily 
activities were recorded at baseline. Fall history, including number of prior falls and fear 
of falling, was obtained during a personal interview according to a standardized and vali-
dated questionnaire."*%"+%", Balance con!dence was assessed using the Activities-speci!c 
Balance Con!dence scale.$- For all cognitively impaired patients, a caregiver was asked 
to con!rm the accuracy of the answers. We de!ned patients as “faller” when at least two 
falls had occurred in the preceding year. ")%$"%$$     
Baseline assessment further consisted of a complete Uni!ed Huntington’s Disease Rat-
ing Scale (UHDRS). Functional assessment included the Total Functional Capacity Score 
(TFC), a score between 0 (maximum disability) and 13 (no disability). The Berg Balance 
scale was used to clinically rate balance.$&
Quantitative gait and balance measurements
Gait analysis was performed using a pressure sensitive walkway (GaitRite), which can reli-
ably identify gait disturbances in healthy subjects and patients with Parkinson’s disease 
and HD.,%$'%$(%$) Following a test trial, subjects were asked to walk straight ahead at a self-
determined and comfortable speed (three trials) and subsequently at a fast speed but 
without running ( three trials). Subjects started walking 2 meters ahead of the carpet and 
stopped 2 meters after the carpet. Because results were comparable for comfortable and 
high speed we only report the !ndings for the comfortable speed condition. Outcome 
measures included gait velocity, stride length and stride-to-stride variability.
During the same gait tasks on the electronic walkway, we also searched for excessive 
trunk movements due to chorea or postural instability, using two digitally-based angular 
velocity transducers (SwayStar)  worn on the lower back.$*%$+  Thesevelocity transducers 
measure angular movements of the trunk in the medio-lateral direction (roll plane) and 
anterior-posterior direction (pitch plane) in freely moving subjects without interfering 
with natural body movements. Outcome variables included peak-to-peak angular dis-
placements in the roll and pitch directions. 
87




Following these baseline examinations, patients recorded  all falls using a standardized, 
validated falls calendar during 3 months."*%"+%", Circumstances and consequences of the 
!rst !ve falls were scored in detail on a standardized fall form, as described previously."*
Statistical analyses
Baseline di#erences between fallers and non-fallers were analyzed using parametric (t-
test) or non-parametric tests (Mann-Whitney test, Chi-Square and Fisher exact). We used 
the Mann-Whitney U test to test for di#erences between patients and controls in spatial 
and temporal parameters of gait, as well as measures of angular trunk displacement. To 
search for associations between motor symptoms and the quantitative gait and balance 
variables, we calculated Pearson correlation coe/cients.Stepwise forward logistic regres-
sion was used to evaluate which symptomswere most strongly related to being a faller.
RESULTS
Frequency of falls
At baseline, 27/45 (60%) of patients reported two or more falls in the preceding year 
and 34/45 (75.6%) had experienced at least one fall. During the prospective 3-month 
follow-up these fall rates were respectively 9/45 (20.0%) and 18/45 (40.0%).
Table 1. Fall characteristics from 40 falls, as ascertained during the prospective follow-up period with 
completed fall sheets returned immediately after each fall. 
Fall characteristics Number of falls (percentage)
Site of the fall (more than 1 option possible):
 Familiar environment              37 (92.5 %)
 Indoors              23 (57.5 %)
Self-reported cause (most reported):
 Obstacle on the .oor              10 (25.0 %)
 Slippery or uneven surface                7 (17.5 %)
 Preceding dizziness                3   (7.5 %)
Speci!c fall circumstance (most reported):
 Multitasking              14 (35.0 %)
 Climbing stairs                8 (20.0 %)
Consequences of falls:
 No consequences              11 (27.5 %)
 Minor injuries              29 (72.5 %)
 Major injuries                0      (0 %)
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Forty completed fall forms were returned and were used to analyse fall circumstances in 
detail (Table 1). A high proportion of falls (72.5%) during this 3-month follow-up caused 
minor injuries, mainly bruises and abrasions. There were no serious injuries (fractures, 
joint dislocations or head trauma). One third of falls occurred while the patients were 
performing multiple tasks simultaneously. Additional factors that commonly led to fall-
ing included obstacles on the .oor and climbing stairs.
Characteristics of fallers and non-fallers
Age and disease duration did not di#er from those of non-fallers (table 2). Total functional 
capacity (TFC) score, as a marker for disease severity, tended to be lower in non-fallers. 
Medication did not di#er between fallers and non-fallers. Fallers were signi!cantly less 
con!dent about their balance than non-fallers. However, only a small proportion of fall-
ers was afraid of falling, and this did not di#er from non-fallers.
The UHDRS items for gait, total chorea (sum of all chorea scores) and body bradykinesia 
(item 10 of UHDRS) were signi!cantly higher in fallers, indicating a worse performance 
among fallers (Table 2). After correction for disease severity (using TFC), these di#erences 
remained signi!cant (p<0.01 for gait; p=0.03 for total chorea; and p=0.05 for body brady-
kinesia). The association between total chorea and body bradykinesia was weak (r=0.23; 
p = 0.13). Balance measures, indexed by the retropulsion test and the Berg balance scale, 
were worse in fallers compared to non-fallers. However, after correction for disease sever-
ity, the retropulsion test scores were no longer signi!cantly di#erent between fallers and 
non-fallers.
Total behaviour score was not signi!cantly di#erent between fallers and non-fallers. Of 
all behaviour items, we only found signi!cantly higher scores in fallers for the aggression 
frequency (p=0.01) and the aggression severity (p=0.02). 
Use of psychotropic drugs and cardiac medication tended to be higher among fallers, 
but di#erences from non-fallers were not signi!cant.
All cognitive scores were signi!cantly lower among fallers, suggesting an association be-
tween cognitive decline and falling (Table 2). The Symbol Digit Modalities test was most 
signi!cantly associated with falling (18.6 among fallers versus 29.6 among non-fallers; 
p<0.01). MMSE scores did not di#er between fallers and non-fallers.
Finally, we performed a multivariate analysis including TFC, body bradykinesia, chorea, 
Berg balance test, total cognitive score and aggression, and with multiple faller status as 
the dependent variable. In this analysis, cognitive performance (p=0.01) and aggression 
(p=0.01) were most strongly associated with falling in HD.
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The various quantitative gait variables will be described separately for fallers and non-
fallers, as compared with controls. Patients walked signi!cantly slower than controls 
(decreased gait velocity) and had a decreased stride length. This was particularly evident 
among patients with falls (Figure 1A&B). Interestingly, increased stride length variability, 
was only observed in fallers but did not di#er in nonfallers compared to controls (fallers 
vs nonfallers; 0.060 vs 0.036, p<0.01, Figure 1C).
Trunk movements 
Angular trunk displacement, as measured by the range of motion in the roll and pitch 
directions, was signi!cantly greater in patients than in controls (Figure 2 A&B). This 
increased trunk sway was more pronounced in fallers compared to nonfallers, but this 
di#erence was only signi!cant for medio-lateral angular motion of the trunk (Figure 
Table 2. Clinical details of fallers and non-fallers (de!ned by presence of historical falls). Data re.ect either 
means and standard deviation, or numbers and percentage.
Fallers (n=27) Non-fallers (n=18)
Age (years)     52.1 ± 11.1      51.6 ± 8.8 
Women     15 (55.6 %)        8 (44.4 %)
Disease duration (years)       6.9 ± 4.0        7.4 ± 4.8
Total functional capacity score (TFC) (0-15)       9.4 ± 2.3      10.2 ± 1.7
Balance con!dence (0-100)     64.4 ± 18.8      83.2 ± 13.8 ††
Fear of falling       4 (14.8 %)        3 (16.7 %)
Medication
     Psychotropic drugs     11 (40.7 %)        5 (27.8 %)
     Cardiac medication       5 (18.5 %)        1   (5.6 %)
     Other       7 (25.9 %)        5 (27.8 %)
Motor score UHDRS (total)     38.7 ± 14.3      27.5 ± 19.5  ††
       Body bradykinesia (item10)       1.7 ± 0.82        1.1 ± 0.10 † 
       Chorea (sum of all chorea scores)     13.2 ± 6.1        8.7 ± 6.5  †
       Gait (item 13)       1.2 ± 0.58     0.50  ± 0.62  ††
       Retropulsion test     0.89 ± 0.42      0.56 ± 0.62 †
Total behaviour score     13.8 ± 10.7      10.8 ± 11.8
       Aggression frequency     2.37 ± 1.18        1.5 ± 0.92 ††
       Aggression severity     1.85 ± 0.95      1.22 ± 0.43 †
MMSE     25.7 ± 3.7      27.2 ± 3.1 
Total cognitive score   167.5 ± 45.4    217.0 ± 62.1  ††
Independence scale (0-100)     82.0 ± 10.7      90.0 ± 9.2 † 
Berg balance score (0-56)     54.0 ± 2.4      55.4 ± 1.1 †
†† < 0.01
†  < 0.05
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2A&B). These increases in trunk sway of HD patients in both the medio-lateral and 
anterior-posterior directions remained signi!cant after correction for gait velocity (linear 
regression; roll angular range p=0.01 and pitch angular range p<0.01) as compared to 
controls.
Modalities test was most significantly associated with
falling (18.6 among fallers versus 29.6 among nonfal-
lers; P < 0.01). MMSE scores did not differ between
fallers and nonfallers.
Finally, we performed a multivariate analysis includ-
ing TFC, body bradykinesia, chorea, Berg balance test,
total cognitive score and aggression, and with multiple
faller status as the dependent variable. In this analysis,
cognitive performance (P 5 0.01) and aggression (P 5
0.01) were most strongly associated with falling in HD.
Gait Analysis
The various quantitative gait variables will be
described separately for fallers and nonfallers, as com-
pared with controls. Patients walked significantly slower
than controls (decreased gait velocity) and had a
decreased stride length. This was particularly evident
among fallers (Fig. 1A,B). Interestingly, increased stride
length variability, was only observed in fallers but did
not differ in nonfallers compared to controls (fallers vs.
nonfallers; 0.060 vs. 0.036, P < 0.01, Fig. 1C).
Trunk Movements
Angular trunk displacement, as measured by the
range of motion in the roll and pitch directions, was
significantly greater in patients than controls (Fig.
2A,B). This increased trunk sway was more pro-
nounced in fallers compared to nonfallers, but the dif-
ference was only significant for medio-lateral angular
motion of the trunk (Fig. 2A,B). These increases in
trunk sway of HD patients in both the medio-lateral
and anterior-posterior directions remained significant
FIG. 1. Gait velocity, stride length and stride variability. *P < 0.05,
**P < 0.01.
FIG. 2. Roll angular range and pitch angular range. *P < 0.05,
**P < 0.01.
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Fig 1 Gait velocity, stride length and stride variability. 
*P < 0.05, **P < 0.01.
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Correlation with clinical scores
Clinical chorea scores were positively correlated to the range of angular trunk motion in 
both the medio-lateral direction (r=0.59, p<0.001) and the anterior-posterior direction 
(r=0.62, p<0.001). As expected, we also found a weak but signi!cant negative correlation 
between body bradykinesia and walking velocity on the electronic walkway (r=-0.32, 
p=0.03).
DISCUSSION
Falls are common in this group of moderately a#ected HD patients. We identi!ed that 
motor de!cits (chorea and bradykinesia), cognitive decline and behavioral disturbances 
(aggression) contributed to falls in HD. Quantitative analyses revealed abnormalities 
of gait and balance that were more pronounced in HD patients with falls compared to 
patients without falls. 
Modalities test was most significantly associated with
falling (18.6 among fallers versus 29.6 among nonfal-
lers; P < 0.01). MMSE scores did not differ between
fallers and nonfallers.
Finally, we performed a multivariate analysis includ-
ing TFC, body bradykinesia, chorea, Berg balance test,
total cognitive score and aggression, and with multiple
faller status as the dependent variable. In this analysis,
cognitive performance (P 5 0.01) and aggression (P 5
0.01) were most strongly associated with falling in HD.
Gait Analysis
The various quantitative gait variables will be
described separately for fallers and nonfallers, as com-
pared with controls. Patients walked significantly slower
than controls (decreased gait velocity) and had a
decreased stride length. This was particularly evident
among fallers (Fig. 1A,B). Interestingly, increased stride
length variability, was only observed in fallers but did
not differ in nonfallers compared to controls (fallers vs.
nonfallers; 0.060 vs. 0.036, P < 0.01, Fig. 1C).
Trunk Movements
Angular trunk displacement, as measured by the
range of motion in the roll and pitch directions, was
significantly greater in patients than controls (Fig.
2A,B). This increased trunk sway was more pro-
nounced in fallers compared to nonfallers, but the dif-
ference was only significant for medio-lateral angular
motion of the trunk (Fig. 2A,B). These increases in
trunk sway of HD patients in both the medio-lateral
and anterior-posterior directions remained significant
FIG. 1. Gait velocity, stride length and stride variability. *P < 0.05,
**P < 0.01.
FIG. 2. Roll angular range and pitch angular range. *P < 0.05,
**P < 0.01.
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Fig 2 Roll angular range and pitch angular range.
*P < 0.05, **P < 0.01.
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This is the !rst detailed examination of fall rates and fall circumstances in HD.$%( The 
observed fall rates were high. Retrospectively, 60% sustained recurrent falls during the 
preceding year, and the majority reported weekly or monthly falls. Prospectively ascer-
tained fall rates were also high, albeit lower compared to the retrospective fall rates, 
presumably because of the relatively brief prospective follow-up (3 months). In addition, 
underreporting of falls during prospective follow-up due to concomitant behavioral or 
cognitive disturbances in HD cannot be excluded. 
Despite the high proportion of falls with minor injuries (more than 70%), no serious 
injuries were reported. One explanation may be that patients usually fell indoors, 
where carpets may have cushioned the impact of the fall. In contrast, major injuries are 
very common in patients with progressive supranuclear palsy, due to a combination 
of a severe and rapidly progressive balance de!cit, along with a lack of insight (“mo-
tor recklessness”).$, Balance de!cits in HD are less prominent and may progress more 
slowly, thereby allowing for compensatory strategies to develop. Our !ndings may also 
indicate that “recklessness” did not contribute much to falls and injuries in HD. Indeed, 
most behavioral measures were not correlated to falls, except for aggression which was 
independently associated with falling. However, the UHDRS behavioral assessment does 
not provide a useful tool to measure recklessness and the available items can only be 
interpreted indirectly.
Surprisingly, only few patients were afraid of falling, and this di#ers from other fall-prone 
patient groups. Among patients with Parkinson’s disease, 53% of fallers expressed a fear 
of falling, compared to only 15% in the present HD group."* Interestingly, fallers with HD 
did realise that their balance was disturbed, as re.ected by their lower balance con!-
dence rating compared to HD patients who were non-fallers. One possible explanation is 
the low incidence of severe injuries (low “penalty” for falling), but a general indi#erence 
to serious consequences (perhaps related to cognitive decline) may also underlie this 
absence of fear in HD.  
We identi!ed several factors that may have contributed to the pathophysiology undeRly-
ing falls in HD. Excessive choreatic trunk movements are a striking feature in HD that 
could lead to unstable walking.(%* In this study, the total UHDRS score for chorea was 
signi!cantly higher in fallers compared to non-fallers, suggesting causative contribution. 
This assumption was supported by our quantitative assessment of trunk movements dur-
ing gait (using accelerometers attached to the lower trunk), which showed an increased 
sway in HD, and more so among fallers than non-fallers. These trunk movements were 
correlated to clinical chorea scores. We therefore speculate that chorea cause increased 
postural sway that may at times exceed the limits of stability and thereby cause falls.
 Bradykinesia could also play a role in falling. . First, falls in our patients were commonly 
related to stumbling over small obstacles on the .oor (presumably caused by a reduced 
step height). Second, clinical scores for body bradykinesia were signi!cantly higher 
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among fallers compared to nonfallers. In addition, quantitative gait assessment showed 
that walking speed was decreased in fallers. Note that body bradykinesia did not correlate 
to chorea, so perhaps both signs of HD play an independent role in the pathophysiology 
of falls in HD. 
A third “motor factor” that could cause falls is balance impairment. Clinical balance 
scores (the retropulsion test and Berg Balance scale) were lower in fallers compared to 
non-fallers, but di#erences were small. Indeed, most patients had a normal retropulsion 
test, suggesting a largely preserved balance. Taken together, we suspect that balance 
abnormalities per se play a relatively minor role in causing falls in HD.
We further observed a strong correlation between falling and cognitive decline, as 
observed earlier in Alzheimer’s disease and Parkinson’s disease.&-%&" This could re.ect a 
mere association between balance disorders and cognitive impairment, both becoming 
more prominent in later stages of the disease but without causal relationship. However, 
in our patients there was no association between falling and disease duration or dis-
ease severity. This would suggest that the observed association is not just a marker of 
disease progression, but that cognitive disturbances themselves play a causative role in 
frequent falling. Indeed the majority of falls in HD ocurred under so-called “multiple task” 
circumstances.  Di/culties handling complex multitask circumstances are particularly 
prominent among patients with mental decline.&$%&&%&'%&( 
Our study had several shortcomings. First, our sample size was too small to run a reliable 
multifactorial analysis, so any claims about factors with a possible independent contribu-
tion to falls must be made with caution. However, our study does represent the largest 
and most comprehensive approach of falling in HD thus far. Second, our quantitative 
measures were selected based on their reliability, validity and feasibility, but their rela-
tive low-tech character implied that this provided only a relative “keyhole” view of gait 
and balance performance., Further detailed posturographic or full body kinematic gait 
analyses remain necessary to fully comprehend the pathophysiology underlying falls in 
HD.*%"$  Such knowledge, along with the !ndings of the present study, should form the 
basis for the development of e#ective treatment strategies aimed to reduce falls in HD.
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Postural instability, recurrent falls and fear of falling are common in advanced Parkinson’s 
disease (PD). We examined the impact of  fall frequency, fear of falling, balance con!-
dence and objectively measured balance impairment (using Tinetti’s Mobility Index) on 
health-related quality of life (HrQoL) in PD.
In 74 subjects HrQoL was assessed using the 39-item Parkinson’s disease Quality of Life 
Questionnaire [PDQ-39]. Patients were interviewed using a validated falls questionnaire, 
addressing fall history, consequences of falls and fear of falling. Neurological examina-
tion included Hoehn and Yahr scale, the Uni!ed Parkinson’s disease Rating Scale and 
Tinetti’s Mobility Index.
Disease severity, age and gender explained 44% of the di#erences in HrQoL across pa-
tients (R$=0.44). The combination of these factors and each of the factors fear of falling, 
balance con!dence and falls frequency lead to 55%, 50% and 45% of declared variability, 
respectively. The standardised regression coe/cients of these risk factors were 0.34 (fear 
of falling), 0.28 (balance con!dence) and 0.13 (fall frequency). This suggests that fear 
of falling is a more important determinant of HrQoL than actual falling. These results 
emphasise the importance of addressing fear of falling in the clinical management of 
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INTRODUCTION
Parkinson’s disease (PD) is a progressive and incapacitating disease, a#ecting many as-
pects of daily life. As the disease progresses, gait and postural disturbances become more 
severe and patients start experiencing falls. Postural instability and gait disturbances 
(PIGD) have been associated with reduced quality of life scores."%$ Speci!cally, freezing of 
gait has an independent and signi!cant impact on HrQoL in PD patients.&%' Freezing also 
has a negative impact on mobility, is associated with falls and can cause emotional stress 
in social situations. Falls are associated with injuries, hospital admissions and immobilisa-
tion, leading to restrictions of daily activities.( Experiencing falls in public can also be 
embarrassing and lead to social isolation. Not surprisingly, PD patients who experience 
falls report reduced quality of life scores.)%*%+%,%"-
 Fear of falling is a frequent consequence of previous falls and may lead to further physi-
cal inactivity."" Furthermore, fear of falling may already develop when patients become 
more unstable without experiencing actual falls. In elderly women without PD, fear of 
falling negatively a#ects HrQoL."$ A more recent study in PD patients showed that fear 
of falling plays a signi!cant role in deterioration of HrQoL."& However, this study used 
questionnaires to rate balance and gait and did not assess objective (clinical observed 
based) measures of balance and gait. 
We hypothesised that objective measures of postural instability and gait impairment, fall 
frequency and fear of falling are all important determinants of HrQoL in PD. To examine 
this, we investigated the di#erential impact of falls, fear of falling, balance and gait dis-
turbances on HrQoL in PD.
METHODS
We included consecutive outpatients with PD of Hoehn & Yahr stages II-V. Exclusion 
criteria were other neurological disorders, psychiatric disorders, disorders which a#ect 
balance and severe cognitive impairment (MMSE < 24). Assessment included Hoehn & 
Yahr staging, UPDRS (motor score), Tinetti’s Mobility Index"', a validated falls question-
naire""%"(%")%"* and the Parkinson’s Disease Questionnaire (PDQ-39). Tinetti’s Mobility Index 
is a set of objective tests assessing balance and gait, expressed as a balance and a gait 
subscore. The balance subscore includes, among others, rising from a chair, balance on 
standing and on turning. The gait subscore includes, among others, initiation of gait 
and step symmetry. Maximum scores (indicating worst mobility) are 16 (for the balance 
subscale) and 12 (for the gait subscale). Tinetti’s Mobility index has been validated for 
use in PD."+ The standardised falls questionnaire enquired about frequency of falls in the 
preceding year, fear of falling, circumstances and consequences of previous falls. 
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Falls were de!ned as ‘any unexpected event that caused the person to unintentionally 
land on any lower surface (object, .oor or ground)’.", The frequency of falls in the past 
year was divided into !ve categories: never; every year or less; every month; every week; 
wheelchair bound (table 1). The question on fear of falling comprised the answers ‘no’, 
’somewhat’ and ‘very’. Balance con!dence was assessed using the Activities-speci!c Bal-
ance Con!dence (ABC) Scale.$- The PDQ-39$" comprises 39 questions, subdivided in eight 
subdimensions (mobility, activities of daily living [ADL], emotional wellbeing, stigma, 
social support, cognition, communication and bodily discomfort). PDQ-39 summary 
index (PDQ-SI) and dimensions were calculated according to the scoring algorithm.$" The 
maximum score is 100, indicating the worst level of HrQoL. 
STATISTICS
First, we carried out univariable linear regression analyses, with dependent variable 
HrQoL (PDQ-SI). This resulted in standardised regression coe/cients for each of potential 
risk factors fear of falling, balance con!dence and fall frequency.
Next we used multivariable linear regression to evaluate to what extent the combination 
of  gender, age, duration of the disease, and UPDRS explained di#erences in HrQoL be-
tween the patients, i.e. we calculated the percentage explained variance (R$). Additionally, 
we extended the regression model by including the potential risk factors fear of falling, 
Table 1. Characteristics and health-related quality of life scores of the study population.
Clinical characteristics (n=74) Mean (SD)
Age 64.2   (9.89) (35-81)
Gender (women) 25      (34%)
Disease duration 11.49 (5.4)
H&Y 2.59   (0.94)
UPDRS total score 40.9   (22.7)
Tinetti total score  5.8    (7.6)
    Balance subscore  3.5    (4.2)
    Gait subscore  2.3    (3.6)
PDQ-39 SI 33.2  (17.3)
    Mobility 48.2  (29.1)
    ADL 40.5  (29.1)
    Emotional well-being 30.0  (20.1)
    Stigma 28.1  (23.3)
    Social support 11.7  (15.9)
    Cognitions 35.9  (24.0)
    Communication 31.2  (27.5)
    Bodily discomfort 36.3  (19.2)
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balance con!dence and fall frequency, both separately and combined. For each analysis, 
we determined the R$ and standardized regression coe/cients of the risk factors.
Finally, in an additional analysis, we explored the role of Tinetti balance. We repeated the 
analysis, with the covariables gender, age, duration of the disease and UPDRS, and the 
potential risk factors Tinetti balance, fear of falling, balance con!dence and fall frequency.
RESULTS
Demographics and disease characteristics are shown in Table 1. 
In univariable analyses, each of the factors fear of falling, balance con!dence and fall fre-
quency were associated with HrQoL (table 2), with standardised coe/cients ranging from 
0.36 to 0.45 and R$ ranging from 0.13 to 0.28. However, these associations may (partly) be 
due to demographic and disease factors. Therefore, we repeated the analyses, adjusted 
for the variables gender, age, duration of the disease, and UPDRS. First, we investigated 
to what extent disease factors, on their own, explained di#erences in HrQoL between the 
patients and found that a multivariable analysis with the independent variables gender, 
age, duration of the disease and UPDRS lead to R$=0.43 Adding the factor fall frequency 
only marginally increased the R$ to 0.45, with a standardised coe/cient 0.13, indicating 
that this was not a relevant factor for HrQoL. 
Table 2. The relationship between di#erent factors and PDQ39-SI
Model Standardised coe%cients
Nr.11 Variables in the model R2 fear of falling balance 
con!dence
Fall frequency
1 fear of falling 0.21 0.45
balance con!dence 0.28 0.53
fall frequency 0.13 0.36
6 only covariables22  0.43
7 covariables plus fear of falling 0.55 0.34
covariables plus balance con!dence 0.50 0.28
covariables plus fall frequency 0.45 0.13
8 covariables plus fear of falling and 
balance con!dence
0.56 0.29 0.12
covariables plus fear of falling and fall 
frequency
0.55 0.33 0.05
covariables plus balance con!dencand 
fall frequency
0.55 0.27 0.10
1 Nr variables in model
2 Gender, age, disease duration, UPDRS
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In contrast, a similar analysis with balance con!dence and fear of falling as additional 
factors lead to an R$ of 0.50 and 0.55, respectively. The standardised coe/cients of the 
two factors were 0.28 and 0.34. 
When fall frequency was added to the model that already included fear, the R$ did not 
further increase. Hence, fear, and to a less extent balance con!dence, seemed to be the 
major risk factors. 
Sex was not a signi!cant factor in any of the above analyses, but age had a p-value 
below 0.05 in all analyses. Duration of the disease was not signi!cant in the analyses, 
but it became signi!cant when the factor UPDRS was omitted. UPDRS and duration of 
the disease were correlated and HrQol seemed more directly related to UPDRS than to 
disease duration. 
In order to explore the contribution of objectively measured balance disturbances the 
Tinetti balance subscore was separately studied. Adding the Tinetti balance subscore to 
the co-variables gender, age, disease duration and UPDRS scores lead to R$=0.44 and a 
standardized regression coe/cient 0.21. The combination of the co-variables and each 
of the factors. fear of falling, balance con!dence and fall frequency resulted in R$= 0.53, 
0.49, 0.43, respectively. These results con!rm the earlier !nding that fear of falling and 
balance con!dence seem to be the major contributing factors.
DISCUSSION
Frequency of falls, fear of falling, objective (clinically observed) postural impairment and 
overall disease severity were all associated with reduced HrQoL. However, after account-
ing for overall disease severity (using the total UPDRS), only fear of falling contributed 
further to poorer HrQoL, whereas actual falls did not. This con!rms the results of an 
earlier study"&, which also found that fear of falling has a greater impact on HrQoL in PD 
than the presence of falls or other gait related disorders such as freezing of gait.  
Overall disease severity, which includes axial symptoms such as postural instability but 
also many other aspects of PD, remained the most important determinant of HrQoL. 
Furthermore, our !ndings are consistent with previous reports, showing that gender was 
not signi!cantly associated with worse HrQoL scores.$%$$ However, in contrast to those 
reports, we found a signi!cant relationship with age and disease duration, although the 
relation with disease duration lost signi!cance when UPDRS was taken into account and 
included in the analyses.
 We conclude that fear of falling is a signi!cant contributor to low health-related quality 
of life scores in patients with PD. Fear of falling appears to be a stronger predictor of 
reduced HrQoL scores than experiencing actual falls or objective clinically based mea-
sures of  balance impairment. This suggests that in clinical practice, fear of falling should 
be tackled as a problem in its own right. We therefore recommend that strategies to 
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improve quality of life in PD should aim not only at the prevention of falling, but also 
include assessment and treatment to reduce fear of falling, for example using balance 
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To summarize the latest insights into the clinical signi!cance, assessment, pathophysiol-
ogy and treatment of falls in Parkinson’s disease.
Recent studies have shown that falls are common in  Parkinson’s disease, even when com-
pared with other fall-prone populations. The clinical impact of falls is considerable, often 
leading to an incapacitating fear of renewed falls. The associated costs for society are 
substantial. Clinical assessment often inculdes the retropulsion test, and recent studies 
have o#ered practical recommendations regarding the execution and scoring of the test. 
Insights into the pathophysiology underlying falls are growing and point ot an important 
role for the loss of inter-segmental .exibility (‘sti#ness’), which predisposes patients to 
falls in a backward or medio-lateral direction. New evidence has clari!ed why Parkinson’s 
disease patients commonly fall during transfers and under ‘dual tasking’circumstances. 
The absence of adequately directed arm movements may explain the relatively high 
proportion of hip fractures in Parkinson’s disease. The importance of freezing of gait as a 
cause of falls is recognized, and we are beginning to understand the di#erent manifesta-
tions of gait freezing. Recent work has de!ned the contributions of pharmacotherapy, 
stereotactic neurosurgery,physiotherapy and multidiscliplinary interventions in the 
treatment of postural instability to prevent falls in Parkinson’s disease. 
No dramatic breakthroughs have occurred during the review period, but new information 
in various areas may be useful for practising clinicians. Interesting new questions have 
been raised theat should fuel studies of pathophysiological meachanisms, which could 
help in the development of improved treatment strategies to reduce falls in Parkinson’s 
disease.
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INTRODUCTION
Recurrent falls have great clinical signi!cance for patients with Parkinson’s disease (PD). 
Proper recognition of falls and knowledge of possible treatment options is important for 
various reasons. First, falls are common. A review of prospective surveys in PD concluded 
that almost 70% of patients falls at least once each year." These fall rates are even higher 
for patients with atypical parkinsonism. Second, falls have an enormous impact on the 
physical and psychological health of a#ected individuals, and negatively a#ect their 
quality of life.$%& Third, the speci!c nature of falls and the timing of their appearance in 
the disease process may help clinicians in di#erentiating PD from atypical parkinsonism. 
This distinction is clinically relevant, because tailored treatment options are available to 
reduce falls in di#erent disorders.'
This review summarizes progress in the !eld of falls in PD (Table 1), covering approxi-
mately the period between January 2003 and March 2004.For  the sake of this review, 
we will assume a theoretical model in which falls in PD are caused by several indepen-
dent, albeit often coexistent, mechanisms. These include postural instability (abnormal 
balance reactions to external perturbations), di/culty with transfers, gait disorders (in 
Table 1. Several topics of interest in the recent literature on falls in PD and atypical parkinsonism
Topic of interest
Clinical signi!cance
-   Epidemiology
-   Fear of falls
-   Costs
Pathophysiology
-   Posturography
-   Proprioceptive de!cits
-   Freezing of gait
-   Transfers
-   Dual tasking









particular freezing of gait, FOG) and orthostatic syncope. New insights about these dif-
ferent causative factors will be addressed with respect to their assessment, their role in 
the pathophysiology of falls, and their treatment.
CLINICAL SIGNIFICANCE
The clinical signi!cance of falls for patients with PD is determined by various di#erent 
factors, including the common occurrence of falls, their association with adverse psy-
chological consequences, and the high costs for society. We will review developments in 
these areas in the sections below.
Epidemiology
Several prospective studies have clari!ed the rates and circumstances of falls in PD.& The 
observed fall rates were consistently high and increased with longer duration of follow-
up. After one year, about 50% of patients has sustained recurrent (two or more) falls.( 
These fall rates are signi!cantly higher than those observed among community-dwelling 
elderly individuals.) Two recent studies extended these !ndings and showed that PD 
is one of the most common neurological disorders leading to recurrent falls.*%+ One 
retrospective study documented the causes for falls among inpatients who were newly 
admitted to a neurological department.* In a group of 489 patients, 34 % had  sustained 
falls in the previous year (as veri!ed from self-report). Out of 44 PD patients, 62% had 
fallen, suggesting that PD was the disorder that was most commonly associated with 
falls. The other study found that, among individuals with recurrent falls in the previous 
year, extrapyramidal signs or a diagnosis of PD were risk factors for renewed falls during 
follow-up.+ Drawbacks included the short follow-up for some patients (lower limit of only 
51 days), the absence of repeated neurological assessments during follow-up (to check 
for disease progression or appearance of new disorders) and the lack of insight into 
therapeutic interventions that might have a#ected the rate of falls.
Fear of falls
An underestimated sequel of falls is a fear of  renewed falls. This may lead to self-imposed 
restriction of daily activities and may therefore cause immobility, which in turn is as-
sociated with social isolation, osteoporosis and reduced !tness.& Previous studies had 
merely asked patients whether or not they were afraid to fall; almost 50% answered 
positively.) This issue was further addressed in a survey which reported that PD patients 
have a signi!cantly reduced balance con!dence compared to age-matched controls., 
Balance con!dence – as a surrogate marker for fear of falling – was estimated in detail 
using the 16-item Activities-speci!c Balance Con!dence (ABC) scale, which had not 
been used previously in PD. Interestingly, low balance con!dence scores correlated with 
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poorer performance on clinical tests for posture and gait, and also with greater disease 
severity(assessed using the Uni!ed Parkinson’s disease Rating Scale, UPDRS). 
Costs
A recent study underscored the impact of falls in PD for the society at large. Analyses of 
Medicare claims in the United States showed that over a 5-year period, individuals with 
parkinsonism were 1.3 times more likely to attend a hospital because of injuries than 
persons without parkinsonism."- This study also showed that fall-related injuries, hip 
fractures in particular, add greatly to the resource use (hospitalisation and skilled nursing 
facility care) and medical costs in PD.
ASSESSMENT
A proper physical examination is crucial to score the degree of postural instability, to 
judge the risk of future falls and to rate disease severity. The most widely test documents 
the postural reactions to an external perturbation, typically a sudden jolt applied to the 
shoulders (the retropulsion test). Despite its widespread application in everyday practice 
and in clinical trials, there is no formal agreement regarding the execution and scoring 
of the retropulsion test. Two recent studies made some practical recommendations. The 
!rst evaluated several variants of the retropulsion test with di#erences in execution and 
scoring."" The most valid test for postural stability in PD was the variant that consists 
of a single and unexpected shoulder pull (that is, no prior warning or instruction), and 
where taking two or more corrective steps backwards is abnormal. This variant best 
discriminated PD patients with and without postural instability. Because there is no gold 
standard for postural instability, patients were classi!ed as having postural instability if 
they had two ore more falls or near falls in the previous 6 months, or used walking aids, 
or used other speci!c measures to prevent falling. The second study identi!ed several 
sources of error in executing the retropulsion test."$ For this purpose, four di#erent raters 
critically evaluated the videotaped performance of a series of retropulsion tests, deliv-
ered by 25 movement disorders specialists. Commonly encountered errors included: tap-
ping or pulling the patient too lightly; not allowing su/cient space to document balance 
recovery strategies fully; holding the feet too closely together or too widely apart before 
the perturbation; pulling continuously, rather than suddenly; and allowing patients to 
brace forward prior to pulling. Unfortunately, judging the videotapes did not permit an 
analysis of previous instructions given to the patients.
Other common clinical tests in PD include the Functional Reach (ability to reach forward 
as far as possible, keeping the feet in place) and the Timed Up and Go test. A medication 
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study of eight patients showed that both tests produced comparable scores on two dif-
ferent days, suggesting good test-retest reliability in this small sample."& 
Falls in PD occur under a variety of di#erent circumstances, and many di#erent patho-
physiological mechanisms contribute to falls. It is therefore unlikely that a single test 
will be able to predict all fall events. It seems best to use a test battery of di#erent 
components of posture, balance and gait. Such rating scales are available, but were 
not speci!cally developed for use in PD. For example, the Tinetti Mobility Index is used 
widely in elderly populations, but is not sensitive to changes in gait of patients with PD. 
"' A recent study made a welcome attempt to develop a comprehensive clinical gait and 
balance scale that could be used in PD(although this was not speci!cally developed for 
this disorder."( The scale included historical information, a physical examination and 
timed tests. Several items of this scale had moderate interrater reliability and correlated 
to some extent with quantitative measures of gait (using an electronic walkway that 
measured spatio-temporal gait parameters) and balance (analysis of weight shifts on a 
forceplate). However, the scale could be criticized for various reasons: many items had 
only fair or even poor interrater reliability; the R$ for the concurrent validity with the 
quantitative measures was rarely impressive; history taking could be improved, e.g. by 
using more detailed questionnaires for FOG")  and by asking about near falls or injuries; 
the physical examination could be improved, including the retropulsion test; and the 
inconsistent use of two-point, three-point and four-point scores. Therefore, much work 
remains necessary to improve this and other rating scales further.
PATHOPHYSIOLOGY
The area in which most progress was reported in recent years was likely the pathophysi-
ology of falls in PD, where new insights were gained with respect to the contribution 
of (among others) axial sti#ness, protective arm movements, central proprioceptive 
integration de!cits and freezing of gait.
Posturography
Clinical observations may generate interesting hypotheses about fall mechanisms, 
but complementary posturography studies – with standardized postural perturba-
tions and quantitative outcome measures"*, are required to unravel fully the complex 
pathophysiology underlying falls in PD. This sequence of events is nicely illustrated by 
recent observations on protective arm movements in PD. For some time, clinicians have 
had the impression that in PD, wrist fractures may be less common than hip fractures. 
This suggestion was underscored by the aforementioned study of health costs in PD, 
which incidentally showed that upper extremity injuries are signi!cantly less common 
than lower extremity injuries."-%"+ At !rst sight, this !nding is unexpected because pa-
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tients with PD fall predominantly forwards.", Such forward falls are typically associated 
with wrist factures because individuals land on the outstretched hand. One possible 
explanation is that arm movements are delayed or abnormally directed in PD. To test 
this hypothesis, a recent study examined protective arm movements in PD patients who 
stood on a suddenly rotating platform.$- Although patients had abnormally early onsets 
of deltoid muscle responses (documented using surface electromyography), this gave no 
functional protection because kinematic analyses showed that patients had a decreased 
arm .exion in the forward-afterward direction, and an increased adduction in the 
medial-lateral direction. These abnormally directed arm movements kept the patients 
from grasping for support, and also prevented the arms from performing a “counterbal-
ance” function (keeping the centre of gravity away from the impending fall-direction).$"%$$ 
These abnormally directed arm responses could explain why upper extremity injuries 
are relatively rare in PD, and could underlie the high incidence of hip fractures because 
patients fall onto the unprotected trochanter (Figure 1). Absence of adequate arm pro-
tection may also explain why fall-related injuries – fractures or soft tissue damage – seem 
more severe among PD patients compared to other neurological patients.*
Three papers described the use of moving platforms that could suddenly move in 
multiple di#erent directions (multidirectional dynamic posturography) to clarify the 
pathophysiology of falls in PD. Two of these papers came from a single study that used 
ankles [20,24 .]. An ther dynamic posturography study
found additional evidence f r axial stiffness in PD
patients who were exposed to relatively slow platform
tilts in the sagittal plane [25 ..]. In that study, patients
had smaller righting responses of the upper body relative
to the lower body, suggesting inter-segmental stiffness.
A further study observed trunk stiffness during gait [26],
as reflect d by reduced lateral bending, reduced rota ion
and smaller pitch movements of the trunk. Mechanisms
that might contribute to axial stiffness include co-
contraction, high background muscle activity, age or
immobility-related changes in the elasticity of joints,
muscles and ligaments, or the fear of falling, which may
cause a tive stiffening [9..,24.,26]. Stiffening has the
dvantage that fewer degrees of freedom need to be
controlled, and that static sway is minimized, thereby
reducing the risk of exceeding the limits of stability.
However, this ‘advantage’ is offset by the loss of the
necessary flexible responses that normally dampen
external perturbations [27 .]. This feature has been
termed ‘postural inflexibility’ and seems to be a critical
factor in causing falls in PD.
Further evidence for ‘postural inflexibility’ in PD came
from a dynamic posturography study in which patients
were forced to stand with a narrow base of support
[23 ..,24.]. Compared with controls, patients were less
able to increase their balance correcting responses and
adapt their reactive postural forces. Interestingly,
patients were less unstable when standing with a
wider-than-normal base of support. This observation
may offer opportunities for fall prevention using e.g.
physiotherapy, because PD patients typically tend to
adopt a narrow base of support.
Recent analyses of unperturbed stance (‘static posturo-
graphy’) provided additional insights into postural
mechanisms in PD. Previous studies of quiet stance
had yielded conflicting results, showing either increased
or reduced excursions of the centre of foot pressure
(CFP) compared with controls. Two studies have now
shown that postural tremor is one factor contributing to
an increased CFP path [25..,28.]. Interestingly, anti-
Parkinson treatment further increased the CFP excur-
sions, despite reduced tremor [25..]. The presence of
dyskinesias offers the simplest explanation for this
finding, but a more thought-provoking possibility is that
treatment reduced axial stiffness and thus unveiled an
underlying problem with regulating quiet stance, per-
haps because of a somatosensory integration deficit
(discussed in the next paragraph).
Proprioceptive deficits
Postural instability is generally thought to be caused by
disturbed motor programming within the basal ganglia.
However, this view is increasingly challenged by
observations that motor deficits in PD are at least partly
caused by proprioceptive disturbances. Afferent informa-
tion itself is presumably normal, but proprioceptive
signals seem abnormally processed within the basal
ganglia because of defective higher level integration. So
far, such proprioceptive disturbances in PD have mostly
been demonstrated for the upper extremities [29 .,30.].
Howev r, proprioceptive disturbances may also contri-
bute to the pathophysiology of postural deficits in PD in
various ways [31]. First, the inability to process changes
in peripheral input properly could explain the fixed gain
of postural responses that underlies the aforementioned
postural inflexibility in PD [20,23..]. Second, patients
might have an abnormally constructed internal map of
their stability limits or have lost their normal sense of
limb and trunk position. Such ‘body schema’ distortions
could explain the difficulties with turning movements
and trunk coordination, as mentioned earlier [20,32,33.].
Interestingly, the abnormal trunk responses to postural
perturbations in PD, as observed in one study [20],
resembled the pattern seen in a ‘deafferented’ patient
[34], suggesting that PD patients resort to a stiffening
strategy to compensate for defective information about
body position in space. The mechanisms underlying
central proprioceptive integration are unclear, but recent
animal work has suggested a role for dopaminergic
pathways [35 ..]. That study observed that rats with
unilateral nigral lesions induced by 6-hydroxydopamine
kept their head deviated to the side of the lesion,
Figure 1. Cartoon illustrating the different fall mechanisms that
occur with aging and in Parkinson’s disease
Aging
Parkinson's disease
(a) Healthy elderly individuals stretch out their arms into the direction of
the impending fall [22], and this may contribute to the high incidence of
wrist fractures with aging. (b) In contrast, Parkinson’s disease (PD)
patients adduct their arms against the trunk, thereby exposing the
unprotected trochanter of the hip [20].
Redrawn from Bloem et al. [18].
Movement disorders408
Fig 1 Cartoon illustrating e di#erent fall mechanismes that occur with aging and in Parkinson’s disease.
(a) Healthy elderly individuals stretch out their arms into the direction of the impending fall $$, and this 
may contribute to the high incidence of wrist fractures with aging. (b) In contrast, Parkinson’s disease 
patients adduct their arms against the trunk, thereby exposing the unprotected trochanter of the hip.$-
Redrawn from Bloem et al."+  
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horizontal translations in eight directions$&%$'; the other study employed support surface 
rotations in six directions.$- Despite di#erences in nature of the postural perturbations, 
both studies yielded strikingly similar results. Key !ndings included: a directional prepon-
derance for falls in a backward and, to a lesser extent, mediolateral direction; presence of 
co-contraction between agonist and antagonist muscles, both in the legs and trunk; and 
presence of excessive background muscle activity.
The multidirectional posturography studies also observed a sti#ening response in the 
pelvis, trunk and ankles.$-%$& Another dynamic posturography study found additional evi-
dence for axial sti#ness in PD patients who were exposed to relatively slow platform tilts 
in the sagittal plane.$( In that study, patients had smaller righting responses of the upper 
body relative to the lower body, suggesting inter-segmental sti#ness. A further study 
observed trunk sti#ness during gait, as re.ected by reduced rotation and smaller pitch 
movements of the trunk.$) Mechanisms that might contribute to axial sti#ness include 
co-contraction; high background muscle activity; age- or immobility-related changes 
in elasticity of joints, muscles and ligaments; or fear of falling which may cause active 
sti#ening.,%$'%$) Sti#ening has the advantage that fewer degrees of freedom need to be 
controlled, and that static sway is minimized. However, this “advantage” is o#set by the 
loss of necessary .exible responses that normally dampen external perturbations.$* This 
feature has been termed “postural in.exibility” and seems a critical factor in causing falls 
in PD.
Further evidence for “postural in.exibility” in PD came from a dynamic posturography 
study where patients were forced to stand with a narrow base of support.$&%$' Compared 
with controls, patients were less able to increase their balance correcting responses and 
adapt their reactive postural forces. Interestingly, patients were less unstable when with 
a wider-than-normal base of support. This observation may o#er opportunities for fall 
prevention using e.g. physiotherapy, because PD patients typically tend to adopt a nar-
row base of support.
Recent analyses of unperturbed stance (“static posturography”) provided additional 
insights into postural mechanisms in PD. Previous studies of quiet stance had yielded 
con.icting results, showing either increased or reduced excursions of the centre of foot 
pressure (CFP) compared with controls. Two studies have now shown that postural tremor 
is one factor contributing to an increased CFP path.$(%$+ Interestingly, antiparkinson treat-
ment further increased the CFP excursions, despite reduced tremor.$( The presence of 
dyskinesias o#ers the simplest explanation for this !nding, but a more thought-provok-
ing possibility is that treatment reduced axial sti#ness and thus unveiled an underlying 
problem with regulating quiet stance, perhaps because of a somatosensory integration 
de!cit (discussed in the next paragraph).
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Proprioceptive de!cits
Postural instability and falls are generally thought to be caused by disturbed motor 
programming within the basal ganglia. However, this view is increasingly challenged 
by observations that motor de!cits in PD are at least partly caused by proprioceptive 
disturbances. A#erent information itself is presumably normal, but proprioceptive 
signals seem abnormally processed within the basal ganglia because of defective 
higher level integration. So far, such proprioceptive disturbances in PD have mostly 
been demonstrated for the upper extremities.$,%&-  However, proprioceptive disturbances 
may also contribute to the pathophysiology of postural de!cits in PD, in various ways.&" 
First, inability to properly process changes in peripheral input could explain the !xed 
gain of postural responses that underlies the aforementioned postural in.exibility in 
PD.$-%$& Second, patients might have an abnormally constructed internal map of their 
stability limits or have lost their normal sense of limb and trunk position. Such “body 
schema” distortions could explain the di/culties with turning movements and trunk 
coordination, as mentioned earlier.$-%&$%&& Interestingly, the abnormal trunk responses to 
postural perturbations in PD, as observed in one study$-, resembled the pattern seen in 
a “dea#erented” patient&', suggesting that PD patients resort to a sti#ening strategy to 
compensate for defective information about body position in space. The mechanisms 
underlying central proprioceptive integration are unclear, but recent animal work sug-
gested a role for dopaminergic pathways.&( That study observed that rats with unilateral 
nigral lesions induced by 6-hydroxydopamine kept their head deviated to the side of the 
lesion, perhaps due to body orientation problems reminiscent of those seen in PD. 
Freezing of gait
Gait impairment and, in particular, FOG episodes are a frequent source of falls in PD.&) The 
aforementioned study of falls among neurological inpatients concluded that, within the 
subgroup of PD, falls were often associated with FOG, and also with turning di/culties.* 
These turning problems are presumably also related to FOG. A recent study con!rmed 
earlier impressions that FOG, at least when present during an “OFF” state – is most 
commonly elicited by sudden turns.&* In keeping with this observation, another study 
showed that PD patients have particular di/culty initiating gait when a step must be 
directed diagonally, along with turning the trunk into the same direction.&&
Other studies challenged the belief that FOG is a paroxysmal gait disorder, leading 
to sudden motor blocks during an otherwise largely preserved gait. Using pressure-
sensitive insoles to analyse strides, Hausdor# and colleagues observed that patients 
with FOG have an increased stride-to-stride variability, even outside episodes with overt 
FOG.&+%&, This observation fuelled interesting speculations. First, the results suggest that 
complete motor blocks are only the most extreme form of FOG, and that more subtle 
disturbances of gait rhythm can be present continuously. In fact, total akinesia is a much 
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rarer manifestation of FOG than walking with small steps or with the legs trembling in 
place.&* Furthermore, the feet oscillate in a fairly organized pattern during FOG episodes 
with a frequency distinct from normal gait or tremor.&+ This suggests that disruption of 
one or possibly more central pattern generators is involved in the pathophysiology of 
FOG. Second, the observations may have clinical relevance, because an increased gait 
variability is related to historical falls in PD.'- Whether gait variability also relates to future 
falls remains to be established.
A preliminary study showed that under everyday circumstances, most PD patients fall 
predominantly forward.", These forward falls might be caused by di/culties with gait 
termination (sudden cessation of stepping while the trunk still continues to move for-
ward). Attempts of the patients to ‘çatch up’ with the trunk would then lead to festination 
or propulsion. Indeed, gait festination was related to historically ascertained falls in one 
study.'' Normal gait termination calls for cessation of locomotor activity, as well as activa-
tion of braking forces. A study of unexpected gait stops showed that PD patients are able 
to launch normally shaped stopping strategies, but with undersized muscle responses, 
leading to weak braking impulses.'$ FOG might also play a role, because this commonly 
occurs when patients reach a destination.&*
Transfers
Falls in PD commonly occur when patients make transfers, such as rising from a chair or 
lying down in bed.&$%'& Better insight is needed to understand why transfers are so prob-
lematical in PD. Two studies showed that leg weakness, particularly at the hip, explains 
at least part of the di/culties experienced by PD patients while attempting to rise from a 
chair.''%'( In the light of such !ndings, one might feel tempted to prescribe strengthening 
exercises, as these are e#ective in improvimg balance in PD.') However, the e/cacy of 
strength training to improve transfers speci!cally remains to be demonstrated for PD 
patients.'* Alternative strategies to improve transfers are available, including the ‘chain-
ing technique’: splitting complex movements into a series of simple components that are 
to be executed sequentially.'+
Dual tasking
Ever since Lundin-Olsson and colleagues', published their seminal paper on the relation 
between falls and inability to simultaneously walk-and-talk, there has been considerable 
interest in the nature and clinical relevance of such “dual tasking problems”. It was logical 
to speculate that PD patients would also be vulnerable when one or more tasks have to 
be performed concurrently with balancing, because the basal ganglia are important for 
organizing sequential or simultaneous movements. However, cognitively intact PD pa-
tients can usually walk and talk at the same time, and inability to do so did not correlate 
with falls in daily life.(- A recent study showed that talking while walking also failed to 
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identify fallers among older persons without overt cognitive impairment.(" At !rst sight, 
this would suggest that dual tasking di/culties are perhaps a better marker for cognitive 
impairment than for postural instability or falls. Lundin-Olsson et al', included mostly 
individuals with cognitive impairment.  However, deleterious e#ects of secondary tasks 
on balance could be detected using advanced electrophysiological analysis of postural 
performance. For example, one study used a static posturography platform to examine 
the e#ect of secondary cognitive or motor tasks on reactive forces under the feet.($ 
Under dual task conditions, CFP excursions increased disproportionately in PD patients 
comparedwith controls. Interestingly, this was particularly true for patients with previ-
ous falls, suggesting relevance for daily life functioning. Another study showed that gait 
variability, which is increased in PD and represents a marker for falls in daily life, increases 
further when PD patients are challenged by a secondary cognitive task.(&
Syncopal falls
Falls due to a preceding loss of consciousness are deemed rare in PD.) When present, such 
syncopal falls are usually ascribed to the intake of dopaminergic medication, which may 
cause orthostatic hypotension. Recent work has suggested that orthostatic hypotension 
can also occur in untreated patients as a result of  sympathetic neurocirculatory failure, 
as re.ected by an abnormal blood pressure responses to a Valsalva manoeuvre, by a 
reduced myocardial dopamine uptake and by reduced plasma norepinephrine levels.($. 
The relation with falls was not investigated, and this should be the subject of future stud-
ies. Timely recognition of orthostatic hypotension has clinical relevance, because various 
therapeutic measures are available to reduce syncopal falls.((
TREATMENT
Reducing falls by treating gait and balance impairment is di/cult for most PD patients. 
Recent studies are largely in keeping with this notion, and highlight not only the limited 
e#ects of pharmacotherapy and stereotactic neurosurgery, but also point to unexpected 
e#ects of alternative treatment strategies such as multidisciplinary teamwork and mobil-
ity aids.
Pharmacotherapy
Dopaminergic medication can sometimes reduce falls in PD. A dopa-responsive cause of 
falling is FOG during “OFF” periods. Levodopa can improve the frequency and duration 
of FOG episodes during “OFF” periods, and also reduces gait variability.&*%&,%'- However, 
the improvements were partial because stride time variability remained increased in the 
subgroup of prior fallers.
120
6
Most other postural disturbances – including falls – generally do not respond poorly to 
antiparkinson medication. This notion was corroborated by a small clinical study that 
examined balance and mobility in moderately a#ected PD patients before and several 
times after intake of the !rst morning dose of antiparkinson medication."& There were 
no .uctuations in gait and balance, which suggests that the underlying pathophysiol-
ogy involves non-dopaminergic pathways. However, interpretation of this study was 
complicated by the fact that a manual tapping test, a measure of bradykinesia, also re-
mained unchanged, suggesting that the dose of antiparkinson medication was perhaps 
insu/cient to produce a full “ON” state. Recent posturography studies also underscored 
that most balance de!cits in PD, in particular the postural reactions to support surface 
perturbations, are largely resistant to dopaminergic therapy.$-%$(
The reasons for the poor e#ect of dopaminergic medication on balance impairment 
remain largely unknown, but several explanations are possible. First, postural instabil-
ity typically appears late in the course of PD. By this time, the dopaminergic de!ciency 
may be so pronounced that pharmacological correction becomes di/cult, particularly 
because adequate dosing is progressively hampered by dose-limiting adverse e#ects in 
late-stage PD. Supporting evidence for this explanation was o#ered by an interesting 
study of rats with unilateral nigral lesions induced by 6-hydroxy dopamine.&( The results 
showed that some postural de!cits, including rotational behaviour induced by apomor-
phine, occurred in animals with moderately severe dopamine loss, but that additional 
postural de!cits only appeared in animals with more severe dopaminergic de!cits. This 
suggests a link between degree of dopamine depletion and balance abnormalities, at 
least in rodents.
Another explanation is that falls are related to the presence of non-dopaminergic 
lesions, which typically emerge with advancing disease.() One way to ‘prove’ that non-
dopaminergic mechanisms play a role is by showing improvements in postural perfor-
mance after the administration of drugs that act via non-dopaminergic pathways. This 
was the topic of two trials. The !rst was a double-blind and placebo-controlled study 
of .upirtine, a functional antagonist of N-methyl-D-aspartate (NMDA) with a con!rmed 
in.uence on automatic postural responses in healthy subjects.(* A single dose of 50 mg 
or 100 mg .upirtine failed to improve automatic postural responses to sudden tilts of a 
supporting platform. Clinical balance scores also remained unchanged, but it is still pos-
sible that higher doses or prolonged administration do relieve balance impairment. The 
second was an open-label study, which showed that intravenous .umazenil, a gamma-
aminobutyric acid antagonist, tended to improve the UPDRS scores for posture, balance 
and gait, and also tended to improve a timed walking test.(+ A placebo e#ect might have 
caused the small improvements, and the short half-life makes this drug impractical for 
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use in clinical practice. The e/cacy of non-dopaminergic drugs therefore remains to be 
demonstrated convincingly.
Stereotactic neurosurgery
Stereotactic neurosurgery of the basal ganglia is a therapeutic alternative for patients 
who respond well to dopaminergic therapy, but su#er from dose-limiting treatment 
complications. The e#ects on axial symptoms, including falls, are incompletely under-
stood, except for the fact that thalamic surgery and bilateral pallidotomy (with lesions 
placed in the internal globus pallidus, GPi) often cause or aggravate balance de!cits.(,
The e#ects of unilateral pallidotomy were examined in a randomised trial of surgery 
versus medication.)- Compared with optimal drug therapy, unilateral pallidotomy sig-
ni!cantly improved clinical gait and balance scores after 6 months of follow-up. However, 
this di#erence was not sustained after 2 years. Another study showed that unilateral palli-
dotomy gave no marked improvement of unperturbed stance (measured quantitatively 
using a static forceplate).$+ A third study showed that unilateral pallidotomy improved 
the walking speed, but reaching movements, which may be relevant for falls in daily life, 
responded inconsistently.)" These results are unimpressive and, along with the contra-
indication for bilateral surgery (which is presumably required for optimal relief of axial 
symptoms), suggest that patients with falls are no good candidates for pallidotomy.
Bilateral stimulation of the subthalamic nucleus (STN) may improve gait and elements 
of postural instability in properly selected patients. A recent paper reported the 5-year 
follow-up of bilateral STN stimulation in 49 patients.)$ Using the UPDRS as clinical out-
come measure, this study showed an improvement of postural stability, gait and FOG 
during the ‘OFF’ phase which persisted after 5 years. However, gait and balance during 
the ‘ON’ phase deteriorated from the !rst year onward, perhaps re.ecting natural disease 
progression (but there was no control group without surgery to prove this). Adverse 
e#ects on balance and gait were not reported, or could the aggravation of ‘ON’ state 
scores be regarded as such? Another comprehensive study, using both static and dy-
namic posturography, showed that bilateral STN stimulation reduced axial sti#ness and 
postural tremor during unperturbed stance.$( However, dynamic postural reactions to 
platform tilts were not improved, and the abnormal response to a moving visual scene 
improved only partially. Other studies showed that bilateral STN stimulation can improve 
gait, both clinically (UPDRS scores) and more objectively (kinematics). Improvements 
were seen for ‘traditional’ measures such as walking velocity or stride length,)& and also 
for abnormal trunk movements during gait.$) Most studies observed a synergistic e#ect 
of STN stimulation with levodopa.$(%$)%)& These joint !ndings are promising, but bilateral 
STN stimulation remains far from a panacea for all balance problems.
122
6
Fig 2 Meta-analysis of published studies, showing the pooled e#ect and 95% con!dence intervals of the 
Uni!ed Parkinson’s disease Rating Scale scores for postural instability and gait disability for three di#erent 
types of surgery, as well as the overall e#ect, both in the ‘OFF’ state and in the ‘ON’ state (b).
Compared with optimal drug therapy, unilateral palli-
dotomy significantly improved clinical gait and balance
scores after 6 months of follow-up. Howev r, th s
difference was not sustained after 2 years. Another st dy
showed that unilateral pallidotomy gave no marked
improvement of unperturbed stance (measured quanti-
tatively using a static forceplate) [28.]. A third study
showed that unilateral pallidotomy improved the walk-
ing speed, but reaching movements, which may be
relevant for falls in daily life, responded inconsistently
[61]. These results are unimpressive and, along with the
contra-indication for bilateral surgery (which is presum-
ably required for the optimal relief of axial symptoms),
suggest that patients with falls are not good candidates
for pallidotomy.
Bilateral stimulation of the subthalamic nucleus (STN)
may improve gait and elements of postural instability in
properly selected patients. A recent paper reported the
5-year follow-up of bilateral STN stimulation in 49
patients [62..]. Using the UPDRS as a clinical outcome
measure, the study showed an improvement of postural
stability, gait and FOG during the ‘OFF’ phase that
persisted after 5 years. However, gait and balance during
the ‘ON’ phase deteriorated from the first year onward,
perhaps reflecting natural disease progression (but there
was no control group without surgery to prove this).
Adverse effects on balance and gait were not reported, or
could the aggravation of ‘ON’ state scores be regarded as
such? Another comprehensive study, using both static
and dynamic posturography, showed that bilateral STN
stimulation reduced axial stiffness and postural tremor
during unperturbed stance [25..]. However, dynamic
postural reactions to platform tilts were not improved,
and the abnormal response to a moving visual scene
improved only partly. Other studies showed that bilateral
STN stimulation can improve gait, both clinically
(UPDRS scores) and more objectively (kinematics).
Improvements were seen for ‘traditional’ measures such
as walking velocity or stride length [63], and also for
abnormal trunk movements during gait [26]. Most
studies observed a synergistic effect of STN stimulation
with levodopa [25 ..,26,63]. These joint findings are
promising, but bilateral STN stimulation remains far
from a panacea for all balance problems.
Only a few studies have directly compared the different
types of deep brain surgery. In a recent randomized trial,
bilateral STN stimulation afforded greater symptomatic
relief compared with unilateral pallidotomy, but im-
provements in postural instability or falls were not
specified [59 .]. The incidence of persistent adverse
effects on balance appeared to be roughly equal. Another
study compared the effects of bilateral STN stimulation
versus bilateral iGP stimulation on unperturbed stance
[64 .]. Significant baseline differences between patients
selected for either type of surgery prohibited a detailed
face-to-face comparison. Finally, a recent meta-analysis
of published trials reviewed the effects of three types of
Figure 2. Meta-analysis of published studies, showing the pooled
effect and 95% confidence intervals of the Unified Parkinson’s
Disease Rating Scale scores for postural instability and gait
isability for three different types of surgery, as well as the overall
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The effect is expressed as the difference score compared with the
preoperative state. A positive score indicates improvement; no overlap of
the confidence interval with zero indicates a significant effect of surgery.
PIGD, Postural instability and gait disability.
~ Unilateral pallidotomy;& bilateral subthalamic nucleus stimulation;~
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Redrawn from Bakker et al. [59.], with permission.
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The e#ect is expressed as the di#er nce score compared with the pr operative state. A positive score 
indicates improvement; no overlap of the con!dence interval with zero indicates a signi!cant e#ect of 
surgery. PIGD, Postural instability and gait disability (!) Unilateral pallidotomy; (!) bilateral nucleus 
stimulation; 6 bilateral inter al globus pallidus stimulation; " overall e#ect.
Redrawn from Bakker et al (,, with permission. 
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Only few studies have directly compared the di#erent types of deep brain surgery. In 
a recent randomized trial, bilateral STN stimulation a#orded greater symptomatic relief 
compared to unilateral pallidotomy, but improvements in postural instability or falls were 
not speci!ed.(, The incidence of persistent adverse e#ects on balance appeared roughly 
equal. Another study compared the e#ects of bilateral STN stimulation versus bilateral iGP 
stimulation on unperturbed stance.)' Signi!cant baseline di#erences between patients 
selected for either type of surgery prohibited a detailed face-to-face comparison. Finally, 
a recent meta-analysis of published trials reviewed the e#ects of three types of deep 
brain surgery, unilateral pallidotomy, bilateral iGP stimulation or bilateral STN stimula-
tion, on UPDRS scores for posture, gait, balance and falls.(, The results showed signi!cant 
and approximately equal improvements in ‘OFF’ scores for bilateral stimulation of iGP or 
STN and, to a lesser extent, for unilateral pallidotomy (Figure 2). Smaller improvements 
were noted for ‘ON’ scores.
Physiotherapy
Many PD patients are referred to a physiotherapist for improvement of everyday activi-
ties, gait and balance.)( The e#ectiveness of physiotherapy was examined in comprehen-
sive meta-analyses.'*%))%)*%)+ All reviewed studies were hampered by methodological 
drawbacks, which made it impossible to con!rm or deny with certainty whether phys-
iotherapy has therapeutic e#ects in PD. However, the meta-analyses did note that most 
reviewed studies showed improvements of gait, everyday activities and quality of life fol-
lowing physiotherapy. Sensory cueing (providing subjects with rhythmic visual, auditory 
or mental stimuli) seems a promising technique to bypass the defective basal ganglia 
circuit and thereby reduce FOG in PD.)+ However, such improvements are no guarantee 
of fewer falls. For example, physiotherapy might render patients more active, thereby 
increasing their risk of falls. Moreover, it is possible that an increased gait velocity, which 
is frequently presented as an ‘improvement’ obtained with physiotherapy, might actu-
ally produce a less safe gait pattern. Unfortunately, falls have never been examined as a 
direct outcome of physiotherapy interventions in PD. As a surrogate outcome measure, 
a recent studie measured the e#ect of physiotherapy on balance.') Nine patients who 
completed a balance improvement exercise program were compared with six patients 
who completed a balance improvement and muscle strengthening programme. Both 
exercise programs lasted 10 weeks. Balance was examined pre- and post-intervention 
using a moveable platform. The results demonstrated a signi!cant improvement of bal-
ance scores in both groups. However, only the combined intervention group retained the 
e#ects after 4 weeks. Regrettably, the number of included patients was low, no control 
group was examined and the clinical relevance of posturography measures remains 





In general elderly populations, the most consistently successful approach to prevent 
falls has been multifactorial risk assessment, followed by tailored multidisciplinary 
interventions to target the identi!ed risk factors.),%*-%*" A similar strategy should be ef-
fective in PD, because the multifactorial pathophysiology underlying falls in this disease 
calls for a multidisciplinary approach. However, the e#ectiveness of multidisciplinary 
team intervention in PD remains to be investigated. A large randomized crossover trial 
recently compared patients and carers who had received multidisciplinary rehabilitation 
4 months before assessment with those who had not.*$ The results were striking, show-
ing a trend towards improved mobility (stand-walk-sit test) in treated patients, but this 
came at the expense of worsened general and mental health, as well as more strain for 
carers. This unexpected result sends us straight back to the drawing board, where new 
studies should be designed that focus on the pros and cons of di#erent mulidisciplinary 
interventions.
Other therapeutic measures
Placing subjects on a rapidly rotating chair might o#er a novel approach to treat FOG, and 
thereby reduce falls.*& Patients who had been placed on a rotating chair (speed between 
4 – 927/sec) until they felt nauseous showed a more than 50% reduction in FOG in daily 
life, with a gradual return to baseline over several days. The study had methodological 
drawbacks (including the open label design), but the time course of the e#ect seemed 
real and warrants further studies.
Walking aids are frequently prescribed for unstable patients, but a recent study showed 
that caution is needed when walkers are given to patients with FOG.*' Wheeled walkers 
gave no reduction in FOG, while standard walkers actually increased FOG. The latter are 
therefore best avoided in patients with FOG.
CONCLUSION
The research that was published in the review period did not produce dramatic break-
throughs in terms of unexpected new insights into the pathophysiology of falls, or a 
revolutionary treatment strategy that e#ectively abolished falls. However, useful new in-
formation was produced that helped to clarify the epidemiology, clinical signi!cance and 
pathophysiology of falls in patients with parkinsonism. Existing fall prevention strategies, 
ranging from pharmacotherapy to individually tailored multidisciplinary programs, have 
been scrutinized, and the results provide a basis for further re!nement of these inter-
ventions. Future studies should continue to elucidate fundamental pathophysiological 
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mechanisms, which could act as starting point for rational development of improved 
strategies to reduce the debilitating impact of falls in PD.
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Evaluating whether persons are unable to walk and talk simultaneously (“stops walking 
when talking”; SWWT) is a simple test with good predictive value for falls in frail, insti-
tutionalized elderly persons." Because it is relevant to know whether this test has similar 
predictive value in other populations prone to falls, we studied SWWT in Parkinson’s 
disease (PD). Recurrent falls in PD are incapacitating, but their prediction is di/cult.$ 
Theoretically, SWWT should be sensitive in PD patients who have di/culty performing 
multiple tasks sequentially or simultaneously.& This is also true when walking is one of 
the tasks.' 
Thirty-eight patients with idiopathic PD (mean age, 60.1 ±10.8 [SD] years; 34% women; 
mean Hoehn and Yahr stage, 2.3 ± 0.7 [SD]) and 35 controls (mean age, 58.0 ± 8.9 [SD] 
years; 74% women) participated. All persons were ambulant community residents with-
out depression or cognitive impairment (MMSE 1 24). SWWT consisted of a conversation 
during a standardized 150-meter walk (positive result if  persons stopped walking for 1 3 
seconds). Because we wanted the conversation to be cognitively challenging, the inves-
tigator (Y.A.M.G.) consistently used open (rather than closed) questions regarding details 
of the medical history and recent changes in medication. Such items are also emotionally 
important for most persons. Persons were followed up prospectively for 6 months, us-
ing standardized scoring forms to document all falls. Persons were also contacted by 
telephone every 2 weeks to ensure that all falls were documented. Recurrent (two or 
more) or injurious fallers were used as outcome measure. Fourteen of the PD patients 
(36.8%) reported 119 falls. Five of the controls (14.3%) reported a total of 7 falls. SWWT 
was abnormal in only 4 patients and in none of the controls. The reverse (stops talking 
while walking) never occurred. SWWT was positive in 2 patients that were fallers and in 2 
patients who did not fall. Comparing fallers with nonfallers within the PD group, SWWT 
had a poor sensitivity (14.3%; 2/14), although the speci!city was adequate (91.7%; 22/24). 
Pooling patients and controls improved the speci!city (96.3%; 52/54) at the expense of 
the sensitivity (10.5%; 2/19). SWWT was an unexpectedly poor predictor of falls in PD. In 
fact, although many patients fell, the test was only rarely abnormal. Hence, even if SWWT 
had greater discriminative power, most falls would not have been predicted. In contrast, 
many frail elderly persons cannot walk and talk simultaneously ", and this inability pre-
dicted falls much better than in PD. Di#erences in test execution are unlikely to underlie 
the discrepancy, although the nature of the conversation while walking was not speci!ed 
in the original report of Lundin-Olsson and colleagues."  The key di#erence is that many 
persons in the earlier study " were demented or depressed, whereas we excluded pa-
tients with cognitive impairment. This suggests that impaired dual-task performance is a 
better marker of falls associated with cognitive impairment than (extrapyramidal) motor 
impairment. In addition, age di#erences may partially explain our observations (includ-
ing those in controls), because all persons in our study were considerably younger than 
those studied by Lundin-Olsson and co-workers (mean age, 80.1 years)." We did con!rm 
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was normal in 17 subjects who were fallers. Finally, the low sensitivity obviously restricts 
the ability to identify eligible candidates for therapeutic intervention. 
We conclude that SWWT does not predict falls when cognition is preserved. The results 
of ongoing studies (www. carestudy.com/falls/intro.htm)( should further delineate the 
clinical use of SWWT. 
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Falls are common in Parkinson’s disease. It remains di/cult to predict these falls, presum-
ably because clinical balance tests assess single components of postural control, whereas 
everyday fall mechanisms are typically more complicated. A substantial proportionof 
everyday falls appears to occur while Parkinson patients attempt to perform multiple 
tasks at the same time. Furthermore, little attention is generally paid to the possible 
contribution of cognitive impairments to falls. The importance of mental dysfunction 
is supported by the fact that cognitive loading while walking or balancing can lead to 
marked deteriorations in postural performance, and there is some evidence to suggest 
that such “dual tasking” is particularly di/cult for elderly persons with dementia or 
depression. We examined what strategies Parkinson patients used when a basic walk-
ing task became increasingly challenging by adding additional tasks (both motor and 
cognitive). Most patients could perform a simple “dual task” test: simultaneously walking 
and answering simple questions. However, as the walking task became more complex, 
patients’ performance began to deteriorate. Interestingly, this was re.ected not only 
by failure to answer questions, but also by an increasing number of blocks in motor 
performance (walking and balancing). This behaviour was di#erent from that of both 
young and elderly controls, who appeared to sacri!ce performance on the cognitive task 
in order to optimise their gait and balance (“posture !rst” strategy). Preliminary evidence 
suggest that impaired multiple task performance is associated with a two-fold increased 
risk of sustaining falls in daily life. We conclude that Parkinson patients are less inclined 
than healthy persons to maintain a safe gait. Instead, Parkinson patients use a “posture 
second” strategy and treat all elements of a complex task with equal priority, which in 
daily life may go at the expense of maintaining balance and lead to falls.
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INTRODUCTION 
Life is about priority, evident even in mundane tasks such as driving a car and using a 
mobile phone at the same time. Most people can achieve this during regular driving, 
but the conversation is likely to cease temporarily when a busy crossing is approaching. 
This “secondary task” (or dual task, as it is more commonly termed) interference is at play 
during everyday tasks, including seemingly simple acts such as walking. In the !eld of 
balance and gait research, perhaps one of the most in.uential publications of the last 
decade was the description of the “stops walking while talking” (SWWT) test by Lundin-
Olsson and colleagues": an inability to walk and talk at the same time had a good predic-
tive value for the occurrence of falls in the next six months. This observation was made 
in a mixed group of elderly persons, may of whom were depressed, had dementia of 
both. Apparently, the two concurrent tasks of walking and talking competed within the 
central nervous system. The inference was that those unable to talk while walking had a 
restricted central processing capacity, permitting them to do only one task at a time to 
avoid a system overload. The restricted central processing capacity could also explain the 
association between ‘ stops walking when talking’ and dementia or depression;whether 
depression or dementia itself is in any way causally related to dual tasking limitations 
has never been demonstrated. Another consequence of this !nding – with a potentially 
far-reaching implication – was that gait was not a simple automatic task that is governed 
solely by subcortical structures, but in fact represents a much more complicated job 
requiring conscious attention and perhaps some ongoing cognitive processing.
The Lundin-Olsson paper left many questions unanswered. For example, it is theoretically 
possible that some persons purposely stopped walking while talking, simply because 
they considered this to be unsafe. If so, then such people who stop walking while talking 
should perhaps have the lowest risk of falling, not the highest, because they opted for 
a safe behaviour. Clearly, this was not true for the group as a whole, where the overall 
riskwas increased, but individual, within the group may have chosen di#erent strategies. 
In other words, dual tasking di/culties may well be solved in di#erent ways by di#erent 
populations, depending on such factors as age, disease status, or prior experience. This 
would set limitations to the generalisation of dual tasking problems. Also, some may 
have stopped walking while talking out of politeness to face the person you are talking 
to, which in e#ect deprives the person of visual feedback of the gait trajectory? This by 
itself may be enough reason for persons who rely heavily upon visual feedback to stop 
walking. And what about the nature of the secondary task, which was actually poorly 
de!ned in the original description as “maintaining a routine conversation”? Might a more 
complex and more demanding secondary task be able to predict falls even better? Is the 
dual task interference restricted to “cognitive” secondary tasks, or is a secondary “motor” 
task also able to jam the system? And, !nally, what about dual task problems in patients 
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with neurodegenerative diseases characterised by cognitive decline, restricted central 
processing capacities, or frequent falls?
Because of these many unanswered questions and the potentially important implica-
tions, the “SWWT principle” was widely followed and extrapolated to a host of other 
tasks – including balancing and a range of other secondary or even tertiary tasks  – and 
to a range of pathological conditions, including e.g. Alzheimer’s disease,$%& Parkinson’s 
disease (PD),'%(%) stroke,* vestibular disorders+ and peripheral neuropathy., Adverse ef-
fects on balance were noted not only for secondary tasks with cognitive loading, but also 
for types of secondary tasks that either stressed the motor systems or called for atten-
tion. For example, di/culty with carrying a glass of water while walking can also predict 
falls in the elderly."- Here, we will brie.y review our own work in this !eld, which mainly 
concentrated on patients with PD, with some extensions to the ageing processes. The 
results provided some new insights into the mechanisms underlying “failure” to execute 
multiple tasks simultaneously – and in particular on the role of priority processes.
PARKINSON’S DISEASE
Background
Falls are very common in patients with PD. Depending on the duration of follow-up and 
the method of falls ascertainment, prospective studies identi!ed an incidence of persons 
with at least one fall from 39 to 68%, and from 25 to 50% for recurrent (twice or more) 
fallers.""%"$%"&%"' The impact of these falls is considerable, due not only to the associated 
injuries, but also because of the secondary immobilisation caused by a fear of renewed 
falls."&%"(%") Prevention of these falls is important. Several strategies may be e#ective."*%"+ 
To implement prevention programs, fallers must be identi!ed in an early stage, but this 
remains di/cult in PD patients, presumably because most clinical balance tests merely 
assess single components of postural control, whereas everyday fall mechanisms are 
typically complicated. Indeed, in daily life, almost half of all falls occur while PD patients 
attempt to perform multiple tasks at the same time, for example carrying an object while 
walking.", Furthermore, falls in PD patients are probably the net result of a complex 
and multifactorial pathophysiology, with contributions of multiple “intrinsic” (patient-
related) and “extrinsic” (environmental) factors.$- Very few tests are speci!cally designed 
to measure this multifactorial character of postural instability.
In light of the Lundin-Olsson publication, we reasoned that a simultaneous challenge 
of posture and cognition might predict falls better than tests of isolated components of 
postural control. Multiple task performance may be particularly informative in PD patients 
because studies on arm motor control suggest that they cannot execute simultaneous or 
sequential tasks adequately.$" In addition, experienced clinicians noted that PD patients 
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may have di/culty with a second task while walking.$$ Finally, PD patients can improve 
their motor performance (including balance and gait) by using external cues or by fo-
cusing attention on the task at hand, allowing the frontal cortex to compensate for the 
defective basal ganglia circuitry.$&%$'%$( These “conscious” motor strategies could make PD 
patients vulnerable during performance of secondary tasks that distract their attention.
Dual task impairment
With these ideas in mind, various groups studied the in.uence of secondary tasks on gait 
or balance in patients with PD (summarised in Table 1). Although no two studies were 
the same, the general picture that clearly emerges from this work is that both gait and 
balance can deteriorate when a secondary task needs to be performed simultaneously. 
This was true both when the secondary task was cognitively demanding (e.g. mental 
arithmetic) or when it required a motor skill, such as carrying an empty or a loaded tray. 
For the “motor” tasks, additional factors may have played a role, including the need to 
pay attention to the task or – in the case of carrying a tray – visual deprivation of the 
gait trajectory and the subjects’ own feet. As expected, patients appeared to have extra 
di/culties when the secondary task was more demanding.'%&$ A recent paper drew at-
tention to extra variables that need to be accommodated in the overall equation when 
interpreting why patients have di/culty performing multiple tasks at the same time.&$ 
This study not only evaluated the in.uence of secondary motor and/or cognitive tasks on 
gait, but also analysed the contribution of common clinical symptoms to the disturbance 
of gait. The results showed that dual task problems are related not only to cognitive 
dysfunction and disequilibrium, but also – at least in part – to symptoms such as fatigue 
and depression.
We also studied the in.uence of secondary tasks on gait and balance. We initially began 
with applying the simple “SWWT” test to patients with PD.$* In that study, we included 
38 patients with idiopathic PD and 35 controls who were all ambulant community 
residents without depression or cognitive impairment (MMSE 424). SWWT consisted of a 
conversation during a standardised 150-meter walk, and we arbitrarily scored a positive 
result if persons stopped walking for 43 s. Persons were also followed prospectively for 
six months, using standardised scoring forms to document all falls. To our initial surprise, 
SWWT occurred in only four patients, and in none of the controls. More importantly, 
SWWT did not predict falls in PD, as the SWWT was positive in two patients that were fall-
ers and in two patients who did not fall. These results were con!rmed when we extended 
the original group to 59 patients and 55 controls in a subsequent study."& What could be 
the explanation for this striking discrepancy between our !ndings and those of Lundin-
Olsson and colleagues?" Setting aside possible small methodological di#erences, the key 
di#erence resided in the degree of cognitive co-morbidity. Indeed, many persons in the 
Lundin-Olsson study were demented or depressed, whereas we excluded patients with 
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better marker of falls associated with cognitive impairment than (extrapyramidal) motor 
impairment.
Some additional insights into dual task performance came from subsequent e#orts. In 
one study, we administered the original SWWT to 17 institutionalised elderly persons 
(mean age 86.3 years, range 79 to 93 years).&& In addition, we asked the subjects to walk 
two trials of 8 m each. During the !rst 8 m trial, no question was asked (control trial). 
During the second 8 m trial, subjects had to answer a simple question (“What is your 
age?”) after 2 m of walking. During both trials, we measured not only the simple trial du-
ration, but we also quanti!ed the amplitude of trunk sway and the angular velocity in the 
forward-backward (pitch) and side-to-side (roll) directions using a trunk sway measuring 
device – containing two orthogonally mounted and highly sensitive angular velocity 
sensors&'%&(  – that was strapped !rmly to the lower back (Swaystar system). Four of the 
17 persons (29%) stopped walking while talking during the SWWT as originallydescribed 
by Lundin-Olsson (i.e. during a routine conversation while walking in the corridor). This 
percentage quite similar to the 21% reported by Lundin-Olsson et al." However, when 
subjects were required to answer a simple question during a short (8 m) walking trajec-
tory, eight persons (47%) stopped walking while answering the question. This may have 
been caused by the greater “urge” to provide the answer because the short trajectory 
a#orded only little time to respond, unlike the SWWT that was applied during a longer 
walk (several hundred meters). In addition, we suspect that the brief test may also have 
caused greater problems because we used a sudden question, unlike the more predict-
able routine conversation during the SWWT. Elderly persons may well have greater 
problems with such sudden and unexpected events than with more predictable routines. 
Unexpected interruption of gait by an abrupt question might mimic an event leading to 
a fall more e#ectively than a predictable conversation during a longer walk. These results 
suggest that a shorter and much simpler version of the SWWT (asking a single question 
during an 8 m walk) may provide a fast and perhaps more e#ective method of identifying 
subjects with impaired dual task performance, classi!ed as “stoppers”, with less space 
requirements.
In the same study&&, we also observed that persons who stopped during the 8 m trial with 
a question had signi!cantly longer walking durations and, more interestingly, a larger 
trunk roll angular displacement. This was evident not only during the dual task trial, but 
also during the control trial without a question. This indicates that the “stoppers” had 
more lateral instability – perhaps an index of a heightened risk to fall sideways – even 
at a time when they did not come to a full stop. This was not apparent to the naked 
clinical eye, but was only unveiled by quantitative measurement of trunk movements 
using the angular velocity sensors. These results suggest that persons with impaired dual 
task performance have a poorer dynamic control of trunk roll. Other studies also used 
more sensitive quantitative outcome measures to document the e#ects of secondary 
tasks on the quality of gait or balance (see Table 1). For example, Hausdor# et al.) used 
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pressure-sensitive insoles to quantify strides, and observed an increase in stride vari-
ability in patients with PD who were subjected to a cognitively challenging task. Future 
studies should clarify whether such quantitative electrophysiological measures of gait or 
trunk movement also have the ability to predict actual falls in daily life.
In another study we determined the predictive value of dual tasking on falls in the gen-
eral population of oldest old (a cohort of 509 individuals, all aged 85 years).36 There were 
no selection criteria on health, and about 30% of subjects were demented (MMSE <24), 
while some 20% were depressed. In this cohort, we measured the walking time over a 
12-meter distance as well as verbal .uency to recite names of animals or professions 
during a 30 seconds period. In the dual task, we assessed performance when participants 
combined walking with reciting names. The incidence of prior falls was assessed by inter-
viewing the participants and checking their medical history. We found that no less than 
45 percent of our participants stopped walking during talking. The results also showed 
that dual task performance was related to prior falls, but – again to our surprise – it was in 
fact not a better predictor for incident falls than single task performance (simple walking 
time). This di#erence in results with prior studies"%"-%&* can be explained by di#erences 
in methods. Instead of a straightforward walk from one place to another, we asked our 
participants to walk back and forth along a 3-meter line. Consequently, participants had 
to make three 180-degree turns, what may have added considerable di/culty to the 
walking task. This could partially explain why so many persons stopped walking while 
talking in this study. Increased di/culty of the single walking task could also explain why 
the dual task provided little additional predictive information.
Such !ndings suggest that the very nature of the primary – and likely also the second-
ary – tasks may a#ect the overall predictive ability of the combined test. Indeed, such 
observations led to speculation that combinations of multiple motor tasks (e.g. walking 
plus carrying an object) may better probe areas of the central nervous system that are 
involved in motor or, even better, postural control than secondary mental tasks."-%"& It may 
also be possible to further increase the sensitivity of detecting balance di/culties by 
combining more or other simultaneous tasks to enhance overall task complexity. Indeed, 
strictly dual task designs do not always distinguish well between patients and controls, 
over and above any baseline di#erences between these groups.$*%$+ As mentioned earlier, 
evidence is now beginning to emerge that more demanding secondary tasks (or a more 
unpractised “primary” postural task) may be needed to fully bring out the balance de!-
cits, not only in elderly subjects&+%&,%'-, but also in patients with PD.'%&$ 
Multiple task impairment
We have explored this concept further in two studies in which we developed a true 
multiple task design. We speculated that combinations of various motor tasks would 
be particularly useful for patients without cognitive impairment, because their falls 
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are not well predicted by combining a single motor task with a mental task.$* We 
further reasoned that falls in daily life would be predicted best by tests that represent 
complex everyday situations.'" We also argued that falls would be predicted best 
by tests that truly challenge postural safety. Finally, we wanted to develop a bal-
ance test that would potentially be easy to apply in a consulting room by clinicians. 
To develop this “multiple task test” (MTT), we !rst identi!ed relevant risk factors for 
falls (from a literature review) and actual fall circumstances (from a prospective survey 
of falls in PD).'$ The factors identi!ed from this review were “translated” into functional 
tests (or postural “components”) that resembled everyday situations. We distinguished 
a “cognitive” component (answering a series of relatively simple questions regarding 
everyday situations, in order to provide a continuous and veri!able cognitive load) from 
largely “motor” components (standing up, sitting down, turning around, walking, avoid-
ing obstacles, and touching the .oor). Four additional components included carrying 
an empty or loaded tray, wearing shoes with slippery soles and reduced illumination. 
These components were combined to yield eight separate tasks of increasing complexity 
that had to be executed sequentially. The !rst and simplest task consisted of standing 
up, undisturbed walking, turning around and sitting down. For each of the next tasks, a 
new component was added to the previous and otherwise identical task. All components 
within each task had to be performed simultaneously. The MTT thus contained all desir-
able ingredients for an optimal multiple task design: perceptual manipulations (reduced 
illumination), cognitive manipulations (answering the questions), motor manipulations 
(e.g. turning) and mechanical manipulations (e.g. avoiding obstacles).'" Unlike some 
other studies'&, we urged subjects only once (at the beginning of the experiment) to not 
purposely prioritise any given component. If this instruction is continuously repeated, 
one might theoretically obscure any tendency to ‘disobey’ the initial instruction and to 
lend priority to what subjects perceive as the primary task (e.g. maintaining balance). 
The study of such priority strategies was a main goal of our study. Impaired multiple task 
performance can be re.ected by slowing&%"-%&* or a complete stop"%''  in executing one or 
more components. Therefore, errors in performance for all tasks were scored as follows: 
rapid performance of all components within the task (“Normal”); obvious slowing in one 
or more components within the task (“Hesitation”); complete stop or inability to perform 
one or more components within the task (“Block”). Hesitations and Blocks were analysed 
separately, and also combined as Errors. The scoring was simply done through clinical 
inspection, without complex electrophysiological instrumentation. Errors were scored 
separately for execution of the motor and cognitive components.
The MTT was !rst administered to 50 young healthy subjects and 13 elderly subjects.'$ 
All subjects completed the MTT without falling. In both age groups, 62% of subjects per-
formed all eight tasks without any Errors in the motor components (Figure 1A). Among 
those making Errors, the proportion of subjects that made motor Errors increased 
signi!cantly as the tasks became more complex. More elderly subjects produced motor 
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phenomenon indeed occurs in healthy subjects who show
Parkinson-like impairments on cognitive tasks if sufficiently
distracted by demanding secondary tasks [46]. Alternatively,
patients may have lost the ability to lend priority to
complete particular components of a complex task. If this
were true, performance of the postural task would deterio-
rate by a challenge to multiple components of postural
control. Patients might even be expected to fall, while
attempting to continuously perform all components of the
task.
We addressed these questions by administering the
MTT to 20 non-demented PD patients, and compared their
performance to that of the previously tested controls [29].
Significantly more patients produced Errors than young
and elderly controls, and only 8% of the patients
completed all tasks without any motor Errors (Fig. 1A).
Patients particularly produced more motor Errors than
controls during the most complex tasks. Interestingly, this
difference between patients and controls disappeared if the
cognitive component was also scored, because more
controls made cognitive Errors during complex tasks than
patients (Fig. 1B). Patients apparently gave less priority to
execution of the motor components. Patients thus seemed
less able than controls to employ a ‘‘posture first’’ strategy,
but instead attempted to perform all tasks simultaneously.
However, due to their balance impairment and restricted
processing resources, neither motor nor cognitive compo-
nents were executed very successfully. This might be
interpreted as a form of ‘‘risky’’ behaviour that might lead
to falls in daily life. In fact, one patient actually had an
imminent fall during the eighth task that was prevented by
the examiner. The clinical relevance of our findings is
further underscored by the fact that more than half of our
patients reported difficulties with simultaneous tasks in
daily life, including simultaneous motor tasks, such as
carrying a tray while walking. Many patients described
falls during situations that resembled the most complex
tasks of the MTT.
In a subsequent follow-up study, we examined the
predictive value of the MTT by asking the 20 PD patients
and 20 matched controls to prospectively monitor their falls
in daily life for 6 months using standardised diaries (Bloem
and Munneke, unpublished observations). Because of the
relatively small sample size, we have pooled the data of
patients and controls. At least one motor Error was made by
21 of the 40 subjects. Only three out of the 19 subjects who
produced no motor Errors during the MTT fell during the 6-
month follow-up, while 7 out of the 21 subjects with !1
motor Error fell during the same time period (Relative Risk
[95% confidence interval]=2.1 [0.63–7.01]). Although the
confidence interval was wide due to the small sample size
and limited number of incident falls, these preliminary
findings do suggest that impaired performance on the MTT
was associated with a two-fold increase in the risk of falling.
Furthermore, it is interesting to note that only 10 out of the
21 falls in the Lundin-Olsson study [1] were identified by
the SWTT, whereas 7 out the 10 falls in our study were
identified by the MTT. This may reflect a good sensitivity
for the MTT, which could be useful for a screening device to
Fig. 1. A. Kaplan–Meier curves for the cumulative proportion of subjects
with a completely Error-free performance for all motor components within
each respective task of the MTT. Subjects who made an Error (Hesitation or
Block) for at least one motor component of any given task were excluded
from the following tasks. Errors in the cognitive component (answering
serial questions) were ignored for this analysis. Only 7.7% of the patients
had an Error-free performance, as opposed to 62.0% in both control groups
( p <0.0001). B. Kaplan–Meier curves for the cumulative proportion of
subjects with a completely Error-free performance for all components (both
motor and cognitive) within each respective task of the MTT. Subjects who
made an Error for at least one component of any given task were excluded
from the following tasks. 16% of the young controls, 30.8% of the elderly
controls and none of the patients completed the test without any Errors (no
significant difference).
B.R. Bloem et al. / Journal of the Neurological Sciences 248 (2006) 196–204 201
Fig 1 A. Kaplan- Meier curves for the cumulative proportion of subjects with a completely Error-free 
performance for all motor components within each respective task of the MTT. Subjects who made an 
Error (Hesitation or Block) for at least one motor component (answering serial questions) were ignored 
for this analysis. Only 7.7% of the patients had an Error-free performance, as oppposed to 62.0% in both 
control groups (p< 0.0001). B. Kaplan-Meier curve  for th  cumulative proportion of subjects with a 
completely Error-free performance for all component (both motor and cognitive) within each respective 
task of the MTT. Subjects who made an Error for at least one component of any given task were excluded 
from the following tasks. 16% of the young controls, 30.8% of the elderly controls and none of the patients 
completed the test without any Errors (no signi!cant di#erence).
145
 The ‘posture second’ strategy: a review
 of w
rong priorities in Parkinson’s disease 
6
Errors during the most complex tasks. Cognitive Errors increased even more than motor 
Errors with task complexity. Interestingly, this increase was most pronounced in young 
subjects, who apparently postponed answering until the motor components had been 
completed safely. This suggests that for complex postural tasks, healthy subjects favour 
execution of motor components over execution of a cognitive component. The results 
thus provided some interesting insights into normal coping strategies with increasingly 
complex postural tasks. On the one hand, we found evidence that impaired multiple task 
performance may re.ect a limited processing capacity. Indeed, most of our healthy sub-
jects were able to integrate fairly complex postural tasks without errors, although errors 
inevitably appeared during the most complex tasks. On the other hand, it also seemed 
that during extremely complex tasks, healthy subjects lent priority to complete certain 
task components at the expense of others. In other words, their “blockades” should 
perhaps not necessarily be regarded as a marker of postural instability or pathologi-
cally impaired central processing capacity, but rather as a form of “prudent” behaviour 
intended to optimise the primary task (maintaining balance). This strategy had been 
observed previously by others and is termed “posture !rst”.&%&,%'"%'&%'( It is indeed a safe 
postural strategy to favour maintaining balance (the “primary” task) over execution of 
e.g. a manual or mental secondary task. Apparently, young subjects are more inclined 
than elderly subjects to use this “posture !rst” strategy, and may therefore be better able 
to avoid falls.
In the second study$,, we studied if performance on the MTT could discriminate between 
healthy subjects and PD patients. We were particularly interested to study the strategies 
for increasingly complex postural tasks in PD. Theoretically, patients might reveal various 
abnormalities. One possibility is that patients use intended “priority processes”, much like 
the young subjects described above. Due to their underlying balance impairment and 
restricted central processing resources, patients would need to prioritise (and thus make 
“errors”) during less complex tasks than healthy subjects. Patients and controls would 
thus show a resemblance, albeit at di#ering task di/culties. This phenomenon indeed 
occurs in healthy subjects who show Parkinson-like impairments on cognitive tasks if 
su/ciently distracted by demanding secondary tasks.') Alternatively, patients may have 
lost the ability to lend priority to complete particular components of a complex task. 
If this were true, performance of the postural task would deteriorate by a challenge to 
multiple components of postural control. Patients might even be expected to fall, while 
attempting to continuously perform all components of the task.
We addressed these questions by administering the MTT to 20 non-demented PD 
patients, and compared their performance to that of the previously tested controls.$, 
Signi!cantly more patients produced Errors than young and elderly controls, and only 
8% of the patients completed all tasks without any motor Errors (Figure 1A). Patients 
particularly produced more motor Errors than controls during the most complex tasks. 
Interestingly, this di#erence between patients and controls disappeared if the cognitive 
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component was also scored, because more controls made cognitive Errors during com-
plex tasks than patients (Figure 1B). Patients apparently gave less priority to execution of 
the motor components. Patients thus seemed less able than controls to employ a “pos-
ture !rst” strategy, but instead attempted to perform all tasks simultaneously. However, 
due to their balance impairment and restricted processing resources, neither motor nor 
cognitive components were executed very successfully. This might be interpreted as a 
form of “risky” behaviour that might lead to falls in daily life. In fact, one patient actu-
ally had an imminent fall during the eighth task that was prevented by the examiner. 
The clinical relevance of our !ndings is further underscored by the fact that more than 
half of our patients reported di/culties with simultaneous tasks in daily life, including 
simultaneous motor tasks, such as carrying a tray while walking. Many patients described 
falls during situations that resembled the most complex tasks of the MTT.
In a subsequent follow-up study, we examined the predictive value of the MTT by asking 
the 20 PD patients and 20 matched controls to prospectively monitor their falls in daily 
life for 6 months using standardised diaries (Bloem & Munneke, unpublished observa-
tions). Because of the relatively small sample size, we have pooled the data of patients 
and controls. At least one motor Error was made by 21 of the 40 subjects. Only three out 
of the 19 subjects who produced no motor Errors during the MTT fell during the 6-month 
follow-up, while seven out of the 21 subjects with 11 motor Error fell during the same 
time period (Relative Risk [95 % con!dence interval] = 2.1 [0.63 – 7.01]). Although the 
con!dence interval was wide due to the small sample size and limited number of inci-
dent falls, these preliminary !ndings do suggest that impaired performance on the MTT 
was associated with a two-fold increase in the risk of falling. Furthermore, it is interesting 
to note that only 10 out of the 21 falls in the Lundin-Olsson study" were identi!ed by the 
SWTT, whereas seven out the 10 falls in our study were identi!ed by the MTT. This may 
re.ect a good sensitivity for the MTT, which could be useful for a screening device to 
pre-select candidates for more detailed evaluations. Larger studies are now underway to 
fully examine the predictive abilities of the MTT.
GETTING THE PRIORITIES ENTIRELY WRONG
We have suggested that young healthy subjects are well able to cope with complex situa-
tions by adopting “safe” strategies (prioritising balance over other concurrent tasks), and 
that such behaviour is less often seen in elderly persons and, in particular, in patients 
with PD. Interestingly, however, even young healthy subjects may occasionally get their 
priorities wrong. In a nicely designed study, Bhateni et al.'* suddenly perturbed upright 
standing young persons who held a cane (or, in some trials, merely a useless top handle 
portion of a cane) in their hand. Instead of optimally using their arms to grab a nearby 
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handrail for support, the subjects tended to cling onto the cane, even when it had no 
stabilizing value (holding a cane during backward falls) or any intrinsic value whatsoever 
(carrying a canetop). These !ndings could have important implications for understand-
ing the mechanisms leading to falls in persons using assistive devices.
There may be subgroups of patients who get their priorities wrong altogether. In PD, 
many patients are afraid to fall"&%"(%"), and this fear of falling may well prevent them from 
engaging in potentially hazardous activities. The .ip side of the coin is that patients with 
excessive fear may su#er from unnecessary immobilisation."& Conversely, patients who 
are overly con!dent (possibly due to coexistent cognitive de!cits and lack of insight) are 
at increased risk of sustaining falls and injuries. Some preliminary evidence suggests that 
this may occur in patients with PD'+, and such patients may be particularly at risk of falls 
due to their hazardous behaviour. 
Such apparent lack of insight is encountered more commonly in patients with progres-
sive supranuclear palsy (PSP), characterised by atypical parkinsonism, supranuclear verti-
cal gaze palsy, pseudobulbar palsy and dementia. Development of postural instability 
and recurrent falls occur early in the course of the disease.',%(, We recently determined 
the frequency and characteristics of falls among 117 patients with PSP, using a detailed 
questionnaire and a 3-month prospective follow-up.(" At least one fall had occurred since 
disease onset in 97% of PSP patients, while daily falls were present in 23% of patients 
who were still mobile. Injuries were also much more common than in PD, not only be-
cause postural instability was more severe, but also owing to “motor recklessness”: many 
patients with PSP move abruptly and seem unable to properly judge the risk of their 
actions. There was no evidence for an overall lack of insight because balance con!dence 
was markedly reduced in PSP patients (mean score of 17.6, on a visual analogue scale 
of 0-100, with 0 being worst performance). The key problem seems to be impulsive-
ness, leading patients to respond immediately to external stimuli in a direct “stimulus-
response” type behaviour. This impulsiveness or recklessness is presumably related to the 
pronounced frontal atrophy in PSP.($  Medical treatment often proves di/cult, and strict 
supervision of activities is typically a mainstay of treatment in this disorder.
Patients with Alzheimer’s disease (AD)  may be another example of a group who fall 
because of bad judgement. Their rates of falls and injuries are also high(&%(', despite much 
less impaired motor function, at least in the early stages of AD. This discrepancy between 
relatively mild motor problems and frequent falls suggests that falling is possibly related 
in part to behavioural problems in AD, such as lack of insight or wandering behaviour. A 
relation with cognitive problems is further suported by studies demonstrating that dual 




Recognition of dual tasking limitations and their impact on the risk of falls may have 
treatment implications. It is conceivable that safer dual tasking strategies can be trained 
by physiotherapists, for example by instructing patients to avoid secondary tasks during 
complex walking or balancing activities.()  Another possibility is the use of cognitive 
rehabilitation.(* Such treatment possibilities and their e#ect on everyday performance 
have thus far not been investigated, and this could be a fruitful subject for future research.
CONCLUSIONS
Evidence is beginning to accumulate that healthy subjects may correctly perceive the 
di/culty of multiple task performance, and purposely lend priority to execution of 
one part of a complex task, at the expense of other elements. Which particular type of 
strategy is chosen may depend on the preference of individual subjects. Some persons 
will adapt their behaviour by decreasing the walking speed and thus avoid the risk of 
a fall. Others may lend priority to the walking task at the expense of the other concur-
rent tasks, an approach referred to as the “posture !rst” strategy. This strategy is typically 
implemented by young persons, but less often by elderly persons. Still others may favour 
the mental task or entirely fail to lend priority to any particular task, but they could pay 
the price by an increased instability or even a fall. This latter mechanism seems to play 
a role in patients with PD, and is seen in an extreme form in patients with PSP whose 
tendency to fall is aggravated by motor recklessness. The opposing e#ect of these di#er-
ent “strategies” obscures simple interpretation of dual or multiple task performance, and 
underscores the importance of accommodating the adopted strategy when using dual 
tasking as a predictor of falls. Another factor that needs to be taken into account is the 
nature of the secondary tasks. A simple dual task design with a combination of motor 
and cognitive tasks is perhaps su/cient to detect abnormalities in patients with mainly 
cognitive decline. For these populations, even measurements of simple walking time may 
su/ce, perhaps supplemented with additional quantitative measures of trunk sway or 
changes in stride. However, more complex tasks such as the MTT (which consists mainly 
of multiple motor components plus a cognitive component) may be more informative for 
subjects with mainly motor disabilities, such as PD patients. Finally, preliminary evidence 
suggests that multiple task performance is perhaps best probed using a sudden and 
unexpected insertion of a secondary task, rather than a more continuous and predictable 
dual loading.
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INTRODUCTION
A chapter on gait and balance impairment is inevitable in this book on non-motor and 
non-dopaminergic features of Parkinson’s disease (PD), for several reasons. First, even 
though gait impairment and postural instability (jointly referred to in this chapter as 
“axial motor disability”) are traditionally regarded as “motor” features of PD, evidence 
is accumulating that our ability to walk or maintain balance are, at least in part, also 
governed by cognitive processes. For example, many PD patients !nd it di/cult to walk 
and talk at the same time, and when they nevertheless try to combine these two seem-
ingly easily tasks, a fall is often the result." Also, the appearance of axial motor disability 
typically coincides with cognitive decline, as becomes obvious in patients with the so-
called PIGD (postural instability and gait disability) subtype of PD.$%&%' This co-occurrence 
could be a chance !nding, simply re.ecting the more widespread disease pathology in 
this subtype of PD. But an interesting alternative explanation is that patients may only 
begin to fall when they fail to consciously compensate for their axial motor de!cits. In its 
most striking form, this is seen in patients with progressive supranuclear palsy (PSP) who 
have an unusually high risk of falling, not only because their balance is so poor, but also 
because they fail to adjust their behaviour due to lack of insight – a feature sometimes 
referred to as “motor recklessness”.( Taken together, these observations suggest that dif-
!culties with gait or balance are perhaps more “non-motor” than one might have initially 
thought.
Second, axial disability can rightly be included among the non-dopaminergic features of 
PD. Gait impairment and postural instability are typically “late” features of PD, appearing 
at a time when the disease extends well beyond the dopaminergic substantia nigra.)%* Sev-
eral observations support a non-dopaminergic basis for axial motor disability in PD. Axial 
motor features are typicaly indequately controlled with dopaminergic medication.+%,%"- 
This is particularly the case for postural instability and, to a lesser extent, also for gait 
abnormalities. Indeed, most falls in PD occur when patients are in their ON state."" Such 
clinical observations have been tested with dynamic posturography: evaluating balance 
quantitatively while upright standing subjects are perturbed by sudden movements of a 
support surface."$ The results suggest that several balance problems (mainly the reactive 
automatic postural responses) in PD are not primarily dopamine-dependent."-%"&%"'%"( In 
fact, dopaminergic medication can paradoxically increase the frequency of falls by induc-
ing ON period freezing, or orthostatic hypotension leading to syncopal falls, or violent 
dyskinesias that can literally throw the patients o# their feet.")%"*%"+%",
Third, neuropathological and biochemical studies suggest that non-dopaminergic 
lesions emerge at about the same time when gait and balance problems develop.$- 
Speci!cally, post-mortem brain studies in patients with gait and balance impairment 
demonstrate substantial cell loss within the locus coeruleus, particularly the caudal part 
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that projects mainly to the spinal cord and cerebellum.$"%$$ Consistent with this cell loss 
in the locus coeruleus, CSF analyses and post-mortem brain studies have shown reduced 
norepinephrine levels in PD. Further, there is a relation between the reduced concentra-
tion of norepinephrine and the severity of gait and postural disturbances, and levels 
of norepinephrine are signi!cantly reduced in PD patients with freezing of gait.$& Gait 
impairment, especially freezing (and possibly also balance abnormalities)  may further 
be linked to dysfunction of the mixed cholinergic-glutamatergic pedunculopontine 
nucleus (PPN) in the dorsal brainstem.$'%$(%$) The PPN normally governs step initiation 
and step maintenance. PPN dysfunction is caused partially by excessive inhibition from 
the internal globus pallidus and substantia nigra pars reticulata. In addition, cell loss oc-
curs within the cholinergic portion of the PPN, and this neurodegeneration likely further 
aggravates the gait problems.$) 
Observations in patients with atypical parkinsonism provide a !nal argument to support 
a non-dopaminergic basis for axial motor disability in PD. Generally, gait and balance 
problems emerge earlier and are more prominent in patients with atypical parkinsonism; 
this includes patients with progressive supranuclear palsy (PSP), multiple system atrophy 
(MSA), corticobasal degeneration (CBD), dementia with Lewy bodies (DLB) and vascular 
parkinsonism.(%$*%$+ These atypical parkinsonian syndromes are all typically characterised 
by more widespread pathology compared to PD, including abundant extranigral and 
non-dopaminergic lesions.
This is not to say, of course, that gait and balance problems can be ascribed entirely to 
the presence of non-dopaminergic lesions. For many patients, dopamine replacement 
therapy can provide a partial bene!t, particularly in early stages of the disease, and more 
so for gait than posture or balance. The bradykinetic gait in early disease stages – char-
acterized by a reduced walking velocity and small, shu0ing steps – usually improves 
with dopaminergic treatment. And freezing of gait – which usually appears later in the 
course of the disease – will also improve in most patients when dopaminergic therapy 
is started or augmented."*%$, Freezing may become more resistant in later stages of the 
disease, but the issue here may be related to inadequate dosing: because of adverse ef-
fects of treatment such as response .uctuations or hallucinations. Indeed, it has been our 
clinical impression that the threshold to obtain a therapeutic response may be higher for 
freezing compared to other motor signs (Figure 1) This could partially explain the pres-
ence of ON period freezing of gait: at certain doses most motor signs will have improved, 
but freezing persists, falsely creating the impression that medication actually induced 
the freezing symptoms. A link to dopaminergic lesions was recently made in a large 
prospective aging study, were during post-mortem examination of brains of 50 subjects 
without PD detected an association between cell loss in the dorsolateral quadrant of 
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The most devastating consequence of gait and balance impairment is falling. In this 
chapter, we summarize the dominant clinical features of axial motor disability in PD, 
provide a pathophysiological framework for falls in PD, and consider how to develop an 
individually tailored and multifactorial falls prevention program. We propose a battery 
of measures that are based on published observations in PD, personal experience and 
knowledge obtained with falls prevention in the elderly. The protocol proposed here 
may serve both as a guide for current clinical use, and also as a basis for future formal 
evaluation in adequately designed randomised clinical trials.
CLINICAL ASSESSMENT OF BALANCE AND GAIT
Importance
Careful recognition of gait and balance abnormalities is crucial, for several reasons (Table 
1). First, axial features can often assist clinicians in re!ning their di#erential diagnosis in 
patients presenting with a hypokinetic-rigid syndrome. It is not rare for the speci!c gait 
or balance features to provide the clue to the diagnosis. Examples include the occurrence 
P1: SFK/UKS P2: SFK Color: 1C













and substantia nigra pars reticulata. In addition, cell loss
occurs within the cholinergic portion of the PPN, and
this neurodegeneration likely further aggravates the gait
problems [26].
Observations in patients with atypical parkinsonism
provide a final argument to support a non-dopaminergic
basis for axial motor disability in PD. Generally, gait and
balance problems emerge earlier and are more promi-
nent in patients with atypical parkinsonism; this includes
patients with PSP, multiple system atrophy (MSA), corti-
cobasal degeneration (CBD), dementia with Lewy bodies
(DLB), and vascular parkinsonism [5,27,28]. These atyp-
ical parkinsonian syndromes are all typically character-
ized by more widespread pathology compared with PD,
including abundant extranigral and non-dopaminergic
lesions.
This is not to say, of course, that gait and balance
problems can be ascribed entirely to the presence of
non-dopaminergic lesions. For many patients, dopamine
replacement therapy can provide partial benefit, particu-
larly in early stages of the disease, more so for gait than
posture or balance. The bradykinetic gait in early dis-
ease stages – characterized by a reduced walking veloc-
ity and small, shuffling steps – usually improves with
dopaminergic treatment. Also, freezing of gait – which
usually appears later in the course of the disease – may
also improve when dopaminergic therapy is started or
augmented [17,29]. Freezing may become more resistant
in later stages of the disease, but the issue here may be
related to inadequate dosing because of adverse effects of
treatment such as motor complications or hallucinations.
Indeed, it has been our impression that the threshold for
obtaining a therapeutic response may be higher for freez-
ing than to other motor signs (Figure 32.1). This could par-
tially explain the presence of ON period freezing of gait:
at certain doses most motor signs will have improved, but
freezing persists, falsely creating the impression that med-
ication actually induced the freezing symptoms. A link
to dopaminergic lesions was made in a large prospective
aging study, where postmortem examination of 50 sub-
jects without PD detected an association between cell loss
in the dorsolateral quadrant of the substantia nigra and
UPDRS scores for postural instability, stooped posture,
and gait disturbances [30].
The most devastating consequence of gait and bal-
ance impairment is falling. In this chapter, we summarize
(a) (b)
Figure 32.1 Treatment of freezing of gait, in relation to other
motor symptoms and signs. The threshold for symptoms and
signs to improve may be lower for appendicular manifestations of
PD (a), compared with the threshold for freezing of gait to
improve (b). This creates an intermediate level, occurring at doses
where patients generally appear to respond well to medication,
but nevertheless experience freezing of gait. Although
counterintuitive, we recommend first increasing the dose of
anti-parkinson medication in these patients, provided that they do
not experience dose-limiting side effects. If freezing improves, the
patient actually has “pseudo ON” freezing. If freezing worsens,
the patient has true ON period freezing, and the dose should be
reduced.
Fig 1 Treatment of freezing of gait, in relation to other motor symptoms and signs. The threshold for 
symptoms and signs to im rove may be lower for appendicular manifestatio s of PD (a), compared with 
the threshold for freezing of gait to improve (b). This creates an intermediate level, occurring at doses 
where pati nts gener lly ap ear to respond well to medication, but nevertheless experience freezing of 
gait. Although counterintuitive, we recommend first increasing the dose of anti-parkinson medication in 
these patients, provided that they do not experience dose-limiting side e#ects. If freezing improves, the 
patient actually has “pseudo ON” freezing. If freezing worsens, the patient has true ON period freezing, and 
the dose should be reduced.
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of seemingly spontaneous backward falls in the !rst year of the disease – suggesting a 
diagnosis of PSP – or the presence of dominant lower-body parkinsonism with early and 
levodopa-resistant freezing of gait – suggesting a diagnosis of vascular parkinsonism.
Second, as indicated earlier, careful clinical assessment provides the basis for subsequent 
treatment, aimed at improving gait and balance, reducing or preventing falls, and mini-
mizing their consequences. Indeed, falls in PD often have devastating consequences, 
leading to a poor overall prognosis. Hip fractures appear in about 25% of patients within 
10 years after the diagnosis&" and are associated with high morbidity, admission to nurs-
ing home, and mortality.&$%&&%&' Fractures of the wrist seem less common, perhaps because 
the hands are not stretched out fast enough after a fall.&( “Minor” injuries such as bruises 
Table  1 Importance of gait and balance assessment in clinical practice 
Importance of gait and balance assessment in clinical practice 
Support for the di#erential diagnosis 
Basis for individually tailored treatment 




– Pressure sores 
– Insomnia 
– Osteoporosis 
– Physical inactivity 
– Loss of independence 
– Social isolation 
– Fear of falling 
– Reduced quality-of-life 
– Caregiver stress 
Marker of poor prognosis/greater disease severity and associated symptoms 
– Depression 
– Anxiety 
– Rapid disease progression 
– Urinary incontinence 
– Cognitive decline 
– Nursing home admission 
– Reduced survival 
Marker for underlying abnormalities 
– Frontal executive deficits 
– Underlying cerebrovascular disease 
Socio-economic impact 
– Loss of productivity 
– Costs related to injuries 
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or lacerations are even more common than fractures. Furthermore, reduced mobility 
is associated with other incapacitating complications, including constipation, pressure 
sores, insomnia and osteoporosis, which in turn increases the fracture risk. Immobility 
also deprives patients of their independence and social contacts. These problems are 
aggravated by a commonly present and incapacitating fear of renewed falls."" When this 
fear of falling becomes excessive, patients become unnecessarily immobilized, with great 
consequences for their social interactions as well as their physical !tness.
Third, the presence of gait and balance abnormalities can serve as a marker for other 
signs that are perhaps less obvious during routine clinical examination, such as frontal 
executive de!cits&)%&*%&+%&, or underlying cerebrovascular disease.'- This will be discussed 
in more detail in the section on clinical manifestations.
Fourth, gait and balance abnormalities have considerable prognostic importance. In a 
large group of 362 patients who were originally enrolled as part of the DATATOP study 
and who were carefully followed for disease progression, the level of gait dysfunction did 
not predict future changes in health-related quality of life.'" However, worsening gait and 
balance over time were accompanied by worsening mental as well as physical health-
related quality of life, underscoring the need to preserve balance in order to prevent 
a worsening of health-related quality of life. Furthermore, a prior fall remains the best 
predictor of future falls'$ , and postural instability and falls are associated with a reduced 
survival.$*%'&%'' This increased mortality is explained by the occurrence of lethal falls and 
by secondary immobilization, which reduces general !tness and increases the risk of 
cardiovascular disease. Importantly, the disease also progresses at a faster rate once falls 
are present.$+
And !nally, gait and balance abnormalities have implications for society at large. Falls 
and fall-related injuries are extremely costly and contribute to the overall costs of PD.'(%') 
Falls are also a major reason for caregiver stress'*%'+ , and health care costs rise consider-
ably when the caregiver support collapses.
In the light of these considerations, it should be appreciated that the clinical examination 
of parkinsonian patients is incomplete without a proper gait and balance assessment. 
Whenever possible, patients should be examined during both the OFF state (preferably 
following withdrawal of antiparkinson medication for at least 12 hours) and the subjec-
tive “best ON” state. It is recommended to have a su/ciently large examination room, or 
else to take the patients to the corridor to examine their gait. At the same time, gait and 
balance need to be challenged using a series of speci!c tests, in order to bring about the 
full range of abnormalities. Note that performance is usually much better in the hospital, 
where lighting is optimal and gait is rarely complicated by obstacles in the pathway. 
Hospital examination is also obscured by a phenomenon termed “kinesia paradoxica”, 
namely the ability of poorly mobile patients with advanced disease to move unexpect-
edly well under emotional circumstances sometimes (which a doctor’s visit). In contrast, 
at home patients are more at ease, and they need to walk in crowded living rooms (forc-
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ing them to make narrow turns), with poor lighting or loose rugs on the .oor. Some of 
these domestic factors can be copied in the examination room, for example by forcing 
patients to turn around in tight quarters to provoke freezing.', Nevertheless it is often 
very informative when a physiotherapist or occupational therapist pays a home visit and 
to witness the patients’ performance in their own habitat.
Gait
For most patients, walking already changes can already be detected in early stages of 
the disease, and can even be the presenting symptom, for example an asymmetrically 
reduced or absent arm swing.(- Other early features include di/culties turning around 
in a standing or recumbent position. As the disease progresses, gait becomes slower 
and the typical parkinsonian gait emerges with shu0ing and short steps, a bilaterally 
reduced arm swing and slow turns which are executed en bloc. In contrast to most other 
gait disorders, gait is typically not wide-based.(" Presence of a broad-based gait generally 
suggests presence of atypical parkinsonism. A simple test is asking patients to take 10 
consecutive tandem steps; patients with idiopathic PD can usually perform this without 
d/culty, even when moderately severely a#ected.($ Hence, taking even a single correc-
tive side step is suggestive for atypical parkinsonism, particularly in early stages of the 
disease. Note that patients may compensate for their “automatic” gait problems by pay-
ing conscious attention to the act of walking. Distraction or asking the patient to perform 
a double or secondary task (answering questions, carrying an object) interferes with this 
compensatory strategy and often aggravates the gait disorder, causing patients to slow 
down or completely stop walking.
Freezing of gait
The features described above represent a form of “continuous” gait abnormality: they are 
more or less consistently present. In addition, PD patients can also experience “episodic” 
gait disorders, that is, walking problems that are only irregularly present, intermingled 
with periods when gait is much better.(& The prime example of these episodic gait dis-
orders is freezing of gait, when patients experience sudden and usually brief moments 
where the feet subjectively become “glued to the .oor”."* For practical purposes, freezing 
of gait was recently de!ned as “a brief episode during which patients !nd it impossible 
to generate e#ective forward stepping movements, in the absence of another cause 
than parkinsonism or higher cortical de!cits”.(' The prevalence of freezing increases with 
disease duration and progression of disease severity, although it can be present in early 
stages of PD, and occasionally even at disease onset. However, early freezing episodes 
should generally alert the clinician to the presence of a form of atypical parkinsonism, 
or a disorder called primary progressive freezing of gait.(( In patients with PD, freezing 
is more common after prolonged dopaminergic treatment, but this does not necessarily 
implicate that the drugs are causally related to freezing (because more severe symptoms 
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also require more medication). Indeed, freezing can occur in drug-naïve patients, and 
most forms of freezing in PD improve with dopaminergic medication. Note that freezing 
is also common in other parkisnonian disorders (e.g. PSP, MSA, vascular parkinsonism 
and normal pressure hydrocephalus).()%(* However, freezing is rare in drug-induced par-
kinsonism.
Freezing most commonly appears while patients are making turns, in particular narrow 
turns in tight quarters. Other circumstances that commonly provoke freezing include 
negotiating a narrow passage such as a door, trying to initiate gait (“start hesitation”), ex-
ecuting a double task (such as talking while walking) or upon reaching a target. It is less 
common for freezing to occur during straight, undisturbed walking. Although the name 
perhaps suggest otherwise, freezing is usually not a complete “immobile” blockade of 
walking movements (complete akinesia), but is a much more dynamic phenomenon. The 
most common presentation is with shu0ing small steps, or a characteristic “trembling” 
of the legs, with the frozen foot in plantar .exion and the forefoot stuck to the .oor.(+ 
Freezing of just one leg may occur, particularly while turning. Most freezing episodes 
are brief, usually lasting only several seconds or less, although in more advanced stages 
of the disease freezing may persist for minutes. Freezing episodes are also much briefer 
during the ON phase, compared to the OFF phase.
Detection of freezing often depends on a careful history taking, with detailed enquiry 
about the feeling of being glued, and attention to the provoking circumstances. It can 
be di/cult to assess freezing reliably during physical examination, because the anxiety 
associated with the doctor’s visit may suppress the phenomenon. A freezing of gait ques-
tionnaire has been developed for this purpose. There is now an updated version where 
patients and their immediate carers are shown video clips of characteristic freezing 
events, in order to facilitate recognition of the phenomenon.(, This updated question-
naire also addresses the impact of freezing on daily life, for example fear of falling.
Physical examination should include a dedicated “freezing of gait trajectory” that features 
speci!c triggers to elicit freezing: gait initiation; undisturbed walking in an open space; 
and walking under challenging situations (crossing a door or other narrow space, turn-
ing around, negotiating obstacles and performing a dual task) (Figure 2). Interestingly, 
many patients only experience freezing during full turns (360 to 540º) and not during 
partial turns (180º), so a standardized gait trajectory should include full turns (in both 
directions, because freezing often shows a directional sensitivity, being much worse 
and sometimes even exclusively present for turns in one direction). In addition to such 
attempts to provoke freezing, it is also useful to evaluate the response to external cues. 
This may have diagnostic importance, because freezing will improve in PD patients, but 
generally not in patients with higher-level gait disorders.(& Evaluating the e#ect of cues 
may also help to determine possible therapeutic interventions. Finally, various quantita-
tive gait assessments have been proposed, but these methods do not yet have a proven 




Changes in posture can provide important diagnostic  information. A gently stooped 
posture can be seen in early stages of PD, and this becomes more pronounced in later 
stages of the disease, usually with some lateral leaning of the trunk. However, severe 
and persistent latero.exion – the so-called “Pisa syndrome” or pleurothotonus – often 
(but not always) suggests neuroleptic-induced dystonia, MSA or post-encephalitic 
parkinsonism.)-%)"%)$ Camptocormia refers to a marked ante.exion of the thoracolumbar 
spine between 30 to 90 degrees, but without forward .exion of the neck.)& This can 
occur in both PD (where it may occasionally improve with dopaminergic medication 
or deep brain surgery) and forms of atypical parkinsonism. Camptocormia is apparent 
on standing, worsens while walking, but decreases while sitting and even disappears 
when patients are lying down. This latter feature separates camptocormia from the !xed 
kyphoscoliosis seen in patients with degenerative changes of the spine. An extreme 
degree of antecollis relative to other body parts, with the neck held in a relatively !xed 
and severely .exed position, or when the chin touches the chest, is unusual and suggests 
a diagnosis of MSA.)'%)( Antecollis develops in about half of pathologically proven MSA 
patients, usually in the middle or late stages of the disease.)( In contrast, retro.exion of 
the neck (retrocollis) suggests a diagnosis of PSP, but this is usually not an early feature.)) 
In PSP axial rigidity of the neck is higher than in the trunk, whereas the opposite pattern 
occurs in PD.)*
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one leg may occur, particularly when turning. Most freez-
ing episodes are brief, usually lasting only a few seconds
or less, although in more advanced stages of the disease
freezing may persist for minutes. Freezing episodes are
also much briefer during the ON than the OFF phase.
Detection of freezing often depends on a careful history
taking, with attention to the provoking circumstances. It
can be difficult to assess freezing reliably during physi-
cal examination, because the anxiety associated with the
doctor’s visit may suppress the phenomenon. A freez-
ing of gait questionnaire has been developed for this pur-
pose. There is now an updated version where patients and
their immediate carers are shown video clips of charac-
teristic freezing events, in order to facilitate recognition
of the phenomenon [59]. This updated questionnaire also
addresses the impact of freezing on daily life, for example,
fear of falling.
Physical examination should include a dedicated
“freezing of gait trajectory” that features specific trig-
gers to elicit freezing: gait initiation, undisturbed walk-
ing in an open space, and walking under challenging sit-
uations (crossing a door or other narrow space, turning
around, negotiating obstacles and performing a dual task)
(Figure 32.2). Interestingly, many patients only experience
freezing during full turns (360–540!) and not during par-
tial turns (180!), so a standardized gait trajectory should
include full turns (in both directions, because freezing
often shows a directional sensitivity, being much worse
and sometimes even exclusively present for turns in one
direction). In addition to attempts to provoke freezing, it
is useful to evaluate the response to external cues. This
may have diagnostic importance, because freezing will
improve in PD patients, but generally not in patients
with higher level gait disorders [53]. Evaluating the effect
of cues may also help to determine possible therapeu-
tic interventions. Finally, various quantitative gait assess-
ments have been proposed, but these methods do not yet
have a proven value for clinical practice.
Figure 32.2 Essential elements of a dedicated “freezing of gait
trajectory”. Reproduced from Snijders et al. [49] with permission
from John Wiley & Sons, Inc.
Postural abnormalities
Changes in posture can provide important diagnostic
information. A gently stooped posture can be seen in
early stages of PD, becoming more pronounced in later
stages of the disease, usually with some lateral leaning
of the trunk. However, severe and persistent lateroflex-
ion – the so-called “Pisa syndrome” or pleurothotonus –
often (but not always) suggests neuroleptic-induced dys-
tonia, MSA, or post-encephalitic parkinsonism [60–62].
Camptocormia refers to a marked anteflexion of the tho-
racolumbar spine (between 30 and 90!), but without for-
ward flexion of the neck [63]. This can occur in both PD
(where it may occasionally improve with dopaminergic
medication or deep brain surgery) and forms of atypi-
cal parkinsonism. Camptocormia is apparent on standing,
worsens while walking, but decreases while sitting and
even disappears when lying down. This last feature sep-
arates camptocormia from the fixed kyphoscoliosis seen
in patients with degenerative changes of the spine. An
extreme degree of antecollis relative to other body parts,
with the neck held in a relatively fixed and severely flexed
position, or when the chin touches the chest, is unusual
and suggests a diagnosis of MSA [64,65]. Antecollis devel-
ops in about half of pathologically proven MSA patients,
usually in the middle or late stages of the disease [65]. In
contrast, retroflexion of the neck (retrocollis) suggests a
diagnosis of PSP [66], but is usually not an early feature
[66]. In PSP, axial rigidity of the neck is greater than in the
trunk, whereas the opposite pattern occurs in PD [67].
Balance impairment
Postural stability is preserved early in the course of PD,
and falls never occur at onset or within the first 2 years of
the disease in pathologically confirmed cases of idiopathic
PD [28]. Balance impairment can gradually develop as
the disease progresses [68], appearing later (and in less
prominent form) in patients with the tremor-dominant
type of PD. Being unable to stand on one leg, for exam-
ple while getting dressed, is one of the earliest signs of
postural instability.
A battery of clinical tests is needed to capture the com-
plex nature of balance problems in patients with basal
ganglia disorders. Functional “every day” tests should be
performed whenever possible. These include rising from
a chair, sitting down, and getting in and out of a bed. It
is particularly important to test the so-called defensive
balance reactions, which are evoked by imminent falls.
Examples include the ability to take corrective steps or to
make protective arm movements (to grasp for support,
or to cushion the impact of an impending fall). Evalu-
ation of these defensive reactions is often difficult in a
clinical setting because patients must be brought close
to (or even beyond) their limits of stability. Quantified
assessment following standardized balance perturbations
– using dynamic posturography – is perhaps more suited
Fig 2 Essential elements of a ded cated “freezi g of gait trajectory”. R produc d from Snijders et al', with 
permission from John Wiley & Sons, Inc. 
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Balance impairment
Postural stability is preserved early in the course of PD, and falls never occur at onset or 
within the !rst two years of the disease in pathologically con!rmed cases of idiopathic 
PD.$+ Balance impairment gradually develops as the disease progresses)+, appearing later 
(and in less prominent form) in patients with the tremor-dominant type of PD. Being 
unable to stand on one leg, for example while getting dressed, is often one of the earliest 
signs of postural instability.
A battery of clinical tests is needed to capture the complex nature of balance problems 
in patients with basal ganglia disorders. Functional “everyday” tests should be performed 
whenever possible. These include rising from a chair, sitting down and getting in and 
out of a bed. It is particularly important to test the so-called defensive balance reactions, 
which are evoked by imminent falls. Examples include the ability to take corrective steps 
or to make protective arm movements (to grasp for support, or to cushion the impact 
of an impending fall). Evaluation of these defensive reactions is often di/cult in a clini-
cal setting because patients must be brought close to (or even beyond) their limits of 
stability. Quanti!ed assessment following standardized balance perturbations  – using 
dynamic posturography – is perhaps more suited for this purpose, although the clinical 
utility for the management of individual patients remains unclear.), In clinical practice, 
the retropulsion test is typically used to test defensive reactions, but this test is not with-
out problems. There is great variability in test performance across clinicians (depending 
on subjective preferences, but also on height or weight of both the patient and investiga-
tor), scoring of the response is subjective, and its interpretation is not straightforward. 
For example, it is unclear how many corrective steps can still be regarded as “normal”. 
Interestingly, taking more steps is usually equated with greater balance impairment, 
but this may not be correct because corrective steps are important defensive reactions. 
Indeed, the most abnormal reaction is not taking any corrective step at all, leading to a 
fall “like a pushed toy soldier” (note that freezing can be a “confounder” here, interfering 
with the ability to step backward and leading to a fall “like a log” into the arms of the 
investigator, even when balance itself is otherwise preserved). We recommend taking 
the speed and quality of balance reactions into account (rather than merely counting 
the number of corrective steps), and to regard a slow response as abnormal even if only 
one or two steps are taken. A particular problem is the inconsistency in the strength 
of the shoulder pull, within and between raters (depending on experience or physical 
strength), as well as within and between patients who may have di#erent degrees of in-
stability.  Consequently, the retropulsion test has an only moderate intra- and inter-rater 
consistency, correlates poorly to objective measures of postural instability (as quantita-
tively ascertained in a balance laboratory) and is a poor predictor of actual falls in daily 
life.*- We usually deliver one shoulder pull without speci!c prior warning, as this may best 
mimic daily life circumstances where falls are usually unexpected events. We then repeat 
the test several times and regard failure to “habituate” to the test as another sign of bal-
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ance impairment. As such, the retropulsion test indexes the degree of postural instability. 
However, the test fails to predict falls, at least in PD, "" probably because falling is the net 
result of a complex interplay between gait, balance and protective mechanisms.
The “Push and Release” test was recently proposed as a more consistent and appar-
ently also more sensitive alternative to the pull test (or retropulsion test).*" The essence 
is to eliminate the inconsistency of the stimulus by instructing subjects to actively push 
backward against the palms of the examiner’s hands (placed on the subject’s scapulae), 
allowing the trunk to move backward while the examiner supports the subject’s weight. 
Balance is then perturbed when the examiner suddenly removes the external support, 
forcing the patient to take a backward step to regain balance. The !rst experience 
showed that the “Push and Release” test correlated better with self-reported prior falls, 
when compared with the retropulsion test, and that it could be used in both the ON and 
the OFF states.*"%*$ A drawback of this Push and Release test is that patients may have 
di/culties following the instructions, and some are hesitant to adequately push back 
into the examiner’s hands due to lack of con!dence. 
Falls
Falls are a devastating consequence of postural and gait disturbances. Prospective surveys 
in PD note high rates of falls that exceed those of community-dwelling elderly subjects.'$ 
The incidence of falls is even higher when near-falls are included*&, and these near-falls 
typically precede the onset of actual falling.*' The risk of falling is highest when patients 
reach Hoehn and Yahr stage 2.5 to 3, when balance becomes impaired but patients are 
still su/ciently mobile to be at risk of falling. In these moderately a#ected PD patients, 
the risk of sustaining a single fall was six times higher than in healthy age-matched peers, 
and the risk of sustaining recurrent falls was nine times higher. The falling rate may level 
o# in later stages of the disease due to disease progression and increasing immobility.'$ 
Indeed, patients in Hoehn and Yahr stage 5 are bound to their bed or wheelchair are for 
this reason unlikely to fall. Furthermore, patients may compensate for their worsening 
balance by moving slower and purposely restricting their activities.
It is important to realize that most falls occur when patients are in their  ON state, possibly 
re.ecting their increased mobility. This observation also underscores that dopaminergic 
medication usually provides little or no improvement of postural instability. In fact, dopa-
minergic medication can cause dyskinesias that may perturb patients and increase falls. 
In addition, medication may cause or aggravate cognitive dysfunction, for example by 
causing delirium and risky wandering behaviour, leading to more falls.Most falls involve 
movements of the trunk, in particular sudden turning movements, presumably because 
this provokes freezing. Changes in posture (“transfers”), such as rising from a chair, are 
also commonly responsible. Orthostatic hypotension has been mentioned as an inde-
pendent risk factor for falls in PD.*( However, falls due to preceding loss of consciousness 
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are rare, and when this occurs clinicians should consider MSA, where syncope due to 
autonomic dysfunction is common.*)
Cognitive de!cits
PD patients with gait and balance problems should always receive a cognitive examina-
tion, especially testing the frontal executive functions and attention. This may seem un-
necessary, because gait and balance control are traditionally considered to be a largely 
automatic process, governed mainly at a subconscious level by spinal and perhaps some 
brain stem neural structures. However, recent studies have shown that neuropsychologi-
cal processes such as attention are necessary for adequate balance maintenance. Walking 
is an even more complex process than standing, involving a range of cognitive systems.** 
This role of cognition is obvious during many activities of daily living, when people need 
to perform multiple actions simultaneously or quickly shift attention and control from 
one task to another. To perform such actions, cognitive abilities are needed to e#ectively 
monitor the environment, choose .exible response patterns to appearing threats and 
to make appropriate motor responses necessary for completing goals - and this is pre-
cisely where patients with PD experience great di/culties, perhaps explaining why gait 
and balance de!cits are such prominent features of PD. Indeed,  cognitive dysfunction 
is particularly prominent in patients with the PIGD subtype of PD.$%&%*+ And it may also 
explain why falls seem to be particularly prominent in disorders that are characterized 
by a combination of both motor de!cits (gait impairment, postural instability) plus a 
concurrent decline in cognitive functions. PD itself is one good example, but there are 
many other such disorders, including various forms of atypical parkinsonism (PSP, Lewy 
body dementia, vascular parkinsonism), and Alzheimer’s disease.*, Patients with PD have 
di/culty executing two di#erent motor tasks simultaneously, such as walking and car-
rying an object+-%+"%+$%+&%+'%+(%+)%+*%++ , and these dual task problems are associated with the 
risk of falling." Various studies have shown that frontal executive dysfunction is related 
to gait impairment in PD patients+, and is associated with an increased risk of falls.,- 
Moreover, frontal executive dysfunction and freezing frequently co-occur, but there is as 
yet no proof of a direct causal interrelationship.&) Recklessness, decreased ability to learn 
cues and an increased sensitivity to cognitive overload (for example when dual tasking) 
may explain why patients with frontal executive dysfunction are more prone to falls. 
Moreover, the presence of frontal executive dysfunction may give a clue to the underly-
ing aetiology, as it is more prominent in atypical parkinsonism than in idiopathic PD. A 
clear example is provided by patients with PSP, where “motor recklessness” combined 
with progressive balance de!cits are jointly responsible for the high rates of falls.( Finally, 
other mental functions should also be examined. Depression is associated with falls," , 





A multifactorial falls prevention program
Adequate treatment of gait and balance impairment is crucial in view of their potentially 
devastating consequences. The key goals should be prevention, preservation of a safe 
mobility and independence. We have recently reviewed the speci!c medical and non-
medical treatment options of speci!c gait and balance problems in PD.,& Rather than reit-
erating these treatment recommendations, we focus on a newly developed protocol for a 
multidisciplinary falls prevention program. To achieve this, it is particularly important to 
consider the pathophysiology of falls, as this o#ers a rationale for preventive strategies. 
Falls in PD patients are usually not just caused by a single factor – such as a reduced step 
height – but are typically the net result of a complex and multifactorial pathophysiology. 
This pathophysiology includes both “extrinsic” or environmental factors (e.g. loose rugs 
on the .oor)  and “intrinsic” or patient-related factors (including balance impairment and 
gait disability, in particular freezing of gait). Many of these factors are speci!c for PD, but 
patients may also fall due to generic risk factors for falls that apply to any elderly person 
(‘generic risk factors’).
It is therefore unlikely that, just by themselves, single interventions will be able to 
prevent patients from falling. Instead, we anticipate that a multifactorial falls preven-
tion program will be needed, including PD-speci!c therapeutic measures plus a set of 
generic strategies. The merits of such a comprehensive falls prevention program have 
never been evaluated in PD, and in fact, there is no accepted menu of the most e#ec-
tive interventions. Here we will propose such a program, based on (a) determination of 
previosly identi!ed risk factors for fals in PD and (b) determination of those factors that 
are potentially amenable to therapeutic intervention. We subsequently tailored a menu 
of therapeutic interventions to address risk factors, including not only disease-speci!c 
strategies, but also a selection of “generic” falls prevention strategies derived from the 
literature and from published national and international falls prevention guidelines 
(Table 2). A challenge here was to identify therapeutic strategies that would be both 
relevant and feasible for PD patients. For example, standing with both legs crossed is an 
accepted intervention to reduce falls caused by orthostatic hypotension, but is unlikely 
to be an acceptable treatment for PD patients given their postural instability. Also, each 
falls prevention strategy needs to strike a balance between being both comprehensive 
(covering every single potential risk factor) and tolerable (in being not too demanding 
for PD patients, given their fatigue and at times limited learning abilities). Based on these 
considerations, we have constructed a concept for a Multifactorial Parkinson Falls Pre-
vention Strategy that accomodates all of the above factors. This protocol is summarized 
in Table 2. We will brie.y discuss a few elements of the multifactorial strategy.
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Table 2 Selected generic and disease-speci!c risk factors for falls, and tailored interventions.
Risk factor for falls Tailored intervention
PD-speci!c
Gait impairment (e.g. reduced step 
height)
· Increase antiparkinson medication
· Physiotherapy (cueing strategies) (94;95)
Freezing of gait · Optimize antiparkinson medication
- ON phase freezing: decrease levodopa
- OFF increase freezing: increase levodopa; MAO-blocker
· Physiotherapy (cueing strategies) (94;95)
· Eliminate domestic hazards (96)
Postural instability · Optimize antiparkinson medication (usually ine#ective)
· Physiotherapy (balance training) (94)
· Lower limb strength training (97)
Bradykinesia (e.g. slow protective arm 
movements)
· Increase dopaminergic medication
Dyskinesias · Optimize antiparkinson medication
Inability to handle dual tasks · Avoiding dual tasks (physiotherapy, occupational therapy) (1;89)
· Cognitive movement strategies (chaining) (94)
Transfers · Increase antiparkinson medication
· Cognitive movement strategies (94)
Generic
Polypharmacy · Reduction of medication (consult a geriatrician)
Sedative drugs (benzodiazepines) · Stop when possible
Daily use of alcohol · Minimize alcohol intake
Fear of falling · Increase balance con!dence (94)
Impaired ADL · Occupational therapist (96)
Physical inactivity ·  Physiotherapy: improve physical capacity, muscle power, 
mobility, muscle length (94)
Improper use of assistive device ·  Train use of assistive devices (physical therapist; occupational 
therapist)
Visual impairment · Consult eye specialist
· Restrict use of multifocal glasses
· Cataract surgery (98)




- Minimize hazardous behaviour
Behavioural disturbances · Atypical neuroleptics
· Restriction of activities (only if all other measures fail)




As outlined at the outset of this chapter, dopaminergic medication has mixed e#ects on 
gait, balance and falls. On the one hand, some axial motor features can improve follow-
ing treatment with dopaminergic medication. For example, freezing is usually seen dur-
ing the OFF state, and such OFF state freezing of gait may improve when dopaminergic 
medication is increased. However, other gait and balance problems are more resistant to 
treatment+%,%"- or are even aggravated by dopaminergic medication.")%"*%"+%", It is therefore 
!mportant to review carefully the relation between falls and the timing of intake of dopa-
minergic medication. When freezing appears to occur during the ON state"-"%"-$ – which is 
the case in only a small proportion of PD patients – the !rst step is to nevertheless further 
increase the dose of dopaminergic therapy, as some patients actually have “pseudo-ON 
freezing” (see Figure 1). In a few patients, freezing will worsen further, suggesting it is a 
true ON period sign, and this necessitates a dose reduction. Benzodiazepines and other 
sedative medication also need to be avoided whenever possible, as this may further 
increase the risk of falling.""
Pharmacotherapy of gait and balance problems should ideally aim at correction of both 
dopaminergic and non-dopaminergic de!cits. Attention is now shifting towards devel-
opment of ‘non-dopaminergic’ drugs directed at other neurotransmitter systems.$-%"-& 
Unfortunately, such drugs are not yet available for treatment of axial disability.
Physiotherapy
There is increasing evidence to support the use of physiotherapy as part of a comprehen-
sive falls prevention program.,'%"-'%"-(%"-)%"-*%"-+ Patients who have di/culties with initiating 
or maintaining gait often report that simple tricks can promote walking; these include 
clues that are environmental (e.g. stepping over an object on the .oor) or generated (e.g. 
counting). This technique of using internal or external cueing can be exploited by phys-
iotherapists, who can train patients to use auditory cues (such as listening to rhythmic 
Table 2 Selected generic and disease-speci!c risk factors for falls, and tailored interventions. (continued)
Risk factor for falls Tailored intervention
Postural  hypotension · Decrease antiparkinson medication
· Decrease other hypotensive medication (100)
· Increase dietary salt and .uid intake
· Anti-orthostatic manoeuvres (if balance is good)
· Pressure stockings  
· Small meals




Urinary incontinence and nocturia · Reduce co#ee and alcohol in the evening
· Adequate night-time lighting
· Incontinence materials
Environmental risk factors · Occupational therapy at home
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sounds of a metronome), visual cues (such as stepping over lines pasted onto the .oor), 
tactile cues (such as tapping on the leg) or mental cues (such as simple arithmetic, or 
generating a mental image of the appropriate step length). Physiotherapists can also 
teach patients how to handle their freezing episodes. The risk of falling appears high-
est in patients who actively try to “overcome” their gait blockade, so patients should be 
instructed to simply wait for the freezing to disappear. Physiotherapists can also address 
the cognitive aspects of falling, for example by teaching patients to avoid multitasking 
in daily life, and to split complex tasks into several less complex sub-movements (a 
technique called “chaining”). Such cognitive movement strategies have been shown to 
improve transfers or rolling over in bed in PD patients.,' Another approach is to restore 
balance con!dence and diminish the fear of falling. This may help to restore mobility and 
promote independence. There is no speci!c evidence for PD, but studies in the elderly 
suggest that group treatment using a behavioural-cognitive approach to change atti-
tudes, as well as training with a physiotherapist, can help."-, The use of an assistive device 
and gait training can enlarge self-con!dence. Instructions on how to stand up after a fall 
may also decrease fear of falling. An entirely di#erent approach is required for cognitively 
impaired patients who can be overly con!dent and inappropriately ‘over-rate’ their own 
balance, resulting in risky behavior and falls. For them, restriction of hazardous activities 
might be the best solution to prevent recurrent falls. It is also important to inform the 
caregiver about activities that should be avoided.
Prevention of complications
Despite all e#orts, most patients will continue to sustain at least occasional falls, and for 
patients with advanced PD the problem may become treatment-resistant. For this latter 
group, attention should increasingly be focused on preventing the complications of falls. 
For example, patients with PD can have a coexisting osteoporosis (caused by immobiliza-
tion and perhaps endocrine disorders)""- , that increase the risk of fracture. In PD patients 
presenting with a fracture, one should consider performing DEXA bone densitometry to 
establish whether osteoporosis is present. Treatment of osteoporosis may then reduce 
the risk of new fractures.
Who should be candidates?
It isnecessary to identify patients who are most at risk of falling. Various factors are 
related to falling, but many are interrelated. Prior falls, disease severity (Hoehn and Yahr 
stage 3) and disease duration appear to be the most consistent predictors of falls. In 
a meta-analysis, the only independent predictor of falling was asking for earlier falls'$, 
and this is not a satisfactory predictor because patients have already begun falling. Less 
robust, but potentially interesting, predictors of falls were fear of falling, avoiding activi-
ties because of this fear, and presence of prior near-falls. This may o#er a way to identify 
eligible candidates for fall prevention, even before the very !rst real fall has occurred.
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One size !ts all?
For clinicians, this is a familiar problem in clinical practice. The good part of the falls 
prevention approach, as described above, is its comprehensive character: this minimizes 
the risk of “missing” relevant risk factors, and theoretically provides the most aggressive 
and complete “gunshot” approach of the falling problem. But there are also less attractive 
sides of the coin. Being comprehensive, the entire program is costly, and importantly, it 
may be excessive for patients where a single factor is obviously responsible for the falling 
problem. For example, when patients exclusively fall while tripping over one particular 
rug in the living room, simply removing this rug may treat  the problem and obviate the 
need for the remainder of the comprehensive falls prevention program. Alternatively, 
when patients fall because of syncope, is it necessary to pay a home visit and eliminate 
domestic risk factors for tripping? There is no evidence to support any particular strategy, 






























Fig 3 Diagnostic algorithm to classify the main types of falls in patients with a hypokinetic–rigid syndrome, 
modified after Voermans et al""". The main categories of falls are shown in gray boxes. TLOC =transient loss 
of consciousness. 3 When patients claim to fall spontaneously, this is usually caused by either freezing 
of gait (that is not recognized as such by the patient), or transient loss of consciousness (which is often 
incorrectly denied by elderly patients). b Although there is only little supportive literature""$, it has been 
our impression that vertigo – in particular that caused by benign position-dependent vertigo – is not rare 
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speci!c type of falls, where one obvious risk factor is consistently responsible for the falls, 
then simply tackling this single factor may su/ce. Figure 3 shows the most common fall 
types, as well as a pragmatic approach to ascertain which speci!c type of falls is present. 
In other patients a comprehensive multifactorial approach is recommended.
CONCLUSION
This chapter underscores that gait disability, postural instability and falls are common 
and frequently devastating features of PD. We have reviewed the clinical features, mainly 
to provide a rational basis for a multifactorial falls prevention program. This approach 
includes identifying both generic and PD-speci!c risk factors, in order to de!ne a mul-
tidisciplinary and multifactorial intervention program that is tailored to each individual 
patient. This program includes: optimizing dopaminergic medication; reducing the use 
of sedative drugs; physiotherapy to improve transfers, gait (including freezing), balance 
and balance con!dence, physical activity and the use of assistive devices; occupational 
therapy (home visits to eliminate domestic hazards); and treatment of orthostatic hy-
potension, urinary incontinence and visual impairments. More research is needed to 
underpin the merits of the proposed multidisciplinary falls prevention program, and 
to evaluate its cost-e#ectiveness. We also need to develop better ways of !nding those 
patients who are most at risk for falling. 
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A main !nding of this dissertation is that falls are common, both in patients with Par-
kinson’s disease (PD) and Huntington’s disease (HD). Moreover, falls are already present 
in early disease stages for both conditions, and the prevalence increases with further 
disease progression. This dissertation also describes the fall circumstances, risk factors 
and consequences of falls in PD and HD. In addition, it provides insights into the patho-
physiology of postural disturbances and falls in these two neurodegenerative disorders. 
Finally, this thesis concludes with a proposal for a possible multidisciplinary and multi-
faceted intervention program to prevent falls in PD.
Postural disturbances are one of the cardinal features of PD. Unfortunately, they gen-
erally improve poorly with dopaminergic therapy or with deep brain surgery aimed at 
the basal ganglia."  In Chapter 2 a ‘noradrenergic hypothesis’ is proposed to explain this 
resistance to dopaminergic treatment. Speci!cally, we propose that lesions in the locus 
coeruleus and a concomitant central noradrenergic de!cit could be responsible for at 
least part of the postural abnormalities observed in PD. This suggestion was based on 
observations from several neurochemical and neuropathological studies in PD, which 
identi!ed signi!cant cell loss in the locus coeruleus (which is the main source of norepi-
nephrine in the central nervous system) as well as a noradrenergic de!cit. 2,3,4 The locus 
coeruleus may well play a role in controlling balance because it projects to many areas 
in the brain and spinal cord, and as such it is involved in the regulation of e.g. attention 
and gain control of spinal re.exes, both of which could be important for maintaining bal-
ance. Other indirect evidence is generated by drug studies that aimed to restore central 
norepinephrine transmission in PD. Some of these studies report a bene!cial e#ect on 
gait and freezing (reviewed in Chapter 2), but unfortunately these trials did not focus 
on balance as primary outcome. This review suggests that further work is justi!ed in this 
area and that new clinical studies of noradrenaline enhancers should test their speci!c 
e#ect on balance and falls.
In Chapter 3 and 4 the frequency of falls, fall circumstances and consequences of falls 
were studied in both PD and HD. A prospective study in 59 PD patients and a meta-
analysis of six prospective studies (including a study of our own that was performed in 
Leiden) showed that falls were common in PD. Speci!cally, during a six-month follow-
up, PD patients had a nine-fold increased risk of sustaining recurrent falls compared to 
healthy age-matched controls. During this same period, 50% of moderately a#ected PD 
patients reported two or more falls. The fall risk increased with disease severity, but at 
UPDRS values of about 50, the fall risk reached a plateau of around 60% chance of falling 
in the next 3 months. At even higher disease severity scores there was a slight decline 
in the risk of falling, perhaps because secondary immobility due to progressive balance 
impairment reduced the risk of falling.( However, the fall risk did not approach zero, as 
might be expected when patients become fully immobilized. Apparently, patients re-
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duced their overall physical activity levels, but did not become fully bedridden. However, 
we should be aware that patients admitted in a nursing home were excluded from this 
study.
In most falls an intrinsic cause, i.e. a patient-related factor, was responsible for the fall. A 
‘centre of mass’ type of fall (involving movements of the trunk) was most common, often 
occurring while turning around. This suggests that balance disturbances frequently 
underlie falls in PD. In hindsight, freezing of gait during turning may well have been re-
sponsible for some of these falls,) but at the time of this study, we did not speci!cally ask 
about freezing of gait as a possible cause of falls. We should note that for six falls, subjects 
indicated that these were related to freezing of gait in our study, although this was not 
speci!cally related to turning. More recent work has con!rmed the strong relationship 
between freezing of gait and falls in patients with PD.*%+ 
Most falls occurred during the on-phase, suggesting that dopaminergic therapy was 
unable to alleviate the intrinsic balance disorder. In fact, most falls occurred when symp-
toms were well controlled or when patients experienced dyskinesias, suggesting that, 
if anything, dopaminergic therapy was associated with an increased risk of falls. Several 
theories may explain this last !nding. When symptoms are relatively well controlled, pa-
tients could experience an increased mobility, but without an improved balance. Indeed, 
recent work suggests that the risk of falls can be expressed as a function of distance 
travelled., Another possibility is the presence of drug-induced dyskinesias, causing an 
increased postural sway leading to imbalance. A shortcoming of our study was that we 
did not correlate the severity of dyskinesias to the presence of falls, and this should be 
the topic of future research.
Most falls happened indoors, and although only a minority of falls had an extrinsic fac-
tor, domestic hazards did play an important role in the underlying mechanisms of falls. 
Importantly, we also found that use of sedative medication increased the risk of falling. 
Speci!cally, use of benzodiazepines was associated with a !ve-fold increase in the risk 
of recurrent falls, over and above the risk of falling conveyed by PD alone. This !nding is 
consistent with studies in other patient groups"-%""%"$%"&  and suggests that use of sedative 
medication should be avoided at all cost in patient groups who are already at risk of 
falling.
The high risk of falls was associated with a high rate of soft tissue injuries, and with a 
fear for future falls. This fear of falling could play an important role in restricting physical 
activities, possible even more so than the physical injuries. Major injuries such as hip 
fractures were relatively rare, but perhaps our follow-up was too short to adequately 
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in fact common in patients with PD"'%"( and this risk is compounded by the concurrent 
osteoporosis which is also common in patients with PD.")%"* 
Another goal of this thesis was to identify possible predictors of future falls in PD (Chap-
ter 3). The best predictor of falls in the near future turned out to be the presence of two 
or more falls during the preceding year. However, the sensitivity (68%) and speci!city 
(81%) were not high, and importantly, prior falls are by de!nition unable to predict the 
very !rst fall. Asking for fear of falling might be able to identify these new-onset fallers, 
but its sensitivity and speci!city were only moderate. Interestingly, none of the com-
monly used clinical tests of balance and gait could predict falls adequately. This included 
the widely used retropulsion test, which could not discriminate between future fallers 
and non-fallers. As the execution of the retropulsion test is under debate it was executed 
six times consecutively in our study, the !rst time without any prior warning. This yielded 
di#erent results (underscoring the importance of test standardisation), but none of the 
six tests could predict future falls properly. Taken together, it currently proves di/cult 
to reliably identify future fallers in PD, and commonly used balance tests are insu/cient 
predictors of falling in PD. These observations highlight the need for development of 
alternative predictors, such as electrophysiological measures of gait, freezing or balance.
We also studied the epidemiology of falls in patients with HD (Chapter 4). This study 
represented the !rst detailed examination of fall rates and fall circumstances in HD. Our 
results showed high retrospective fall rates. Speci!cally, 60% of patients reported two or 
more falls in the past year. Prospectively documented fall rates (assessed over a period 
of three months) were lower (20% of patients reported two or more falls, and 40% one 
or more falls), but the prospective follow-up period was relatively short. Similar high 
retrospective fall rates were found in a later study in HD patients."+  As in PD, most falls 
occurred indoors and resulted in a high rate of minor injuries.  A surprising !nding was 
that, unlike PD, only few subjects were afraid of falling. They did show a low balance 
con!dence, suggesting that they were aware of the high risk for falling. A possible expla-
nation could be the low rate of serious injuries. Another explanation may be behavioural 
or cognitive disturbances, leading to a general indi#erence to the possible consequences 
of a fall. 
Similar to what was observed in PD, commonly used clinical balance tests could not ad-
equately discriminate fallers from non-fallers in the HD group. A more recent retrospec-
tive study reports reasonable predictive values of the Tinetti Mobility Test in predicting 
falls in HD (sensitivity of 74% and a speci!city of 60%).", Another study found signi!cant 
di#erences in Berg Balance Scores and Timed Up and Go test between fallers and non-
fallers, but this was only an explorative study in a small group of patients."+ 
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To further identify tests that can predict future falls we added quantitative measurements 
of balance and gait, using highly sensitive accelerometers that were attached to the 
lower trunk (see Box 1.3 in Chapter 1). Increased medio-lateral trunk sway, as measured 
with these velocity transducers, was signi!cantly higher in fallers, and this correlated 
with clinical chorea scores. Analysis of gait parameters showed a decreased walking 
velocity with a decreased stride length, and this was signi!cantly associated with falls. 
These !ndings provide a !rst step towards development of an objective test algorithm 
that might be able to reliably predict future falls, either alone or in combination with 
clinical parameters.
Chapter 5 addresses the impact of falls, fear of falling and balance disturbances on 
quality of life in PD. Quality of life in PD is associated with many di#erent aspects of the 
disease, including disease severity, motor disturbances and behavioural symptoms.$-%$" 
We found that experiencing falls, fear of falling and balance disturbances were all as-
sociated with lower quality of life scores in PD. In a multivariable analysis only fear of 
falling and disease severity were signi!cantly related to the quality of life. Fear of falling 
was a stronger predictor of reduced quality of life scores than experiencing actual falls 
or objective clinical measures of balance impairment. This signi!cant impact of fear of 
falling was also found in an earlier study in PD, which found that fear of falling was a 
stronger determinant of quality of life than falls or gait related disorders.$$ These !ndings 
indicate that fear of falling should be an important target in future strategies to improve 
the quality of life for patients with PD.
Use of the ‘stops walking when talking test’ (SWWT), !rst published by Lundin-Olsson 
et al$&, introduced a new insight into balance strategies and fall risks in the elderly. An 
inability to walk and talk at the same time had a good predictive value for the occurrence 
of falls in the ensuing 6 months, at least in the speci!c population that was tested (elderly 
subjects with cognitive decline). The interference between these two tasks apparently in-
duced an inability to walk while subjects engaged in a routine conversation, suggesting 
that they had a restricted central processing capacity. As this test is easy to perform in an 
outpatient clinic we also tested it in a PD population.  Interestingly we !nd no di#erence 
in performance of the SWWT between fallers and non-fallers in PD (Chapter 6.2). In fact, 
only very few patients with PD stopped walking when they were talking at the same 
time. A possible explanation for this !nding could be the di#erence in cognitive status of 
the participants. In the Lundin-Olsson study many subjects had cognitive impairment or 
were depressed, but in our study subjects with cognitive impairment were excluded. This 
may suggest that impaired dual task performance is a better marker of falls associated 
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To further investigate dual task impairment in PD we reviewed studies that described the 
e#ect of dual tasking on walking and balance (Chapter 6.3). Although all study designs 
di#ered, they consistently showed deterioration of balance and gait when a secondary 
task was added. This was true for both cognitive tasks (such as mental arithmetic) and for 
motor tasks (such as carrying a tray). One of these studies reasoned that patients with 
PD without dementia would still prove to be vulnerable to multitasking if the secondary 
task load was made su/ciently di/cult.$' For this purpose a ‘multiple task test’ (MTT) 
was developed that included, among others, cognitive and motor challenges that could 
be combined until a very complex situation arose, where subjects had to execute up to 
eight tasks simultaneously. This study showed a di#erent strategy between controls and 
PD patients. Speci!cally, controls favoured execution of motor tasks over execution of a 
cognitive task, but patients attempted to perform all tasks simultaneously. Patients thus 
seemed less able than controls to employ a so-called ‘posture !rst’ strategy, i.e. a strategy 
where the safety of maintaining upright balance or gait is prioritised over the execution 
of any secondary task [Bloem J Neurol Sci 2006]. This inability of PD patients to prioritise 
their postural safety is an interesting !nding that should probably be implemented in 
future fall prevention programs, for example by instructing patients to avoid secondary 
tasks during walking or balancing activities, or to postpone a complex secondary task 
until a safe (e.g. seated) position has been obtained. Interestingly, however, recent work 
points to an alternative strategy, namely the possibility to train patients to better perform 
multiple tasks simultaneously.$(.A great advantage to this latter approach is that it closer 
resembles daily life performance, where multitasking can never be avoided completely. 
So ideally patients should be trained to better cope with these complex situations, and 
the latest research results are promising in this respect.
Chapter 6.1 reviews the above !ndings on the assessment, pathophysiology and treat-
ment of falls, and places these results into perspective with other current literature on 
falls in PD.
In Chapter 7 a design for a multifactorial falls prevention program for PD is proposed. This 
program should include PD-speci!c therapeutic measures, as well as generic strategies 
(because patients with PD are not exempt from the ‘normal’ risk factors that are associ-
ated with ageing). For this purpose, we reviewed the literature on all previously identi!ed 
risk factors for falls in PD, we examined existing fall prevention strategies in the literature, 
and we evaluated published national and international falls prevention guidelines. Based 
on these sources we developed a menu of therapeutic interventions tailored to each of 
the possible risk factors, and bundled these into a concept protocol for a Multifactorial 
Parkinson Falls Prevention strategy. A challenge was to identify therapeutic strategies 
that would be feasible for PD patients. For example, an accepted strategy to prevent 
falls from orthostatic hypotension is standing with both legs crossed. This is an unstable 
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posture for PD patients with marked postural instability, and is therefore not a suitable 
intervention in this patient group.
The suggested intervention program includes one or more of the following approaches 
(depending on the speci!c risk pro!le that is present in each individual patient): optimiz-
ing dopaminergic therapy (for example, to reduce o#-state freezing of gait); reducing 
the use of sedative medication; physiotherapy to improve transfers and gait (including 
freezing of gait); balance and balance con!dence training; promoting physical activity; 
training the use of assistive devices; occupational therapy; and treatment of orthostatic 
hypotension, urinary incontinence and visual impairment. This concept for a multifac-
eted falls prevention program is currently being examined and re!ned by an interna-
tional panel of experts. Once accepted, this program could serve two purposes: !rst, it 
could help clinicians in current clinical practice when they strive to prevent falls in their 
patients; and second, it could serve as the active intervention arm in future randomised 
clinical trials that aim to evaluate the merits of a new program for the prevention falls in 
PD.
Future perspectives
Additional work is required to !nd algorithms that can reliably predict falling in PD and HD, 
in order to identify subjects at risk for falls, and to determine who are the best candidates 
for fall intervention programs. Such models should include well studied instruments to 
measure this risk for future falls, including the use of validated falls questionnaires and 
the use of prospective diaries to document faller status, as was used in this dissertation. 
Assessing the presence of fear of falling is important, as this is not only a risk factor for 
falls, but also an important determinant of quality of life in PD. The questionnaires should 
also ask about any negative consequences of physical inactivity in PD. Many patients 
with PD are prone to develop a sedentary lifestyle$) and fear of falling is among the many 
reasons why patients start to avoid participating in physical activities, such as walking 
outdoors for pleasure or to engage in physiotherapy. A crucial challenge that lies ahead 
of us is to !nd ways to promote physical activity in PD, considering safety limits. This is 
now being taken to the test in the ParkFit trial, a large study of exercise for patients with 
PD, aiming mainly to achieve a behavioural change that will lead to sustained increase in 
physical activities.$)  
Any prediction model to identify future fallers should also include the best available 
clinical tests of gait and balance. The current thesis suggests that testing for dual tasking 
abilities should be part of the test battery, certainly when the second load can be graded 
to ascertain that the task is also su/ciently challenging for patients without depression 
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test, at least as a predictor of falls, although it probably remains a simple test to screen for 
and score balance abnormalities in clinical practice. 
Given the shortcomings of currently available clinical test batteries, we anticipate that 
objective electrophysiological assessments of gait and balance will play an important 
role in these fall prediction paradigms. There are now many examples of such devices, 
including ambulatory equipment that can detect freezing episodes or other basic gait 
parameters$*%$+, transfers$,, or trunk sway measures during a variety of tasks.&-%&" 
Recent !ndings (published after completion of our studies) point to two particularly 
important developments : (a) the strong relationship between falling and freezing of gait 
in patients with PD*%+, suggesting that this should be an important component of the 
assessment battery, as well as a key target for future therapeutic intervention (optimising 
dopaminergic treatment; and use of cueing strategies); and (b) the strong relationship 
between falling and cognitive decline.&$ This latter association is clearly important, both 
for patients with PD and for patients with HD. It is becoming increasingly clear that gait 
and balance are not fully automatic and subconscious motor tasks, but in fact represent 
complex actions that require considerable monitoring and attention. This probably ex-
plains why frontal executive de!cits are particularly strong related to both gait disability, 
postural instability and falls in various neurological populations. Whether this associa-
tion with cognitive decline may also have any therapeutic implications remains unclear. 
However, cognitive decline has been linked to central cholinergic de!cits, and interesting 
new work is now pointing to the possible therapeutic merits of cholinesterase inhibitors 
for the prevention of falls;&&%&'  We expect that this will be an important area of research 
in the next few years.
Medication to adequately treat balance disturbances is still not available. Next to le-
vodopa - which can help to improve gait and freezing of gait, but which only partially 
improves balance - there is a need for development of non-dopaminergic therapies. 
We already mentioned the ongoing work on cholinesterase inhibitors as important 
candidates to improve freezing of gait and balance. Chapter 2 suggests that it is 
worth trying to improve balance using central noradrenergic enhancers. In addition, 
non-pharmacological treatments need to be improved as well. Stereotactic deep brain 
stimulation of the subthalamic nucleus (STN) or the internal globus pallidus does not 
su/ciently alleviate balance disorders. Recent studies aimed at the pedunculopontine 
nucleus as a promising new target for gait and balance de!cits, by these have shown 
con.icting results.8&(%&) Better physiotherapy programs are currently being developed, 
and their e#ectiveness has been documented in a recent evidence-based guideline.&*%&+ 
Finally, because falling is complex and related to many aspects of the disease, multidis-
ciplinary care is probably needed to optimally treat balance disorders and to reduce fall 
risks. In Chapter 7, we proposed a concept for a multidisciplinary team intervention, but 
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such programs now need to be studied further and taken to the test in large randomised 
clinical trials. The intervention programs should always be tailored to the individual with 
their speci!c disease features. For example, relatively few HD patients experience fear of 
falling, and they may therefore bene!t less from interventions addressing fear of falling 
than patients with PD, where a fear of falling is very common and incapacitating. Simply 
prescribing walking aids could be hazardous in HD patients, because this carries the risk 
of tripping over the aid when taking a corrective side step or when patients sway the 
device around because of their involuntary movements.8&, Patients with PD also often 
use their walking aids inappropriately, and sometimes this further increases their risk of 
falling. Such observations underscore the importance of developing intervention pro-
grams that contain disease-speci!c strategies, next to ‘generic’ fall interventions. In late 
stages of PD and HD balance may become so severely compromised that it is no longer 
possible to make safe transfers; in this stage fall prevention strategies may need to focus 
on wheelchair use and a reduction of unsupervised mobility. Again, the merits of such a 
multifaceted falls prevention strategy, tailored to individual needs and disease severity, 
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De belangrijkste bevinding van dit proefschrift is dat vallen frequent voorkomt bij de 
ziekte van Parkinson (ZvP) en de ziekte van Huntington (ZvH). Al vroeg in het beloop kan 
vallen optreden en naarmate de ziekte vordert, neemt de prevalentie toe. Het onderzoek 
in dit proefschrift beschrijft bij beide aandoeningen de risicofactoren en consequenties 
van vallen en de omstandigheden waarin zij optreden. Verder wordt de pathofysiologie 
van houdingsstoornissen en vallen nader bestudeerd. Het proefschrift sluit af met een 
voorstel voor een multidisciplinair interventie programma ter voorkoming van vallen bij 
de ziekte van Parkinson.
Houdingsinstabiliteit is een van de hoofdsymptomen van de ziekte van Parkinson. Het 
reageert echter minder goed op dopaminerge therapie dan andere symptomen zo-
als bradykinesie en rigiditeit." Ook chirurgische therapie gericht op de basale ganglia 
biedt tot nu toe minder resultaat op de houdingsstoornissen. In Hoofdstuk 2 wordt 
een verklaring gezocht voor deze slechte reactie op dopaminerge therapie en wordt 
de hypothese geopperd dat een noradrenerg tekort medeverantwoordelijk is voor de 
posturele stoornissen bij de ZvP. Meerdere neuropathologische studies vonden een 
celverlies in de locus coeruleus (de belangrijkste bron van noradrenaline in het centraal 
zenuwstelsel) en een daarmee gepaard gaand tekort aan noradrenaline.$%&%' De locus 
coeruleus heeft verbindingen met vele gebieden in de hersenen en het ruggenmerg en 
is daardoor bijvoorbeeld betrokken bij de controle van de spinale re.exen. Hierdoor zou 
deze kern een rol kunnen spelen bij het onderhouden van een goede balans. Indirecte 
aanwijzingen volgen uit studies waarin noradrenaline wordt gesuppleerd bij de ZvP (zie 
hiervoor Hoofdstuk 2). Enkele van deze studies vinden een gunstig e#ect op lopen en 
bevriezen, maar hebben helaas niet het verdere e#ect op balans onderzocht.
In Hoofdstuk 3 en 4 worden de frequentie, de omstandigheden en de consequenties 
van vallen bij de ZvP en de ZvH besproken. Dat vallen frequent voorkomt blijkt uit een 
prospective studie van 59 patiënten met de ZvP en een later gepubliceerde meta-analyse 
van zes prospectieve studies. Parkinson-patiënten hadden een negen maal verhoogd 
risico op herhaaldelijk vallen vergeleken met gezonde leeftijdgenoten, gedurende 
een prospectieve  onderzoeksperiode van zes maanden. Vijftig procent van de matig 
aangedane parkinson-patiënten viel gedurende deze zes maanden twee of meer keer. 
Het risico op vallen nam toe met de ziekteduur maar bereikte een plateaufase bij een 
Uni!ed Parkinson’s Disease Rating Scale (UPDRS) score van 50. Hierna bleef het risico 
steken op een kans van ongeveer 60% op een nieuwe val in de komende drie maanden. 
Bij nog hogere UPDRS scores nam het risico zelfs weer wat af, mogelijk door de inmid-
dels ontstane immobiliteit als gevolg van de balansstoornissen.( Het risico daalde echter 
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niet naar nul, wat erop duidt dat patiënten niet volledig geïmmobiliseerd waren. Dit was 
echter ook inherent aan de studie, waaraan geen verpleeghuispatiënten deelnamen.
De meeste vallen hadden een ‘intrinsieke’ oorzaak. Dat wil zeggen dat de oorzaak gele-
gen was in patiënt gerelateerde factoren. De meeste vallen traden op als gevolg van 
verplaatsingen van het zwaartepunt van het lichaam, veroorzaakt door rompbewegin-
gen. Dit gebeurde met name tijdens omdraaien. Dit onderschrijft het idee dat balans-
stoornissen ten grondslag liggen aan het vallen bij de ZvP. Achteraf bezien zou bevriezen 
tijdens draaien ook een belangrijke rol kunnen hebben gespeeld), maar in het kader van 
deze studie hebben we daar niet speci!ek naar gevraagd. Wel waren zes gerapporteerde 
vallen gerelateerd aan bevriezen tijdens lopen en dit is in latere studies ook een grote 
risicofactor voor vallen gebleken.*%+
Tijdens de ‘on’-fase werden de meeste vallen gerapporteerd. Dit suggereert dat dopa-
minerge therapie onvoldoende de intrinsieke balansstoornis verbetert of mogelijk zelfs 
vallen kan veroorzaken. Hiervoor zijn verschillende verklaringen theorieën mogelijk. 
Tijdens de ‘on’-fase zijn patiënten mobieler omdat de rigiditeit en bradykinesie verbetert. 
Maar indien de balansstoornis minder goed reageert op dopaminerge therapie kan dit 
juist tot vallen leiden. Een recente studie beschreef het risico op vallen als functie van de 
afgelegde loopafstand., 
Een andere verklaring zou kunnen zijn gelegen in het optreden van dyskinesieën. Een 
toename van de rompzwaai kan de patiënt daarbij uit evenwicht brengen. In onze studie 
hebben we de relatie tussen dyskinesieën en vallen niet bestudeerd. Dit zou in een vol-
gende studie moeten worden onderzocht.
Verder vonden de meeste vallen binnenshuis plaats en hoewel de minderheid een 
‘extrinsieke’ oorzaak had, speelden huisgerelateerde gevaren (zoals kleedjes) een belan-
grijke rol in het veroorzaken van vallen. 
In overeenstemming met studies bij andere patiëntgroepen was het gebruik van sedativa 
geassocieerd met een verhoogd valrisico."-%""%"$%"& Het gebruik van benzodiazepinen vero-
orzaakte binnen onze patiëntengroep zelfs een vijfmaal verhoogd risico. Dit impliceert 
dat het gebruik van sedatieve medicatie bij valgevaarlijke patiënten zou moeten worden 
voorkomen.
Het frequent vallen leidde tot een groot aantal weke delen verwondingen en een toe-
name van angst om te vallen. Deze angst om te vallen kan een vermindering van licha-
melijke activiteiten tot gevolg hebben. Ernstige verwondingen kwamen in onze studie 
weinig voor, maar dit is toe te schrijven aan de relatief korte follow-up. In retrospectieve 
studies wordt een verhoogde incidentie van heupfracturen bij de ZvP gevonden"'%"(; een 





In het voorkómen van vallen is het belangrijk om vallen in de toekomst te kunnen voor-
spellen. In hoofdstuk 3 hebben wij mogelijke voorspellers van vallen bestudeerd. De 
aanwezigheid van twee of meer vallen in het afgelopen jaar gaf de beste voorspelling 
van nieuwe vallen in de toekomst. De sensitiviteit (68%) en speci!citeit (81%) waren 
echter niet hoog. Bovendien zou het beter zijn het verhoogde risico te onderkennen 
voordat de eerste vallen plaatsvinden. Angst om te vallen zou mogelijk vooraf kunnen 
gaan aan de eerste val, maar het vragen hiernaar had slechts een matige sensitiviteit en 
speci!citeit.
Een interessante bevinding bleek dat geen van de momenteel veel gebruikte klinische 
testen voldoende toekomstig vallen kon voorspellen. Ook de zeer bekende en veel 
gebruikte retropulsietest kon vallers niet van niet-vallers onderscheiden. Omdat er over 
de uitvoering van de retropulsietest veel discussie is, hebben wij deze in onze studie 
zes maal achtereen uitgevoerd en apart geanalyseerd. Dit gaf ten eerste verschillende 
resultaten, wat er op wijst dat de uitvoering gestandaardiseerd zou moeten worden, 
en ten tweede was geen enkele test in staat toekomstige vallers te onderscheiden. Uit 
deze bevindingen blijkt dat het belangrijk is om andere risicofactoren te bestuderen en 
nieuwe testen (zoals bijvoorbeeld elektrofysiologische metingen van lopen en balans) 
te ontwikkelen die een verhoogd risico op vallen in de toekomst adequaat kunnen 
voorspellen.
In Hoofdstuk 4 hebben wij de epidemiologie van vallen bij de ZvH bestudeerd. Deze 
studie was het eerste gedetailleerde onderzoek naar valfrequentie en omstandigheden 
bij de ZvH. Het bleek dat ook bij deze ziekte de valfrequentie hoog was. Zestig procent 
van de patiënten rapporteerde meerdere vallen in het afgelopen jaar. In een prospec-
tieve periode van 3 maanden was dit 20% en 40% viel één keer. Een latere studie vond 
vergelijkbare retrospectieve valfrequenties."+
Evenals bij de ZvP vonden de meeste vallen binnenshuis plaats en hadden zij veel kle-
ine verwondingen tot gevolg. Opvallend was dat patiënten met de ZvH echter weinig 
angst om te vallen bleken te hebben, terwijl zij wel een verminderd vertrouwen in hun 
balans rapporteerden. Mogelijk wordt dit veroorzaakt door de gedrags- of cognitieve 
stoornissen die gepaard gaan met de ZvH, waarbij er onvoldoende besef kan zijn van de 
mogelijke gevolgen van een val. Een andere verklaring zou kunnen zijn dat er ook weinig 
ernstige gevolgen werden gezien.
Ook bij de ZvH konden klinische balans testen vallers niet onderscheiden van niet-
vallers. In een recente retrospectieve studie bleek de Tinetti Mobility test een redelijk 
voorspellende waarde te hebben (sensitiviteit 74%, speci!citeit van 60%).", Een andere 
studie toonde signi!cante verschillen tussen vallers en niet-vallers bij de Berg Balance 
test en de Timed Up en Go test."+ Deze studie bevatte echter een kleine groep patiënten.
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Om andere mogelijke voorpellers te onderzoeken hebben we kwantitatieve meetin-
strumenten toegevoegd in de vorm van accelerometers, bevestigd aan de romp, en een 
drukgevoelige loopmat (zie box 1.3 in Hoofdstuk 1). Hierbij bleek er bij vallers sprake te 
zijn van een signi!cant hogere laterale rompzwaai, wat correleerde met klinische chorea 
scores. Bij analyse van het looppatroon waren verlaagde loopsnelheid en een kleinere 
paslengte signi!cant geassocieerd met een verhoogd valrisico. Deze bevindingen zijn 
een eerste stap in de richting van het ontwikkelen van een objectieve test maat, waar-
mee toekomstige vallen voorspeld zouden kunnen worden.
Hoofdstuk 5 behandelt de consequenties van balansstoornissen, vallen en angst om 
te vallen voor de kwaliteit van leven bij de ZvP. Vele factoren, zoals ziekte-ernst, mo-
toriekstoornissen en gedragsstoornissen, bepalen de kwaliteit van leven bij de ZvP. $-%$" 
Balansstoornissen, vallen en angst om te vallen waren in onze studie allen geassocieerd 
met een verlaagde kwaliteit van leven. Angst om te vallen bleek hiervan de belangrijkste 
factor te zijn en dit is in overeenstemming met een eerdere studie, waarin angst om 
te vallen belangrijker was dan loopstoornissen of daadwerkelijk vallen.$$  Dit impliceert 
dat bij behandelingen, gericht op het verbeteren van de kwaliteit van leven bij de ZvP 
aandacht voor angst om te vallen een belangrijke plaats moet innemen. 
Lundin-Olsson et al$& publiceerden de ‘stops walking when talking test’ (SWWT) en intro-
duceerden hiermee een nieuw inzicht in balansstrategieën van ouderen. Het onvermogen 
om te kunnen lopen en praten tegelijkertijd bleek geassocieerd met een verhoogd risico 
om te vallen in de volgende zes maanden bij ouderen. Bij het bestuderen van de waarde 
van deze test voor patiënten met de ZvP werd in onze studie echter geen onderscheid 
gevonden tussen toekomstige vallers en niet-vallers (Hoofdstuk 6.2). Slechts enkele 
patiënten stopten met lopen tijdens het praten. Mogelijk werd dit veroorzaakt door het 
feit dat de Lundin-Olsson studie veel patiënten bevatte met geheugenstoornissen en 
depressie, terwijl ernstige geheugenstoornissen een exclusie criterium waren voor onze 
studie. Dit zou erop kunnen wijzen dat het onvermogen om dubbele taken uit te voeren 
eerder een marker is voor cognitieve stoornissen dan voor motoriekstoornissen.
In navolging van de SWWT volgen er meer studies die het e#ect van dubbele taken op 
lopen en balans onderzoeken. In Hoofdstuk 6.2 worden deze artikelen besproken en 
hoewel alle studies een wat verschillende opzet hadden, lieten zij wel een verslechtering 
van het lopen en de balans zien wanneer er een tweede taak moest worden uitgevoerd. 
Dit gold voor zowel cognitieve (bijvoorbeeld rekenen) als motorische taken (bijvoorbeeld 
het dragen van een dienblad). Eén van deze studies suggereerde dat een multipele taken 
test mogelijk duidelijkere verschillen kon laten zien bij patiënten met de ZvP zonder 
geheugenstoornissen.$' Hiervoor werd de zogenoemde ‘multiple task test’ ontwikkeld, 





voegd, totdat er acht taken tegelijk moesten worden uitgevoerd. Dit liet verschillende 
strategieën zien bij parkinsonpatiënten en gezonde controlepersonen. De controles 
gaven voorrang aan de motorische taken boven de cognitieve taken en de patiënten 
probeerden tevergeefs alle taken tegelijk uit te voeren. Parkinsonpatiënten leken daarbij 
minder goed in staat om een zogenaamde ‘posture !rst’ strategie te hanteren, waarbij de 
balans voorgaat op andere taken. Het onvoldoende voorrang geven aan de balans zou 
daarom wellicht onderdeel moeten uitmaken van valpreventie programma’s  bij de ZvP. 
Hierbij kan bijvoorbeeld geleerd worden om extra taken tijdens het lopen uit te stellen 
totdat er sprake is van een veilige positie. Een recente studie wijst juist op een andere 
meer succesvolle strategie, waarbij er juist geadviseerd wordt om te oefenen meerdere 
taken tegelijk uit te voeren, hiermee ook beter tegemoet komend aan de dagelijkse situ-
atie.$( 
In Hoofdstuk 7 wordt een concept ontwikkeld voor een multifactorieel valpreventie 
programma voor de ZvP. Dit programma zou gericht moeten zijn op zowel interventies 
gericht op de ZvP, als op algemene preventie strategieën die voor ouderen gelden. In dit 
kader hebben we de een literatuur review verricht, waarbij alle beschreven valrisicofac-
toren en valpreventie strategieën werden geëvalueerd met daarbij de huidige nationale 
en internationale valpreventie richtlijnen. Hierop werd een concept protocol gebaseerd 
waarin er een overzicht werd gegeven van de mogelijke interventies, passend bij speci-
!eke risicofactoren. Deze interventies moesten dan ook geschikt zijn voor patiënten met 
de ZvP. Zo is bijvoorbeeld het kruisen van de benen een veel gebruikte strategie om 
orthostatische hypotensie te verminderen tijdens staan. Dit is uiteraard geen geschikte 
methode indien er sprake is van een bijkomende ernstige balansstoornis.
Het voorgestelde preventieprogramma bevat onder meer de volgende interventies 
(afhankelijk van het speci!eke risicopro!el van de individuele patiënt): het optimaliseren 
van de dopaminerge therapie (bijvoorbeeld verminderen van ‘o# ’-freezing); het ver-
minderen of staken van sedativa; fysiotherapie ter verbetering van lopen en transfers; 
balanstraining en het vergroten van het vertrouwen in de balans; het bevorderen 
van lichamelijke activiteit; trainen van het gebruik van hulpmiddelen; ergotherapie; 
behandeling van orthostatische hypotensie, urine incontinentie en visusstoornissen. 
Dit valpreventie programma wordt momenteel getest en wordt beoordeeld door een 
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